US20060278588A1 - Apparatus and method for separating and concentrating fluids containing multiple components - Google Patents

Apparatus and method for separating and concentrating fluids containing multiple components Download PDF

Info

Publication number
US20060278588A1
US20060278588A1 US11/442,631 US44263106A US2006278588A1 US 20060278588 A1 US20060278588 A1 US 20060278588A1 US 44263106 A US44263106 A US 44263106A US 2006278588 A1 US2006278588 A1 US 2006278588A1
Authority
US
United States
Prior art keywords
fraction
bone marrow
cells
volume
marrow aspirate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/442,631
Inventor
Jennifer Woodell-May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomet Biologics LLC
Original Assignee
Biomet Manufacturing LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/445,381 external-priority patent/US7179391B2/en
Priority claimed from US10/932,882 external-priority patent/US7374678B2/en
Application filed by Biomet Manufacturing LLC filed Critical Biomet Manufacturing LLC
Priority to US11/442,631 priority Critical patent/US20060278588A1/en
Assigned to BIOMET MANUFACTURING CORP. reassignment BIOMET MANUFACTURING CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOODELL-MAY, JENNIFER E.
Publication of US20060278588A1 publication Critical patent/US20060278588A1/en
Assigned to BIOMET BIOLOGICS, INC. reassignment BIOMET BIOLOGICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOMET MANUFACTURING CORP.
Assigned to BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES reassignment BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES SECURITY AGREEMENT Assignors: BIOMET, INC., LVB ACQUISITION, INC.
Assigned to BIOMET BIOLOGICS, LLC reassignment BIOMET BIOLOGICS, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIOMET BIOLOGICS, INC.
Priority to US13/663,637 priority patent/US20130226149A1/en
Priority to US14/510,828 priority patent/US9897589B2/en
Assigned to LVB ACQUISITION, INC., BIOMET, INC. reassignment LVB ACQUISITION, INC. RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 020362/ FRAME 0001 Assignors: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Priority to US15/866,658 priority patent/US10393728B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/491Blood by separating the blood components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D21/00Separation of suspended solid particles from liquids by sedimentation
    • B01D21/26Separation of sediment aided by centrifugal force or centripetal force
    • B01D21/262Separation of sediment aided by centrifugal force or centripetal force by using a centrifuge
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D21/00Separation of suspended solid particles from liquids by sedimentation
    • B01D21/30Control equipment
    • B01D21/307Passive control mechanisms without external energy, e.g. using a float
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5021Test tubes specially adapted for centrifugation purposes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5021Test tubes specially adapted for centrifugation purposes
    • B01L3/50215Test tubes specially adapted for centrifugation purposes using a float to separate phases
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L1/00Enclosures; Chambers
    • B01L1/52Transportable laboratories; Field kits
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02Adapting objects or devices to another
    • B01L2200/026Fluid interfacing between devices or objects, e.g. connectors, inlet details
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/06Auxiliary integrated devices, integrated components
    • B01L2300/0681Filter
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0403Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0409Moving fluids with specific forces or mechanical means specific forces centrifugal forces
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0475Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0478Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/06Valves, specific forms thereof
    • B01L2400/0605Valves, specific forms thereof check valves
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L9/00Supporting devices; Holding devices
    • B01L9/54Supports specially adapted for pipettes and burettes

Definitions

  • the present teachings relate to a multiple component fluid and a concentrator/separator and, more particularly, relates to a container operable with a centrifuge to separate and/or concentrate various biological components.
  • whole blood samples may include a plurality of constituents that may be separated by density in a device such as a centrifuge.
  • the whole blood sample may be placed in a test tube, or other similar device, which is then spun in a centrifuge. In the centrifuge the whole blood is separated into different fractions depending upon the density of that fraction. The centrifugal force separates the blood or other sample into different fractions.
  • various elements may be added to the test tube to create more than two fractions.
  • gels may be used to divide the whole blood into a plurality of different fractions which may include fractions such as platelets, red blood cells, and plasma.
  • fractions such as platelets, red blood cells, and plasma.
  • Various other biological fluids may be separated as well.
  • nucleated cells may be separated and extracted from bone marrow or adipose tissue sample.
  • the top fraction of whole blood is plasma, or other blood constituents suspended in plasma.
  • the plasma fraction must either be removed for further extracting procedures or spun again to obtain the constituents suspended in this plasma. It is difficult to pierce the top fraction without commingling the sample. Accordingly, obtaining the other fractions is difficult with commonly known systems.
  • the present teachings provide an apparatus that separates and concentrates a selected fraction or component of a fluid, such as a biological fluid.
  • a fluid such as a biological fluid.
  • undifferentiated cells such as mesenchymal stem cells, platelet fraction, buffy coat, or white blood cell fraction can be separated from bone reaming material, whole blood, bone marrow aspirate, and other materials.
  • the apparatus when used with a centrifuge, is generally able to create at least two fractions.
  • the present teachings also provide for a new method of creating at least three fractions extracting a third fraction from a sample such as, for example, a buffy coat fraction.
  • the apparatus includes a container to be placed in a centrifuge after being filled with a sample and the container includes a buoy or fraction separator having a selected density that may be less than one fraction but greater than a second fraction, that is disposed therein.
  • a second buoy may be placed in the container with the first.
  • the extraction system is connected to the buoy system or to the collection chamber such that the fraction in the container can be collected and drawn outside of the chamber.
  • the buoy is forced away from a bottom of the container as the denser fraction collects at the bottom of the container.
  • the buoy is generally able to physically separate the denser fraction from another fraction of the sample.
  • the fractions can be withdrawn using an extraction system.
  • a buoy system in addition to providing a first buoy and/or a second buoy, may be provided.
  • the buoy system may separate the sample into at least three fractions. The fractions may be separated and extracted from the container without substantially commingling the various fractions.
  • a first buoy and a second buoy operate together to separate the sample into the various fractions and a syringe or tube may then be interconnected with a portion of the buoy system to extract the selected fractions.
  • a first buoy may be tuned to a density less than the density of a red blood cell fraction of a whole blood sample, bone marrow aspirate sample, or combinations thereof
  • a second buoy may be tuned to a density less than the density of a buffy coat fraction.
  • a method of forming an enriched scaffold for application relative to an anatomy may include obtaining a volume of a first whole material and obtaining a volume of a second whole material. A first fraction of the first whole material and a second fraction of the second whole material may be formed. At least one of the first fraction or the second fraction may be applied to the scaffold and at least one fraction for application relative to an anatomy is provided. The method may include obtaining a volume of heterogeneous whole material and separating the material into the desired fraction(s). At least one of the fractions may be applied to the scaffold.
  • a method of withdrawing a material directly from a patient and collecting a selected fraction of the material in a container may include forming an access to port to the patient.
  • a pressure differential in a collection container may be formed relative to the patient.
  • a connection may be made between the patient and the collection container via the port.
  • the collection container may be filled with the material and then the material may be separated to form the selected fraction.
  • a method for concentrating bone aspirate can include obtaining a volume of bone marrow aspirate from a mammal and loading the volume bone marrow aspirate into a separator, the separator operable to separate the aspirate into three of more fractions. The method also includes centrifuging the separator to create a fraction that is a concentrated bone marrow aspirate and extracting and removing the fraction from the separator.
  • a method for concentrating bone marrow aspirate and blood includes collecting bone marrow aspirate and blood from a patient then loading the bone marrow aspirate and blood into a separator that can separate the aspirate and the blood into three or more fractions.
  • the method includes centrifuging the separator containing the bone marrow aspirate and the blood creating a fraction that has a concentrated bone marrow aspirate and a concentrated blood.
  • a concentration may be referred to as a buffy coat.
  • the method also include withdrawing the fraction comprising the concentrate or buffy coat.
  • a method for treating a defect in a mammal using a concentrated bone marrow aspirate includes drawing bone marrow aspirate from the mammal and loading the bone marrow aspirate into a separator that can separate the bone marrow aspirate into three or more fractions.
  • the method includes centrifuging the separator separating the bone marrow aspirate into fractions and one fraction is concentrated bone marrow aspirate.
  • the method also can include the concentrated bone marrow aspirate and applying the bone marrow aspirate to a site of a defect in the mammal.
  • a method for treating a defect in a patient includes drawing bone marrow aspirate and whole blood from the patient then adding anticoagulants to the bone marrow aspirate and the blood.
  • the method includes the loading of the bone marrow aspirate and the blood into a separator that can separate the bone marrow aspirate and blood into three or more fractions.
  • the method also includes centrifuging the separator then withdrawing a fraction comprising at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells, then applying the fraction to the site of the defect in the patient.
  • a method of treating a patient with a combination of concentrated bone marrow aspirate and buffy coat includes obtaining blood and bone marrow aspirate from the patient, forming a buffy coat fraction of the whole blood and forming a concentrated bone marrow aspirate fraction, and applying at least one of the buffy coat or concentrated bone marrow aspirates to the patient.
  • FIG. 1 is a plan view of a separator including a depth gage affixed to a plunger in a tube according to various embodiments of the present teachings;
  • FIG. 2 is a cross-section view taken along line 2 - 2 of FIG. 1 ;
  • FIG. 3 is an exploded of the separator apparatus according to various embodiments
  • FIG. 4 is a kit including the separator according to an embodiment of the present teachings.
  • FIG. 5A is a plan view of the separator, according to various embodiments, being filled
  • FIG. 5B is a plan view of a blood sample in the separator after the centrifuge process
  • FIG. 5C is a plan view of the plunger plunged into the tube with the depth gage to further separate the blood sample
  • FIG. 5D is a plan view of the buffy coat and the plasma fractions being extracted from the separator according to various embodiments
  • FIG. 6A is a side plan view of a buoy system according to various embodiments.
  • FIG. 6B is a cross-sectional view of the buoy system of FIG. 6 a;
  • FIG. 7A is a plan view of a separator, according to various embodiments, being filled
  • FIG. 7B is a plan view of a separator, according to various embodiments, after a centrifugation process
  • FIG. 7C is a plan view of a separator system, according to various embodiments, being used to extract a selected fraction after the centrifugation process;
  • FIG. 7D is a plan view of a second fraction being extracted from the separator according to various embodiments.
  • FIG. 8 is a schematic view illustrating an assisted blood withdrawal device according to various embodiments.
  • FIG. 9 is a block diagram illustrating a method for applying selected fractions of a fluid.
  • a separator 10 also referred to as a concentrator
  • the separator 10 generally includes a tube or container 12 that is adapted to hold a fluid sample, such as an anti-coagulated whole blood sample, for further processing.
  • a fluid sample such as an anti-coagulated whole blood sample
  • the tube 12 may hold other solutions including constituents of more than one density, such as bone marrow or a mixture of whole blood and bone marrow.
  • the tube 12 includes a top or open end 12 a , which is closeable, and a bottom or closed end 12 b .
  • the bottom 12 b may also be selectively closeable.
  • a first piston or buoy 14 that is able to move along a central axis A of the tube 12 .
  • the buoy 14 is generally nearer the bottom end 12 b of the tube 12 rather than the open end 12 a .
  • the buoy 14 is able to move along a central axis A of tube 12 .
  • a second piston or plunger 16 disposed within the tube 12 .
  • the plunger 16 is also able to move within the tube 12 generally between a position closer to the open end 12 a to a position closer to the closed end 12 b of the tube 12 .
  • a cap 18 substantially mates with the open end 12 a of the tube 12 to close the tube 12 save for ports formed in the cap 18 .
  • a plasma valve or port 20 that communicates with an area, described further herein, within the tube 12 defined between the plunger 16 and the cap 18 .
  • the plasma port 20 is merely exemplary in nature and simply allows for removal of a selected fraction of a sample such as, for example, plasma from whole blood.
  • the cap 18 also includes a depth gage port 19 . Extending from the plunger 16 and through the depth gage port 19 is a first plunger port 22 .
  • a depth guide or gage 24 includes a female connector 26 adapted to connect with the first plunger port 22 .
  • the depth gage 24 also includes a depth gage housing or cannula 28 .
  • the depth gage housing 28 defines a depth gage bore 30 .
  • Incorporated in the depth gage housing 28 and extending distal from the end mating with the plunger 16 is a neck 32 .
  • the neck 32 includes external neck threads 34 .
  • the external neck threads 34 are adapted to engage appropriate internal threads of a mating member.
  • the mating member may include a compression nut 36 that mates with the external neck threads 34 to lock a depth gage rod 38 in a predetermined position.
  • a split bushing 39 is also provided to substantially seal the depth gage housing 28 when the depth gage rod 38 is locked in place.
  • the depth gage rod 38 extends through the depth gage housing 28 and terminates at a rod handle 40 .
  • the rod handle 40 may be a form easily manipulated by a human operator.
  • the depth gage rod 38 extends coaxially with axis A of the tube 12 .
  • the depth gage rod 38 extends through the plunger 16 a predetermined distance and may be locked at that distance with the compression nut 36 .
  • the tube 12 is described herein as a cylinder, it will be understood that other shapes may be used, such as polygons.
  • the internal portions, such as the cap 18 , buoy 14 , and plunger 16 would also include this alternate shape.
  • the tube 12 is formed of a thermal plastic material which is flexible under the forces required to separate blood.
  • the tube 12 may be made of a material that includes the properties of both lipid and alcohol resistance. These properties helps increase the separation speed and decrease the amount of material which may cling to the tube wall 42 .
  • Cyrolite MED2® produced by Cyro Industries of Rockaway, N.J., may be used to produce the tube 12 .
  • the tube 12 has a tube wall 42 with a thickness of between about 0.01 millimeters and about 30.0 millimeters, although the tube wall 42 may be any appropriate thickness.
  • the thickness of the tube wall 42 allows the tube wall 42 to flex during the centrifuge process yet be rigid enough for further processing of a blood sample disposed in the tube 12 .
  • the tube 12 is closed at the bottom end 12 b with a tube bottom 44 formed of the same material as the tube wall 42 and is formed integrally therewith.
  • the tube bottom 44 has a thickness which is substantially rigid under the forces required to separate the sample such that it does not flex.
  • the buoy 14 includes an upper or collection face 46 that defines an inverse cone or concave surface.
  • the cone has an angle of between about 0.5° to about 45°, and may be about 0.5° to about 90° from a vertical axis, wherein the apex of the cone is within the buoy 14 .
  • the collection face 46 forms a depression in the buoy 14 which collects and concentrates material during the separation process.
  • the buoy 14 has a bottom face 48 that defines an inverse cone, dome, or covered surface.
  • the buoy bottom face 48 includes an apex 50 that engages the tube bottom 44 before a buoy edge 52 engages the tube bottom 44 .
  • the buoy 14 includes a material that is a substantially rigid such that the buoy edges 52 never meet the tube bottom 44 . Therefore, there is a gap or free space 54 formed between the buoy edges 52 and the tube bottom 44 along the perimeter of the buoy 14 .
  • the separator 10 is generally provided to separate a multi-component fluid that generally includes various components or constituents of varying densities that are commingled or mixed together.
  • the separator 10 includes the buoy 14 that is of a selected density depending upon a selected constituent of the multi-constituent liquid.
  • the buoy 14 may be tuned or of any selected density, the following example relates to separation of whole blood to various components. Therefore, the buoy 14 will be discussed to include a selected density relative to whole blood separation. It will be understood, however, that the buoy 14 may be of any appropriate density depending upon the multi-component fluid being separated including, for example, the concentrating of bone marrow aspirate.
  • the buoy 14 may be formed of any appropriate material that may have a selected density.
  • the buoy 14 when the separator 10 is to separate blood, the buoy 14 generally has a density which is greater than that of red blood cells in a whole blood sample, but less than the plasma or non-red blood cell fraction of a whole blood sample.
  • the density of the buoy 14 may be between about 1.00 g/cc to about 1.12 g/cc or between about 1.02 g/cc and about 1.09 g/cc.
  • the buoy 14 may be formed as a composite or multi-piece construction, including a plurality of materials.
  • a first or outside portion 56 defines the upper or collection face 46 and the buoy edges 52 and is formed of the same material as the tube 12 .
  • the outside portion 56 defines a cup or void into which a plug or insert 58 is placed.
  • the insert 58 has a mass such that the density of the entire buoy 14 is within the selected range, for example, the range described above.
  • a high density polyethylene may be used, but the material and size of the insert 58 may be altered to produce the desired density of the buoy 14 .
  • the buoy 14 may be formed of a single suitable material that has a density in the selected range. Nevertheless, the buoy 14 formed unitarily or of a single material would still include the other portions described in conjunction with the buoy 14 .
  • the outside portion 56 of the buoy 14 also defines the outside circumference of the buoy 14 .
  • the outside circumference of the buoy 14 is very close to the internal circumference of the tube 12 . Due to the operation of the buoy 14 , however, described further herein, there is a slight gap between the outside of the buoy 14 and the inside of the tube 12 . Generally, this gap is between about 1 and about 10 thousandths of an inch around the entire circumference of the buoy 14 . Generally, it is desired that the distance between the outside circumference of the buoy 14 and the inside circumference of the tube 12 is great enough to allow a selected material or component to pass. For example, in whole blood the distance is selected so that red blood cells may pass through the gap without being lysed, damaged, or activated.
  • the plunger 16 includes a plunger front or collection face 60 and a plunger wall 62 that extends from the plunger front face 60 .
  • the plunger wall 62 extends relatively perpendicular to the plunger front face 60 and substantially parallel to the tube wall 42 .
  • Extending from the center of the plunger 16 is a sample collection projection 64 .
  • Extending from the top of the sample collection projection 64 is the first plunger port 22 .
  • the sample collection projection 64 includes a plunger sample collection bore 68 defined therethrough.
  • the plunger sample collection bore 68 terminates at a sample collection aperture 70 that is substantially in the center of the plunger front face 60 .
  • the plunger front face 60 also defines an inverse cone where the sample collection aperture 70 is the apex of the cone.
  • the plunger front face 60 defines a cone with an angle substantially similar or complimentary to the collection face 46 of the buoy 14 . In this way, the plunger front face 60 may mate substantially completely with the collection face 46 for reasons described more fully herein.
  • the plunger 16 also includes a back face 72 . Extending from the plunger front face 60 to the back face 72 is a bore 74 .
  • a check valve 76 is operably connected to the bore 74 .
  • the check valve 76 allows a liquid to move from the plunger front face 60 to the back face 72 while not allowing the liquid to move from the back face 72 to the plunger front face 60 . Therefore, the check valve 76 is substantially a one-way valve which allows a material to move in only one direction.
  • the check valve 76 may also operate automatically allowing flow in only one predetermined direction. Alternatively, the check valve 76 may be operated manually and include a portion extending from the check valve 76 requiring manipulation to stop or start a flow through the check valve 76 .
  • the plunger 16 may be made out of any appropriate material which does not interfere with the separation of the fractions of the fluid, such as whole blood.
  • the plunger 16 is made of a material that is flexible or at least partially deformable.
  • a flexible material allows the plunger 16 to have an external circumference defined by the plunger walls 62 that is substantially equal to the internal circumference of the tube 12 . Because of the deformability of the plunger 16 , however, the plunger 16 is still able to move within the tube 12 .
  • the plunger 16 is able to move through the tube 12 and also substantially wipe the interior of the tube wall 42 . This creates, generally, a moveable seal within the tube 12 .
  • substantially no material escapes the action of the separator 10 when the plunger 16 is plunged into the tube 12 . This also helps concentrate the portion of the sample desired to be collected, described more fully herein.
  • the cap 18 provides a structure to substantially close the tube 12 .
  • the cap 18 particularly includes a plate 78 that has an external circumference substantially equal to the external circumference of the tube 12 . Extending from the plate 78 and into the tube 12 is a flange 80 . The external circumference of the flange 80 is substantially equal to the internal circumference of the tube 12 . In this way, the cap 18 substantially closes the tube 12 . It will be understood the cap 18 may be in any form so long as the cap 18 substantially closes and/or seals the tube 12 when installed.
  • the depth gage port 19 is Formed through the center of the plate 78 .
  • the depth gage port 19 is also adapted to receive the sample collection projection 64 .
  • the first plunger port 22 extends above the plate 78 through the depth gage port 19 .
  • the circumference of the depth gage port 19 is substantially equal to the external circumference of the sample collection projection 64 such that a liquid seal is formed.
  • the plate 78 defines a sample face 84 that includes an interior side of the cap 18 .
  • the area between the sample face 84 of the cap 18 and the back face 72 of the plunger 16 define a plasma collection area 86 .
  • the plasma collection area 86 is exemplary called the plasma collection area, it will be understood that the plasma collection area 86 may also collect any appropriate fraction of the sample that is positioned within a separator 10 .
  • the plasma collection area 86 is merely an exemplary name and an example of what material may be collected in the area of the separator 10 .
  • the separator 10 may used to separate whole blood into various fractions, therefore, the plasma collection area 86 is used to collect plasma.
  • the plasma collection area 86 also allows a space for the check valve 76 to be installed.
  • a second bore 88 is formed in the plate 78 . Extending through the second bore 88 is the plasma collection valve 20 . In liquid communication with the plasma collection valve 20 is a plasma collection tube 92 .
  • the plasma collection tube 92 has a length such that the plasma collection tube 92 is able to extend from the plasma collection valve 20 to substantially the tube bottom 44 .
  • the plasma collection tube 92 is flexible enough such that it may be folded or compressed to fit within the plasma collection area 86 when the plunger 16 is substantially near the open end 12 a of the tube 12 .
  • the plasma collection tube 92 may also be connected to a hose barb 93 that includes a plasma collection bore 93 a .
  • the plasma collection bore 93 a is substantially level with the plunger back face 72 .
  • the plasma collection bore 93 a may be positioned below the plunger back face 72 but in fluid communication with the plasma collection tube 92 .
  • the outboard side of the plasma collection valve 20 may include external threads 94 to mate with internal threads of a plasma valve cap 96 . Therefore, the plasma collection valve 20 may be selectively opened and closed via the plasma valve cap 96 . It will be understood, however, that other appropriate means may be used to open and close the plasma collection valve 20 such as a clip or a plug. It will be understood that the plasma collection valve 20 , plasma collection tube 92 , plasma collection bore 23 a may be used to collect any appropriate material or fraction from the separator 10 .
  • vent bore 98 Also formed in the plate 78 is a vent bore 98 .
  • the vent bore 98 allows air to flow into the plasma collection area 86 as the plunger 16 is being plunged into the tube 12 .
  • the vent bore 98 may include a filter 100 such that liquid cannot escape from the tube 12 .
  • the filter 100 allows air to enter or escape from the plasma collection area 86 while maintaining the liquid seal of the tube 12 produced by the cap 18 .
  • the depth gage 24 is selectiveively attachable to the first plunger port 22 .
  • the female connector 26 interconnects the depth gage housing 28 to the first plunger port 22 .
  • Internal threads in the female connector 26 mate with an external thread 102 formed on the first plunger port 22 .
  • a snap connection rather than a threaded connection between the two may be used.
  • the depth gage housing 28 is formed to be substantially rigid. Suitable materials, when sized properly, include polycarbonate and CYRO MED2®. The material preferably is both rigid and does not substantially react with the sample. It is rigid enough to provide a mechanism to plunge the plunger 16 into the tube 12 .
  • the external circumference of the depth gage housing 28 is substantially equal to the circumference of the depth gage port 19 in the plate 78 . Therefore, as the plunger 16 is being plunged into the tube 12 with the depth gage 24 , no liquid material is allowed to escape around the depth gage housing 28 and through depth gage port 19 .
  • the depth gage rod 38 extends through the plunger sample collection bore 68 of the sample collection projection 64 and protrudes through the sample collection aperture 70 a predetermined length.
  • the depth gage rod 38 extends through the sample collection aperture 70 a length such that when an end 104 of the depth gage rod 38 meets the buoy 14 , the volume defined by the collection face 46 and the plunger front face 60 is between about 5% and about 30% of the total volume of the sample that the tube 12 holds.
  • the projection of the depth gage rod 38 allows for an easily reproducible collection amount and concentration over several trials.
  • the compression nut 36 locks the depth gage rod 38 in the predetermined position. Nevertheless, once the plunger 16 has been plunged to the desired depth in the tube 12 , the compression nut 36 may be loosened so that the depth gage rod 38 may be removed from the plunger 16 and the depth gage housing 28 without moving the plunger 16 . A syringe or other appropriate device may then be affixed to the external neck threads 34 of the depth gage 24 to extract the fraction or phase that is between the plunger front face 60 and the collection face 46 . As described further herein, the fraction or phase that is left between the plunger front face 60 and the collection face 46 may be the buffy coat of a whole blood sample. Nevertheless, it will be understood that the fraction between the plunger front face 60 and the collection face 46 may be any appropriate fraction of the sample that is disposed in the separator 10 .
  • the separator 10 may be provided alone or in a kit 200 , as illustrated in FIG. 4 .
  • the kit 200 may be placed in a tray 202 which is covered to provide a clean or sterile environment for the contents of the kit 200 .
  • the kit 200 may include at least a first separator 10 and a second separator 10 ′.
  • a first depth gage 24 and a second depth gage 24 ′ are also provided, one for each separator 10 , 10 ′.
  • the kit 200 also generally includes a first syringe 204 , including a needle, to draw a biological sample, such as blood from a patient.
  • the first syringe 204 may also be used to place the sample in the first separator 10 .
  • a second device or syringe 210 may be used to extract a first fraction of the sample, while a third device or syringe 212 may be used to extract a second fraction of the sample.
  • a tourniquet 214 and other medical supplies such as gauze 216 and tape 218 , may be provided to assist the practitioner. It will be understood the elements of the kit 200 are merely exemplary and other appropriate items or elements may be included.
  • a method using the separator 10 is illustrated according to various embodiments.
  • the following example relates specifically to the taking and separating of a sample of whole blood from a patient.
  • another appropriate biological material may be separated and concentrated using the separator 10 .
  • bone marrow may be separated and concentrated using the separator 10 .
  • the various fractions of the bone marrow are similar to the fractions of whole blood.
  • the bone marrow includes a fraction that includes substantially dense material and a second phase that is less dense and has other components suspended therein such as, for example, nucleated cells.
  • the bone marrow sample may be positioned in the separator 10 , similarly to the whole blood as described herein, and separated in a substantially similar manner as the whole blood.
  • the separator 10 can then be used to remove nucleated cells from the bone marrow sample (which may be referred to as buffy coat), whereas the separator 10 , as described herein, is used to remove the buffy coat from the whole blood which includes platelets and other appropriate materials (which may be referred to as platelet rich plasma (PRP)).
  • PRP platelet rich plasma
  • a mixture of whole blood and bone marrow may be positioned in the separator 10 for separation and concentration. Similar methods and steps will be used to separate the mixture of whole blood and bone marrow with a main difference being the material that is separated. It will also be understood that various centrifuge times or forces may be altered depending upon the exact material that is being separated with the separator 10 . It will also be understood that the separation of whole blood, bone marrow, or a mixture of whole blood and bone marrow are merely exemplary of the materials that may be separated using the separator 10 .
  • a sample of whole blood taken from a patient is placed in the tube 12 with an anticoagulant using the first syringe 204 or other appropriate delivery method.
  • the first syringe 204 may be connected to the first plunger port 22 .
  • the blood sample is provided to the tube 12 via the sample collection bore 68 and sample collection aperture 70 .
  • a cap 220 is then placed over the first plunger port 22 to substantially seal the tube 12 .
  • the separator 10 is placed in a centrifuge.
  • the second separator 10 ′ substantially identical to the first, is placed opposite the first separator 10 including the sample in a centrifuge.
  • the second separator 10 ′ may also include a second sample or may include a blank, such as water, so that the centrifuge is balanced.
  • the second separator 10 ′ balances the centrifuge by both weight and dynamics.
  • the separator 10 is then spun in the centrifuge in a range between about 1,000 and about 8,000 RPM. This produces a force between about 65 and about 4500 times greater than the force of normal gravity, as generally calculated in the art, on the separator 10 and the blood sample placed in the separator 10 . At this force, the more dense material in a whole blood sample is forced toward the bottom end 12 b of the tube 12 .
  • the dense material such as red blood cells or a red blood cell fraction 222 , collects on the tube bottom 44 . Because the buoy 14 has a density that is less than the red blood cell fraction 222 , it is forced in a direction toward the top end 12 a of the tube 12 in the centrifuge. Nevertheless, because the buoy 14 is denser than a plasma fraction 224 , the buoy 14 does not reach the top end 12 a of the tube 12 .
  • the forces also affect the tube wall 42 .
  • the forces compress the tube 12 linearly along axis A thereby bowing or flexing the tube wall 42 .
  • the bottom face 48 defining an inverse cone, helps the initial movement of the buoy 14 . Because the buoy 14 is not substantially flat along its bottom, it does not form a vacuum interaction with the tube bottom 44 . Therefore, the initial movement of the buoy 14 away from the tube bottom 44 is quicker than if the bottom of the buoy 14 was flat.
  • the red bloods cells of the red blood cell fraction 222 force the buoy 14 in the direction of the top end 12 a of the tube 12 because the buoy 14 is less dense than the red blood cell fraction 222 .
  • the whole blood sample, including the red blood cells is loaded above the buoy 14 , the red blood cells are able to move between the buoy 14 and the tube wall 42 because the circumference of the buoy 14 is less than the internal circumference of the tube 12 .
  • the buoy 14 stops at an interface of a plasma fraction 224 and the red blood cell fraction 222 because of the selected or tuned density of the buoy 14 .
  • the centrifuge process has been completed and the buoy 14 has moved to the interface of the red blood cell fraction 222 and plasma fraction 224 .
  • the tube wall 42 decompresses which helps support the buoy 14 at the interface position. It is also understood that applying an external pressure to the tube 12 via fingers or another apparatus may help stabilize the buoy 14 during the plunging procedure described herein.
  • a middle fraction 226 On or near collection face 46 is a middle fraction 226 , including a small, yet concentrated, amount of red blood cells, white blood cells, platelets, and a substantial portion of a buffy coat of the blood sample.
  • the plasma is also present near the collection face 46 at this point, the solid portions of the buffy coat are more compressed against the collection face 46 .
  • the position of the buoy 14 also helps in this matter. Because the buoy 14 is a single body it defines the interface of the plasma fraction 224 and the red blood cell fraction 222 . Also the density of the buoy 14 assures that it has not passed into the plasma fraction 224 . Therefore, the fractions remain separated after the centrifuge process.
  • the buoy 14 is tuned to the density of the red blood cell fraction 222 , it is not affected by variations in the density of the plasma fraction 224 and the buoy's 14 position is always at the interface of the red blood cell fraction 222 and the plasma fraction 224 .
  • the depth gage 24 is affixed to the first plunger port 22 of the sample collection projection 64 .
  • the plunger 16 is plunged into the tube 12 by pushing on the depth gage 24 .
  • the plasma fraction 224 formed and separated above the buoy 14 , is able to flow through the check valve 76 into the plasma collection area 86 . This displacement of the plasma fraction 224 allows the plunger 16 to be plunged into the tube 12 containing the blood sample.
  • the plunger 16 is plunged into the tube 12 until the point where the end 104 of the depth gage rod 38 reaches the buoy 14 .
  • the volume left in the collection face 46 is the middle fraction 226 and is determined by the depth gage 24 . It may be adjusted by selectively determining the amount that the depth gage rod 38 extends below the plunger front face 60 . By adjusting the depth gage 24 , the concentration of the middle fraction 226 can be adjusted depending upon the desires of the operator.
  • the plasma fraction 224 is held in the plasma collection area 86 for later withdrawal. Therefore, the use of the plunger 16 and the buoy 14 creates three distinct fractions that may be removed from the tube 12 after only one spin procedure.
  • the fractions include the red blood cell fraction 222 , held between the buoy 14 and the tube bottom 44 .
  • the middle or buffy coat fraction 226 is held between the plunger 16 and the buoy 14 .
  • the plasma fraction 224 is collected in the plasma collection area 86 .
  • the middle fraction 226 may be a platelet rich plasma (PRP) fraction and the plasma fraction 224 may be a platelet poor plasma (PPP) fraction.
  • PRP platelet rich plasma
  • PPP platelet poor plasma
  • the middle fraction 226 may be extracted from the tube 12 first, without commingling the other fractions, through the sample collection bore 68 .
  • the depth gage rod 38 may be removed from the depth gage housing 28 . This creates a sample collection cannula which includes the depth gage bore 30 , the sample collection bore 68 , and the sample collection aperture 70 .
  • the second syringe 210 may be affixed to the depth gage housing 28 via the external neck threads 34 .
  • the second syringe 210 may be substantially similar to the first syringe 204 .
  • the separator 10 may be agitated to re-suspend of the platelets and concentrated red blood cells in a portion of the plasma remaining in the collection face 46 . This allows for easier and more complete removal of the middle fraction 226 because it is suspended rather than compressed against the collection face 46 .
  • a vacuum is then created in the second syringe 210 by pulling back the plunger 16 to draw the middle fraction 226 into the second syringe 210 .
  • the plunger 16 moves toward the buoy 14 . This action is allowed because of the vent bore 98 formed in the cap 18 . Atmospheric air is transferred to the plasma collection area 86 through the vent bore 98 to allow the middle fraction 226 to be removed. This also allows the movement of the plunger 16 toward the buoy 14 . This action also allows the plunger 16 to “wipe” the collection face 46 . As the plunger front face 60 mates with the collection area 46 the middle fraction 226 is pushed into the sample collection aperture 70 . This ensures that substantially the entire middle fraction 226 collected in the collection area 46 is removed into the second syringe 210 . It can also increase the repeatability of the collection volumes.
  • the second syringe 210 does not protrude out the sample collection aperture 70 , it does not interfere with the collection of the middle fraction 226 .
  • the second syringe 210 is removed from the first plunger port 22 . Also the extraction of the middle fraction 226 leaves the plasma fraction 224 and the red blood cell fractions 222 separated in the tube 12 .
  • a third syringe 212 may be affixed to the plasma collection valve 20 .
  • the third syringe 212 is connected to the external threads 94 of the plasma collection valve 20 to ensure a liquid tight connection. It will be understood, however, that another connection mechanism such as a snap or compression engagement may be used to connect the third syringe 212 to the plasma collection valve 20 .
  • a vacuum is then created in the third syringe 212 to draw the plasma fraction 224 from the plasma collection area 86 through the plasma collection tube 92 .
  • the plasma collection tube 92 is connected to the hose barb 93 . Therefore, the plasma flows through the plasma collection bore 93 a through the hose barb 93 , and then through the plasma collection tube 92 .
  • the plasma collection tube 92 may alternatively simply rest on the plunger back face 72 to collect the plasma fraction 224 . In this way, the plasma fraction 224 may be removed from the blood separator 10 without commingling it with the red blood cell fraction 222 . After the plasma fraction 224 is removed, the separator 10 may be dismantled to remove the red blood cell fraction 222 . Alternatively, the separator 10 may be discarded in an appropriate manner while retaining the red blood cell fraction 222 .
  • the separator 10 allows for the collection of three of a whole blood sample's fractions with only one centrifugation spin.
  • the interaction of the buoy 14 and the plunger 16 allows a collection of at least 40% of the available buffy coat in the whole blood sample after a centrifuge processing time of about 5 minutes to about 15 minutes.
  • the complimentary geometry of the plunger front face 60 and the collection face 46 help increase the collection efficiency. Although only the cone geometry is discussed herein, it will be understood that various other geometries may be used with similar results.
  • the plunger front face 60 being flexible also helps ensure a complete mating with the collection face 46 . This, in turn, helps ensure that substantially the entire volume between the two is evacuated.
  • the process first begins with the suction withdrawal of the middle fraction 226 via the second syringe 210 , but is completed with a fluid force action of the middle fraction 226 as the plunger front face 60 mates with the collection face 46 . As the plunger front face 60 mates with the collection face 46 , the fluid force assists in removal of the selected fraction.
  • the plunger 16 also substantially wipes the tube wall 42 . Because the plunger 16 is formed of a flexible material it forms a seal with the tube wall 42 which is movable. Therefore, substantially no liquid is able to move between the plunger wall 62 and the tube wall 42 . Material is substantially only able to go past the plunger front face 60 via the check valve 76 .
  • the complimentary geometry also helps decrease the collection time of the middle fraction 226 . Therefore, entire time to prepare and remove the middle fraction 226 is generally about 5 to about 40 minutes. This efficiency is also assisted by the fact that the separator 10 allows for the removal of the middle fraction 226 without first removing the plasma fraction 224 , which includes the buffy coat, and re-spinning the plasma fraction 224 . Rather, one spin in the separator 10 with the whole blood sample allows for the separation of the buffy coat for easy extraction through the plunger 16 .
  • the separator 10 may be used to separate any appropriate multi-component material.
  • a bone marrow sample may be placed in the separator 10 to be centrifuged and separated using the separator 10 .
  • the bone marrow sample may include several fractions or components that are similar to whole blood fractions or may differ therefrom. Therefore, the buoy 14 may be altered to include a selected density that is dependent upon a density of a selected fraction of the bone marrow.
  • the bone marrow may include a selected fraction that has a different density than another fraction and the buoy 14 may be designed to move to an interface between the two fractions to allow for a physical separation thereof. Similar to the whole blood fraction, the plunger 16 may then be moved to near a collection face 46 of the buoy 14 .
  • the middle fraction 226 in the bone marrow sample may include a fraction of undifferentiated or stem cells.
  • the middle fraction 226 in a bone marrow sample may include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, or endothelial cells.
  • the middle fraction 226 is concentrated bone marrow aspirate.
  • mixtures of various fluids may be separated in the separator 10 .
  • a mixture of whole blood and bone marrow may be positioned in the separator 10 at a single time.
  • the buoy 14 may be tuned to move to an interface that will allow for easy removal of both the buffy coat, from the whole blood sample, and the undifferentiated cells, from the bone marrow sample.
  • the separator 10 may be used within any appropriate biological material or other material having multiple fractions or components therein. Simply, the buoy 14 may be tuned to the appropriate density and the plunger 16 may be used to cooperate with the buoy 14 to remove a selected fraction.
  • the buoy system 300 generally includes a first buoy or fraction separator member 302 and a second buoy member or fraction separator 304 .
  • the first buoy 302 and the second buoy 304 may be operably interconnected with a buoy system cylinder or member 306 .
  • the buoy system 300 may be placed in a tube, such as the tube 12 .
  • the tube 12 may be formed of any appropriate material, such as the Cryolite Med®2 as discussed above. Nevertheless, the buoy system 300 may be designed to fit in the tube 12 or may be formed to fit in any appropriate member that may be disposed within a selected centrifuging device.
  • buoy system 300 may be substantially matched to the size of the tube 12 is merely exemplary. As the buoy 14 may be sized to fit in any appropriate tube, the buoy system 300 may also be sized to fit in any appropriate tube. It will be further understood that the tube 12 may be any appropriate shape. The tube 12 need not only be cylindrical but may also be or include conical portions, polygonal portions, or any other appropriate shapes.
  • the first buoy 302 of the buoy system 300 may be generally similar in geometry to the buoy 14 . It will be understood that the first buoy member 302 may be formed in the appropriate manner including shape or size to achieve selected results. Nevertheless, the first buoy member 302 generally includes an exterior diameter that may be slightly smaller than the interior diameter of the tube 12 . Therefore, the first buoy member 302 may be able to move within the tube 12 during the centrifugal process. Also, as discussed above, the tube 12 may flex slightly during the centrifuging process, thus allowing the first buoy member 302 to include an exterior diameter substantially equivalent to the interior diameter of the tube 12 . As discussed further herein, during the centrifugation process, a portion of the fraction of a sample may pass between the exterior wall of the first buoy member 302 and the tube 12 .
  • the first buoy member 302 may generally include a density that is substantially equivalent to a first or selected fraction of the sample. If the sample to be separated includes whole blood and is desired to separate the red blood cells from the other portions of the sample, the first buoy member 302 may have a selected density that may be about 1.00 grams per cc (g/cc) to about 1.10 g/cc. It will be understood that the density of the first buoy member 302 may be any appropriate density, depending upon the fraction to be separated, and this range of densities is merely exemplary for separating red blood cells from a whole blood sample.
  • the first buoy member 302 includes a collection face or area 308 at a proximal or upper portion of the first buoy member 302 .
  • the collection face 308 generally defines a concave area of the first buoy member 302 and may have a selected angle of concavity.
  • the buoy assembly 300 defines a central axis D.
  • the collection face 308 defines a surface E that is formed at an angle ⁇ to the central axis D of the buoy system 300 .
  • the angle ⁇ may be any appropriate angle and may be about 0.5° to about 90°.
  • the angle ⁇ may, however, be between about 45° and 89.5°. Nevertheless, it will be understood that the angle ⁇ may be any appropriate angle to assist in collection of a selected fraction or portion of the sample by the first buoy member 302 .
  • a bottom or lower surface 310 of the first buoy member 302 may define a bottom face.
  • the bottom face 310 may also be formed at an angle D relative to the central axis D.
  • the bottom surface 310 defines a surface or plane F that may be formed at an angle ⁇ relative to the central axis D of the buoy system 300 .
  • the angle ⁇ may be any appropriate angle and may be about 90° to about 160°.
  • the angle ⁇ may be about 15°.
  • the bottom surface 310 defines an apex 312 that may first engage the bottom 12 d of the tube 12 , such that most or the majority of the bottom surface 310 does not engage the tube 12 .
  • the apex 312 allows for a free space or gap to be formed between the bottom face 310 of the first buoy member 302 and the bottom 12 b of the tube 12 .
  • the second buoy member 304 may include an outer diameter substantially equivalent to the outer diameter of the first buoy member 302 . Therefore, the second buoy 304 may move with the first buoy 302 , particularly if the second buoy 304 is interconnected with the first buoy 302 with the buoy central cylinder 306 . Nevertheless, the second buoy member 304 may be allowed to move substantially freely within the tube 12 during the centrifuging process.
  • the second buoy member 304 also includes an upper or superior surface 314 that defines a plane G that is formed at an angle relative to the central axis D of the buoy system 300 .
  • the angle ⁇ of the plane G relative to the central axis D of the buoy system 300 may be any appropriate angle.
  • the angle ⁇ may be about 90° to about 150°.
  • the angle ⁇ may assist in allowing a selected fraction or a portion of the sample to pass over the top surface 314 and past the second buoy member 304 during the centrifuging process.
  • the second buoy member 304 also define a bottom or inferior surface 316 that also defines a plane H that may be formed at an angle K relative to the central axis D of the buoy system 300 .
  • the angle K may be any appropriate angle, such as about 90° to about 150°. Nevertheless, the angle K may be substantially complimentary to the angle ⁇ of the collection face 308 of the first buoy member 302 . For example, if the angle ⁇ is about 80°, the angle K may be about 100°, such that substantially 180° or a straight line is formed when the first buoy member 302 engages the second buoy member 304 . This may be for any appropriate reason, such as extraction of a fraction that may be disposed near the collection face 308 of the first buoy member 302 . Nevertheless, the angle K may be any appropriate angle as the angle ⁇ .
  • the second buoy member 304 may be formed to include any appropriate density.
  • the second buoy member 304 may include a density that is less than the plasma fraction of a whole blood sample. It will be understood that the second buoy member 304 may include any appropriate density and a density that is less than the plasma fraction of a whole blood sample is merely exemplary. Nevertheless, if a whole blood sample is desired to be separated and the plasma sample is to be substantially separated from another fraction, the second buoy member 304 may include a density that is less than the plasma fraction of the whole blood sample. Therefore, the density of the second buoy member 304 may be about 0.01 g/cc to about 1.03 g/cc.
  • the buoy system 300 may be substantially positioned near an interface between the red blood cell fraction and the plasma fraction of a whole blood sample. Therefore, as discussed above, and further described herein, the platelet or buffy coat fraction of the whole blood sample may be substantially collected near or in the collection face 308 of the buoy system 300 .
  • the buoy post 306 may operably interconnect the first buoy member 302 and the second buoy member 304 .
  • the buoy post 306 may be any appropriate connection member.
  • the buoy post need not be a single cylindrical portion.
  • the buoy post 306 may include one or more members interconnecting the first buoy member 302 and the second buoy member 304 , such as around a perimeter thereof.
  • the buoy post 306 may include any appropriate shape or geometry.
  • the buoy system post 306 may be rigidly affixed to the first buoy member 302 and the second buoy member 304 , such that the first buoy member 302 may not move relative to the second buoy member 304 and vice versa.
  • the buoy post 306 may be slide ably connected to either or both the first buoy member 302 and the second buoy member 304 .
  • the buoy post 306 is generally fixedly connected to the first buoy member 302 and slide ably interconnected to the second buoy member 304 .
  • the buoy post 306 may include a catch portion or lip 320 that is able to engage a portion of the second buoy member 304 , such that a range of travel of the second buoy member 304 , relative to the first buoy member 302 is limited. Nevertheless, the range of travel of the second buoy member 304 toward the first buoy member 302 may be substantially unlimited until the second buoy member 304 engages the first buoy member 302 .
  • the buoy post 306 may also define a central cannula or bore 322 .
  • the post bore 322 may include a connection portion 324 substantially defined near an upper or a proximal end of the buoy post 306 . This may allow for interconnection of various components with the buoy post 306 , such that various components may be moved through the bore 322 from an exterior location.
  • the buoy post 306 may also define a port or cannula 326 that connects the post cannula 322 with the collection face 308 . Therefore, a substance may travel through the post cannula 322 and through the port 326 . Various substances may then be provided to or removed from the collection face 308 of the first buoy member 302 .
  • the buoy system 300 may be used to separate a selected multi component sample, such as a whole blood sample.
  • a method of using the buoy system 300 is illustrated and described.
  • FIGS. 7A-7D like reference numerals are used to indicate like portions of the tube 12 and the associated mechanisms described in FIGS. 1-3 . Therefore, it will be understood that the buoy system 300 may be used with the tube 12 or any other appropriate tube or container system or apparatus. Nevertheless, for simplicity, the description of a method of use of the buoy system 300 will be described in conjunction with the tube 12 .
  • the tube 12 may include the cap 18 that further defines a plasma valve or port 20 . Extending through the cap 18 and interconnecting with a first flexible tube or member 92 , the plasma port 20 may be used to extract a selected fraction of the sample that is positioned above the second buoy member 304 .
  • the tube 12 may also define a second port 21 , which may also be referred to as a platelet rich plasma (PRP) port.
  • a second flexible member such as a flexible tube 21 a , may interconnect the PRP port 21 and a connection portion 324 of a buoy cylinder 306 .
  • the first tube 92 may also be interconnected with a selected portion of the system, such as the top surface 314 of the second buoy member 304 .
  • a valve may be positioned and is operably interconnect the tube 92 with the upper surface 314 of the second buoy member 304 . Nevertheless, such a valve is not necessary and it may be provided merely for convenience.
  • buoy system 300 may be included in the tube 12 and used with the buoy system 300 . Nevertheless, once the buoy system 300 is interconnected, it may be positioned in the interior of the tube 12 and the syringe 204 used to place a sample into the tube 12 .
  • the sample may be expressed from the syringe 204 into the interior of the tube 12 and the sample may be any appropriate sample, such as a whole blood sample. Nevertheless, it will be understood, such as discussed above, various other samples may be used, such as bone marrow samples, a mixture of bone marrow and whole blood or non-biological fluids or materials. It will be understood that two buoys 302 and 304 may generally be near one another when the sample is positioned in the tube 12 , but are illustrated apart for clarity of the present discussion.
  • the sample may be placed in the tube 12 according to various embodiments.
  • an anticoagulant or other components may be mixed with the whole blood sample, if a whole blood sample is used, before the whole blood sample is positioned within the tube 12 .
  • an anticoagulant or other components may be mixed with a bone marrow aspirate sample or a sample of bone marrow aspirate and whole blood, if such samples are used before such sample is positioned within the tube 12 .
  • the syringe 204 is connected with the plunger port 22 extending from the cap 18 , although a plunger may not be used in various embodiments.
  • a cap may be positioned over the port 22 , such that the sample is not allowed to escape from the tube 12 .
  • the tube 12 including the sample and the buoy system 300 may be centrifuged.
  • substantially three fractions of the sample may be formed.
  • a first fraction 330 may be positioned between the bottom face 310 and the bottom of the tube 44 .
  • a middle fraction 332 may be positioned between the collection face 308 and the bottom surface 316 of the second buoy 304 .
  • a third fraction 334 may be positioned between the upper surface 314 and the cap 18 of the tube 12 .
  • the first fraction 330 , the middle fraction 332 , and the third fraction 334 are substantially physically separated with the buoy system 300 .
  • the tube 12 may flex slightly to allow for ease of movement of the buoy system 300 through the tube 12 and the sample.
  • the buoy system 300 during the centrifugation process, substantially creates the three fractions 330 , 332 , and 334 without the operation of an operator. Therefore, the formation of at least three fractions may be substantially simultaneous and automatic using the buoy system 300 .
  • the buoy system 300 substantially separates the fractions 330 , 332 , and 334 , such that they may be easily removed from the tube 12 .
  • a syringe or other instrument 340 may be used to extract the middle fraction 332 by interconnecting a cannula or bored tube 342 with the connection portion 324 of the buoy cylinder 306 .
  • a vacuum or upward force is produced within the extraction syringe 340 . This force draws the middle fraction 332 through the ports 326 of the buoy post 306 and through the buoy cannula 322 .
  • the middle fraction 332 may be extracted from the tube 12 without substantially commingling the middle fraction 332 with either the first fraction 330 or the third fraction 334 .
  • the middle fraction 332 is drawn in the direction of arrow M through the cannula 322 and into the extraction syringe 340 .
  • the second tube 21 a may also be used.
  • the extraction syringe 340 may be interconnected with the PRP port 21 that is interconnected with the connection portion 324 of the buoy cylinder 306 .
  • the buoy cylinder allows access to the middle fraction 332 (platelet rich portion) between the buoy portions.
  • the middle fraction 332 platelet rich portion or buffy coat of the sample
  • the PRP port 21 would allow for extraction of undifferentiated nucleated cells.
  • the PRP port 21 allows for extraction of the buffy coat.
  • the post 306 is not provided other portions may be provided to gain access to the middle fraction 332 .
  • a valve portion such as a puncture-able valve, may be provided in the second buoy 304 to be punctured with an object. In this way an extraction needle may puncture the valve to gain access to the middle fraction 332 .
  • the buoy system 300 may be able to form a plurality of fractions, such as the three fractions 330 , 332 , and 334 and at least the middle fraction 332 may be extracted without substantially commingling the various fractions.
  • the second buoy member 304 may move in the direction of arrow M toward the first buoy member 302 .
  • the collection face 308 of the first buoy member may include an angle ⁇ that is substantially complementary to the bottom face 316 of the second buoy member 304 . Therefore, if the second buoy member 304 is allowed to move along the buoy cylinder 306 , the bottom face 316 of the second buoy member 304 may be able to substantially mate with the collection face 308 of the first buoy member 302 .
  • the second buoy member 304 may be provided with a vent port or valve, such that the extraction of the middle fraction 332 from the collection face 308 may not be hindered by the buildup of undesirable forces. Nevertheless, if the second buoy member 304 may move, the interaction of the bottom face 316 of the second buoy member 304 may assist in substantially removing the entire middle fraction 332 from the tube 12 . As described above, the bottom face 60 of the plunger 16 may also serve a similar purpose when engaging the collection face 46 of the buoy 14 .
  • the second buoy member 304 may substantially mate with a portion of the first buoy member 302 .
  • the second buoy member 304 may substantially only mate with the first buoy member 302 if the second buoy member 304 is able to substantially move relative to the first buoy member 302 . Therefore, it will be understood that the second buoy member 304 need not necessarily mate with the first buoy member 302 and is merely exemplary of an operation of various embodiments.
  • the port 20 may be used in conjunction with a selected instrument, such as a plasma extraction syringe 212 to remove the plasma or the third fraction 334 from the tube 12 using the extraction tube 92 interconnected with the port 20 .
  • a selected instrument such as a plasma extraction syringe 212 to remove the plasma or the third fraction 334 from the tube 12 using the extraction tube 92 interconnected with the port 20 .
  • the tube 92 allows for extraction of the third fraction 334 from the tube 12 without commingling the third fraction 334 with the remaining first fraction 330 in the tube 12 . Therefore, similar to the separator and extraction system 10 , three fractions may be substantially formed within the tube 12 with the buoy system 300 and may be extracted without substantially commingling the various fractions.
  • the buoy system 300 may be removed from the tube 12 , such that the first fraction 330 may be removed from the tube 12 .
  • the first fraction 330 may be discarded with the tube 12 and the buoy system 300 as a disposable system.
  • the system may be substantially reusable, such that it can be sterilized and may be sterilized for various uses.
  • the description of the method of use of the buoy system 300 is exemplary of a method of using a system according to various other embodiments. It will be understood, however, that various specifics may be used from various embodiments to allow for the extraction of selected fractions.
  • the centrifugation process may be substantially a single step centrifugation process.
  • the buoy system 300 may allow for the formation of three fractions during a single centrifugation process. This centrifugation process may occur at any appropriate speed, such as about 1000 RPM to about 8000 RPM. This speed may produce a selected gravity that may be approximately 4500 times greater than the normal force of gravity. Nevertheless, these specifics are not necessary to the operation of the buoy system 300 according to various embodiments.
  • the buoy system 300 may be used to extract a plurality of fractions of a sample after only a single centrifuging process and without substantially commingling the various fractions of the sample.
  • the blood collection and separation system that includes the tube 12 may be filled with a multi-component fluid or solution, such as blood from a patient, is illustrated.
  • the tube 12 may include any appropriate separation system, such as the separation system 300 .
  • any appropriate method may be used to fill the tube 12 . For example, when a solution, including a plurality of components, is placed into the tube 12 it may be collected directly from a source.
  • a patient 350 may be provided.
  • the patient 350 may be provided for a selected procedure, such as generally an operative procedure or other procedure that requires an intravenous connection 352 , such as a butterfly needle, to be provided in the patient 350 .
  • the intravenous connection 352 generally provides a tube 354 extending therefrom.
  • the tube 354 may be used to withdraw fluids from the patient 350 or provide materials to the patient 350 , such as medicines or other selected components.
  • the intravenous connection 352 is generally provided for various procedures and may be used to fill the tube 12 .
  • the tube 354 may interconnect with the plunger port 22 or any appropriate portion of the tube 12 .
  • the port 22 may be used to connect with the tube 354 in a similar manner as it would connect with the syringe 204 , if the syringe 204 was provided. Nevertheless, it will be understood that the tube 354 may be provided directly to the tube 12 from the patient 350 . This may reduce the number of steps required to fill the tube 12 and reduce possible cross-contamination from the patient 350 with the various components. Moreover, making a connection directly with the patient 350 may make the withdrawal and collection of blood from the patient 350 more efficient.
  • a vacuum system 356 may be provided The vacuum system 356 may include a vacuum inducing portion or member 358 , such as a resilient bulb. The vacuum inducing member 358 may be interconnected with the tube 12 through a selected connecting portion 360 .
  • the vacuum connecting portion 360 may interconnect with an orifice 362 .
  • the orifice 362 may be interconnected or extend from the cap 18 or provided in any appropriate portion with the tube 12 .
  • a first one-way valve 364 may be provided along the connection portion 360 or near the orifice 362 .
  • the first one-way valve 364 provides that a flow of a fluid, such as a gas, may pass in a first direction but not in a second.
  • a second one-way valve 366 may also be provided downstream from the first one-way valve 364 . In this way, a vacuum may be created with the vacuum inducing member 358 , such that air is drawn out of the tube 12 and removed through the second one-way valve 366 in the direction of arrow V.
  • the air is generally withdrawn from the tube 12 without substantially allowing the air to flow back into the tube 12 .
  • a vacuum can be created within the tube 12 to assist with removing a selected volume of fluid, such as blood, from the patient 350 .
  • the tube 12 may be filled substantially directly from the patient 350 , the collection of the fluid, such as blood, may be provided substantially efficiently to the tube 12 .
  • the vacuum system 356 may be provided including the vacuum inducing member 358 .
  • Any appropriate vacuum creating device may be used, such as a mechanical pump or the like. Nevertheless, the tube 12 may be filled for use during a selected procedure.
  • the tube 12 may be used to separate a selected portion of the blood obtained from the patient 350 substantially intraoperatively. Therefore, the collection or separation of the various components may be substantially autologous and substantially intraoperatively. Moreover, obtaining the fluid directly from the patient 350 may increase the efficiency of the procedure and the efficiency of the intraoperative or the operative procedure.
  • the separator 10 may be used to separate any appropriate material.
  • the material may be separated for any purpose, such as a surgical procedure.
  • a selected fraction of a bone marrow aspirate or a bone marrow portion may be produced with the separator 10 according to various embodiments.
  • the selected fraction of the bone marrow aspirate may include various components, such as undifferentiated cells.
  • the various undifferentiated cells may be positioned in a selected scaffold or relative to a selected portion of a patient for providing a volume of the undifferentiated cells to the patient.
  • a selected portion of the patient may include bone, cartilage, connective tissue, or any other tissue.
  • a selected portion of the patient may include a defect in bone, cartilage, connective tissue and/or any other tissue. It will be understood that the method described according to FIG. 9 is merely exemplary of various embodiments that may be used to provide a selected fraction of a bone marrow aspirate or other material to a patient or selected position.
  • the selected portion may be placed on the scaffold in any appropriate manner, such as by spraying, dipping, infiltrating, or any appropriate method.
  • FIG. 9 A method of selecting or creating a selected fraction of a bone marrow aspirate in a selected scaffold according to a method 400 is illustrated in FIG. 9 .
  • the method 400 may start in block 402 in obtaining a bone marrow aspirate volume.
  • the bone marrow aspirate (BMA) may be obtained in any selected or generally known manner. For example, a selected region of bone, such as a portion near an operative procedure, may be used to obtain the bone marrow aspirate.
  • an accessing device such as a syringe and needle, may be used to access an intramedullary area of a selected bone. The BMA may then be withdrawn into the syringe for various procedures.
  • the BMA may be positioned in the separator 10 according to various embodiments in block 404 .
  • the BMA may be positioned in any appropriate separator, such as those described above including the separator 10 .
  • a selected fraction of the BMA may be separated from the BMA in block 406 .
  • BMA is a complex tissue comprised of cellular components (that contribute to bone growth) including red and white blood cells, their precursors and a connective tissue network termed the stroma.
  • Bone marrow stromal cells or mesenchymal stem cells have the potential to differentiate into a variety of identifiable cell types including osteoblasts, fibroblasts, endothelial cells, reticulocytes, adipocytes, myoblasts and marrow stroma.
  • the selected fraction of the BMA may include undifferentiated cells or any appropriate portion of the BMA.
  • the fractionation or separation of various fractions of the BMA may allow for a volume of BMA to be taken from a single location and the separation or concentration of the selected portion may be performed in the separator 10 .
  • obtaining a small volume of the selected portion from a plurality of locations may be used to obtain an appropriate volume of BMA or selected fraction of the BMA.
  • the separator 10 may allow for separating a selected volume from a single location from which the BMA is obtained. This may reduce the time of a procedure and increase the efficiency of obtaining the selected fraction of the BMA.
  • a volume of whole blood may be obtained in block 408 .
  • the volume of blood obtained in block 408 may then be positioned in the separator 10 , in block 410 .
  • the whole blood may be positioned in any appropriate separator, such as those described above or a separator to separate a selected fraction of the whole blood.
  • the whole blood may be separated into an appropriate fraction, such as a fraction including a platelet portion or buffy coat.
  • the whole blood may be separated into selected fractions in block 412 . It will be understood that the BMA and the whole blood volume may be obtained substantially simultaneously or consecutively in block 402 and 408 .
  • concentrated BMA such as the middle fraction 332 , 226 comprising nucleated cells in separator 10 has a concentration of nucleated cells that is at least 4 times the concentrate of nucleated cells in BMA.
  • the selected fractions of the BMA obtained in block 406 and whole blood obtained in block 412 may also be performed substantially sequentially or simultaneously.
  • the separator 10 including the volume of the BMA may be positioned in a separating device, such as a centrifuge, substantially opposite, so as to balance, the separator 10 including the volume of the whole blood. Therefore, a single separation, such as centrifuge procedure may be used to separate both the BMA and the whole blood into selected fractions. This again may increase the efficiency of the procedure to provide both a selected fraction of the BMA and a selected fraction of the whole blood substantially simultaneously.
  • the selected fractions of the BMA and the whole blood, provided in block 406 and 412 may be harvested in block 414 .
  • the selected fractions of the BMA and the whole blood may be harvested in block 414 for appropriate purposes, such as those described herein.
  • the separator 10 may be used to obtain the selected fractions of the BMA and the whole blood, through various procedures, such as those described above.
  • a plurality of separators 10 may be used to obtain a larger quantity of the selection fractions and such quality of selected fractions may be pooled together.
  • the BMA aspirate can be concentrated alone or in combination with whole blood.
  • whole blood may be added to the separator 10 , and the resulting buffy coat fraction (middle fraction 332 , 226 ) may not only contain the at least 4 times greater concentration of nucleated cells from bone marrow, and may include at least 5 times greater concentration of white blood cells from the whole blood and at least 8 times greater concentration in platelets from the whole blood.
  • circulating stem cells from whole blood may be concentrated with the mature white blood cells in the buffy coat.
  • the scaffold in block 416 may be any appropriate scaffold, such as synthetic bone substitutes or allergenic tissue.
  • a scaffold include, but are not limited to, bone, cartilage, bone substrates, ceramics, biopolymers, collagens, metal, and the like.
  • the scaffolds may be used for appropriate procedures, such as hard or soft tissue grafting, including uses in non-union or chronic wounds.
  • the undifferentiated cells of the BMA may allow for a substantial source of cells for use during a substantially natural healing after an operative procedure, for example, the natural healing of a patient may use the supplied undifferentiated cells.
  • the undifferentiated cells may be applied to a wound, a defect, a graft site, a bone, cartilage, connective tissue. and the like. Therefore, the scaffold may be positioned in a selected portion of the anatomy and the cells may be allowed to grow and differentiate into selected portions in the implanted position.
  • bone marrow contains hematopoietic and mesenchymal stems cells that are precursors for most of the cells found within the body.
  • the hematopoietic cells along with angiogeneic growth factors, such as those found in platelets, will promote angiogenesis.
  • Angiogenesis is a necessary stage in wound healing of most tissues and treatment of ischemia.
  • the mesenchymal stem cells are the cells responsible for the formation of bone, tendon, ligament, articular cartilage, muscle, fat, intervertebral discs, meniscus, skin, and any other structural tissue found in the body.
  • a concentration and delivery of these precursor cells will improve therapeutic uses over the native bone marrow.
  • the platelets of the whole blood may be positioned on or near the scaffold of block 418 .
  • the platelets of the whole blood fraction positioned in the scaffold of block 418 may assist the undifferentiated cells and the anatomy into which the scaffold is positioned to allow for a substantially efficient and complete healing.
  • the platelet rich fraction of the whole blood sample may include various healing and growth factors that may assist in providing an efficient and proper healing in the anatomy. Therefore, the undifferentiated cells of the BMA, or other selected fraction obtained from the separation of the BMA, and the selected fraction of the whole blood, obtained from the separator, may be used with the scaffold to provide a substantially efficient implant.
  • harvest block 414 may be combined with a growth factors which may include any of the well-known growth factors such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF- ⁇ ), Insulin-Like Growth Factor (IGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Bone Morphogenetic Proteins (BMPs), and vectors for gene therapy.
  • PDGF Platelet-Derived Growth Factor
  • TGF- ⁇ Transforming Growth Factor Beta
  • IGF Insulin-Like Growth Factor
  • FGF Fibroblast Growth Factor
  • EGF Epidermal Growth Factor
  • VEGF Vascular Endothelial Growth Factor
  • BMPs Bone Morphogenetic Proteins
  • harvest block 414 may be combined with cellular solutions, suspensions, and materials including osteoblasts, osteoprogenitor cells, chondroblasts, stem cells, or fibroblasts may also be used, as may solutions or suspensions containing other therapeutic agents such as antibiotics, analgesics, pharmaceutical agents, antithrombinolytics, or chemotherapeutic agents.
  • the buffy coat, platelet fraction, and/or undifferentiated cell fraction may be combined with an activator such as thrombin solutions and the like.
  • the middle fraction 332 , 226 may be used alone for cartilage repair.
  • the platelet rich fraction may be used to fill a cartilage defect with a fibrin matrix, or it may be mixed with other cell sources such as autologous chondrocytes, synovial cells, bone marrow cells, or to mix with the blood clot formed during microfracture.
  • the separator 10 or any appropriate separator, such as that described above, may allow for a substantially quick and efficient separation of the BMA and the whole blood into an appropriate fraction for use in the procedure.
  • Other examples include pooling whole blood and/or BMA from different sites of the anatomy or from different sources.
  • the concentrated bone marrow cells can also be included with a carrier to aide in delivery and to help maintain the cells' location after implantation.
  • carriers can include fibrin, concentrated fibrin, demineralized bone matrix, gelatin, collagen, porous calcium based ceramics, porous metal, synthetic fiber matrices, or resorbable matrices.
  • carriers can be made from other autogeneic, allogenic, and xenogeneic tissues.
  • the scaffold may be implanted in block 420 .
  • the scaffold may be implanted in any appropriate position in the block 420 for various procedures. It will be understood that the scaffold may be implanted for any appropriate procedure and may allow for positioning the selected portion of the BMA, such as undifferentiated cells, and the selected portion of the whole blood, such as platelets, relative to a selected portion of the anatomy.
  • the scaffold may allow for a bone ingrowth, such as allowed with the undifferentiated cells, to assist in healing of a selected portion of the anatomy.
  • concentrated bone marrow aspirate can be used in articular cartilage repair.
  • the middle fraction 332 , 226 can be added to a focal defect or to an osteoarthritic defect.
  • the defects can be in any joint that contains articular cartilage.
  • the middle fraction 332 , 226 can promote the formation of repair tissue.
  • these cells can be added to a microfracture technique in order to increase the mesenchymal cells present in the defect and increase the amount and quality of repair tissue that forms.
  • the middle fraction 332 , 226 can be delivered in one of the carriers listed above.
  • the middle fraction 332 , 226 in an autologous fibrin or concentrated fibrin is activated with an activating solution so that it forms a 3-D gel in situ and holds the middle fraction 332 , 226 within the cartilage defect.
  • the concentrated bone marrow can also be used in meniscus repair.
  • the concentrated bone marrow can be used to fill a tear with the meniscus, or in can be used to soak a graft used to replace the meniscus after a full or partial meniscectomy.
  • concentrated bone marrow aspirate used in combination with platelet rich plasma can also be used for repair of meniscus.
  • concentrated bone marrow aspirate can be used to repair bone.
  • the middle fraction 332 , 226 can used alone, or mixed with an appropriate carrier such as demineralized bone matrix, calcium based ceramics, fibrin, or concentrated fibrin.
  • an appropriate carrier such as demineralized bone matrix, calcium based ceramics, fibrin, or concentrated fibrin.
  • the defects in bone could be found in long bones, cranium, sternum, and spine.
  • concentrated bone marrow aspirate would be to deliver the undifferentiated cells to a freeze dried demineralized bone product (such as the Bonus DBM product from Biomet Biologics) under vacuum.
  • the concentrated bone marrow can infiltrate the graft, and the plasma in the bone marrow may hydrate the bone matrix and create an injectable carrier.
  • the undifferentiated cells may have differentiating growth factors included within the demineralized bone to stimulate cartilage and bone formation.
  • the concentrated bone marrow can be delivered to the patient with a growth factor that will induce proliferation, chemotaxis, and/or morphogeneis.
  • growth factors include PDGF, TGF-b, IGF, VEGF, EGF, CTGF, FGF, and any of the BMPs.

Abstract

An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation-in-part of U.S. patent application Ser. No. 10/932,882, filed on Sep. 02, 2004, entitled “APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS”, which is a continuation-in-part of U.S. patent application Ser. No. 10/445,381, filed on May 23, 2003, entitled “APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS” that claimed the benefit of U.S. Provisional Application No. 60/383,013, filed on May 24, 2002. The disclosures of the above applications are incorporated herein by reference.
  • FIELD
  • The present teachings relate to a multiple component fluid and a concentrator/separator and, more particularly, relates to a container operable with a centrifuge to separate and/or concentrate various biological components.
  • BACKGROUND
  • Various fluids, such as whole blood or various other biological fluids, may be separated into their constituent parts, also referred to as fractions or phases. For example, whole blood samples may include a plurality of constituents that may be separated by density in a device such as a centrifuge. The whole blood sample may be placed in a test tube, or other similar device, which is then spun in a centrifuge. In the centrifuge the whole blood is separated into different fractions depending upon the density of that fraction. The centrifugal force separates the blood or other sample into different fractions. In addition, various elements may be added to the test tube to create more than two fractions. In particular, commonly used gels may be used to divide the whole blood into a plurality of different fractions which may include fractions such as platelets, red blood cells, and plasma. Various other biological fluids may be separated as well. For example, nucleated cells may be separated and extracted from bone marrow or adipose tissue sample.
  • Many of these systems, however, do not provide a simple or efficient method to extract any more than one fraction and, especially, a fraction other than the top fraction. The top fraction of whole blood is plasma, or other blood constituents suspended in plasma. Thus, to extract other fractions the plasma fraction must either be removed for further extracting procedures or spun again to obtain the constituents suspended in this plasma. It is difficult to pierce the top fraction without commingling the sample. Accordingly, obtaining the other fractions is difficult with commonly known systems.
  • Other systems have attempted to alleviate this problem by providing a float or other device that is disposed within the sample at the interfaces of the different fractions during the centrifuge process. Nevertheless, these systems still do not allow a simple way to remove the different fractions without remixing the sample fractions. In addition, many of the systems do not allow an easy and reproducible method to remove the desired sample fraction.
  • Therefore, it is desired to provide a device to allow for the easy and reproducible removal of a particular fraction which does not happen to be the top fraction of a sample. It is desired to remove the required sample without mixing the different fractions during the extraction process. In addition, it is desired to provide a device which allows for a consistent extraction which includes known volumes or concentration of the fraction elements. Moreover, it is desired to separate and concentrate a selected fraction with one centrifugation step.
  • SUMMARY
  • The present teachings provide an apparatus that separates and concentrates a selected fraction or component of a fluid, such as a biological fluid. For example, undifferentiated cells, such as mesenchymal stem cells, platelet fraction, buffy coat, or white blood cell fraction can be separated from bone reaming material, whole blood, bone marrow aspirate, and other materials. In various embodiments, the apparatus, when used with a centrifuge, is generally able to create at least two fractions. The present teachings also provide for a new method of creating at least three fractions extracting a third fraction from a sample such as, for example, a buffy coat fraction.
  • In various embodiments, the apparatus includes a container to be placed in a centrifuge after being filled with a sample and the container includes a buoy or fraction separator having a selected density that may be less than one fraction but greater than a second fraction, that is disposed therein. In various embodiments, a second buoy may be placed in the container with the first. The extraction system is connected to the buoy system or to the collection chamber such that the fraction in the container can be collected and drawn outside of the chamber. During the centrifuge processing, the buoy is forced away from a bottom of the container as the denser fraction collects at the bottom of the container. The buoy is generally able to physically separate the denser fraction from another fraction of the sample. In various embodiments, the fractions can be withdrawn using an extraction system.
  • According to various embodiments, in addition to providing a first buoy and/or a second buoy, a buoy system may be provided. Generally, the buoy system may separate the sample into at least three fractions. The fractions may be separated and extracted from the container without substantially commingling the various fractions. Generally, a first buoy and a second buoy operate together to separate the sample into the various fractions and a syringe or tube may then be interconnected with a portion of the buoy system to extract the selected fractions. For example, a first buoy may be tuned to a density less than the density of a red blood cell fraction of a whole blood sample, bone marrow aspirate sample, or combinations thereof, and a second buoy may be tuned to a density less than the density of a buffy coat fraction.
  • According to various embodiments, a method of forming an enriched scaffold for application relative to an anatomy is provided. The method may include obtaining a volume of a first whole material and obtaining a volume of a second whole material. A first fraction of the first whole material and a second fraction of the second whole material may be formed. At least one of the first fraction or the second fraction may be applied to the scaffold and at least one fraction for application relative to an anatomy is provided. The method may include obtaining a volume of heterogeneous whole material and separating the material into the desired fraction(s). At least one of the fractions may be applied to the scaffold.
  • According to various embodiments, a method of withdrawing a material directly from a patient and collecting a selected fraction of the material in a container is provided. The method may include forming an access to port to the patient. A pressure differential in a collection container may be formed relative to the patient. A connection may be made between the patient and the collection container via the port. The collection container may be filled with the material and then the material may be separated to form the selected fraction.
  • According to various embodiments, a method for concentrating bone aspirate can include obtaining a volume of bone marrow aspirate from a mammal and loading the volume bone marrow aspirate into a separator, the separator operable to separate the aspirate into three of more fractions. The method also includes centrifuging the separator to create a fraction that is a concentrated bone marrow aspirate and extracting and removing the fraction from the separator.
  • According to various embodiments, a method for concentrating bone marrow aspirate and blood includes collecting bone marrow aspirate and blood from a patient then loading the bone marrow aspirate and blood into a separator that can separate the aspirate and the blood into three or more fractions. The method includes centrifuging the separator containing the bone marrow aspirate and the blood creating a fraction that has a concentrated bone marrow aspirate and a concentrated blood. In various embodiments, such a concentration may be referred to as a buffy coat. The method also include withdrawing the fraction comprising the concentrate or buffy coat.
  • According to various embodiments, a method for treating a defect in a mammal using a concentrated bone marrow aspirate includes drawing bone marrow aspirate from the mammal and loading the bone marrow aspirate into a separator that can separate the bone marrow aspirate into three or more fractions. The method includes centrifuging the separator separating the bone marrow aspirate into fractions and one fraction is concentrated bone marrow aspirate. The method also can include the concentrated bone marrow aspirate and applying the bone marrow aspirate to a site of a defect in the mammal.
  • According to various embodiments, a method for treating a defect in a patient includes drawing bone marrow aspirate and whole blood from the patient then adding anticoagulants to the bone marrow aspirate and the blood. The method includes the loading of the bone marrow aspirate and the blood into a separator that can separate the bone marrow aspirate and blood into three or more fractions. The method also includes centrifuging the separator then withdrawing a fraction comprising at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells, then applying the fraction to the site of the defect in the patient.
  • According to various embodiments, a method of treating a patient with a combination of concentrated bone marrow aspirate and buffy coat is provided. The method includes obtaining blood and bone marrow aspirate from the patient, forming a buffy coat fraction of the whole blood and forming a concentrated bone marrow aspirate fraction, and applying at least one of the buffy coat or concentrated bone marrow aspirates to the patient.
  • Further areas of applicability of the present teachings will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating various embodiment of the teachings, are intended for purposes of illustration only and are not intended to limit the scope of the teachings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The present teachings will become more fully understood from the detailed description and the accompanying drawings, wherein:
  • FIG. 1 is a plan view of a separator including a depth gage affixed to a plunger in a tube according to various embodiments of the present teachings;
  • FIG. 2 is a cross-section view taken along line 2-2 of FIG. 1;
  • FIG. 3 is an exploded of the separator apparatus according to various embodiments;
  • FIG. 4 is a kit including the separator according to an embodiment of the present teachings;
  • FIG. 5A is a plan view of the separator, according to various embodiments, being filled;
  • FIG. 5B is a plan view of a blood sample in the separator after the centrifuge process;
  • FIG. 5C is a plan view of the plunger plunged into the tube with the depth gage to further separate the blood sample;
  • FIG. 5D is a plan view of the buffy coat and the plasma fractions being extracted from the separator according to various embodiments;
  • FIG. 6A is a side plan view of a buoy system according to various embodiments;
  • FIG. 6B is a cross-sectional view of the buoy system of FIG. 6 a;
  • FIG. 7A is a plan view of a separator, according to various embodiments, being filled;
  • FIG. 7B is a plan view of a separator, according to various embodiments, after a centrifugation process;
  • FIG. 7C is a plan view of a separator system, according to various embodiments, being used to extract a selected fraction after the centrifugation process;
  • FIG. 7D is a plan view of a second fraction being extracted from the separator according to various embodiments;
  • FIG. 8 is a schematic view illustrating an assisted blood withdrawal device according to various embodiments; and
  • FIG. 9 is a block diagram illustrating a method for applying selected fractions of a fluid.
  • DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS
  • The following description of various embodiments is merely exemplary in nature and is in no way intended to limit the teachings, its application, or uses. Although the following description exemplary refers to a bone reaming material, whole blood and/or bone marrow aspirate separation, it will be understood that the present teachings may be used to separate and concentrate any appropriate material. It will be further understood that many multi-component materials containing particles may be separated. The components or fractions are generally intermingled in the whole sample but may be separated with a centrifuge device that causes increased local gravity or gravitational forces.
  • With reference to FIGS. 1-3, according to various embodiments, a separator 10, also referred to as a concentrator, is illustrated. The separator 10 generally includes a tube or container 12 that is adapted to hold a fluid sample, such as an anti-coagulated whole blood sample, for further processing. It will be understood that the tube 12 may hold other solutions including constituents of more than one density, such as bone marrow or a mixture of whole blood and bone marrow. The tube 12 includes a top or open end 12 a, which is closeable, and a bottom or closed end 12 b. The bottom 12 b may also be selectively closeable.
  • Disposed within the tube 12 is a first piston or buoy 14 that is able to move along a central axis A of the tube 12. The buoy 14 is generally nearer the bottom end 12 b of the tube 12 rather than the open end 12 a. The buoy 14 is able to move along a central axis A of tube 12. Also disposed within the tube 12 is a second piston or plunger 16. The plunger 16 is also able to move within the tube 12 generally between a position closer to the open end 12 a to a position closer to the closed end 12 b of the tube 12. A cap 18 substantially mates with the open end 12 a of the tube 12 to close the tube 12 save for ports formed in the cap 18. Extending from the cap 18 is a plasma valve or port 20 that communicates with an area, described further herein, within the tube 12 defined between the plunger 16 and the cap 18. It will be understood that the plasma port 20 is merely exemplary in nature and simply allows for removal of a selected fraction of a sample such as, for example, plasma from whole blood.
  • The cap 18 also includes a depth gage port 19. Extending from the plunger 16 and through the depth gage port 19 is a first plunger port 22. A depth guide or gage 24 includes a female connector 26 adapted to connect with the first plunger port 22. The depth gage 24 also includes a depth gage housing or cannula 28. The depth gage housing 28 defines a depth gage bore 30. Incorporated in the depth gage housing 28 and extending distal from the end mating with the plunger 16 is a neck 32. The neck 32 includes external neck threads 34. The external neck threads 34 are adapted to engage appropriate internal threads of a mating member.
  • The mating member may include a compression nut 36 that mates with the external neck threads 34 to lock a depth gage rod 38 in a predetermined position. A split bushing 39 is also provided to substantially seal the depth gage housing 28 when the depth gage rod 38 is locked in place. The depth gage rod 38 extends through the depth gage housing 28 and terminates at a rod handle 40. The rod handle 40 may be a form easily manipulated by a human operator. The depth gage rod 38 extends coaxially with axis A of the tube 12. The depth gage rod 38 extends through the plunger 16 a predetermined distance and may be locked at that distance with the compression nut 36.
  • Although the tube 12 is described herein as a cylinder, it will be understood that other shapes may be used, such as polygons. The internal portions, such as the cap 18, buoy 14, and plunger 16, would also include this alternate shape. Preferably the tube 12 is formed of a thermal plastic material which is flexible under the forces required to separate blood. The tube 12 may be made of a material that includes the properties of both lipid and alcohol resistance. These properties helps increase the separation speed and decrease the amount of material which may cling to the tube wall 42. For example, Cyrolite MED2® produced by Cyro Industries of Rockaway, N.J., may be used to produce the tube 12.
  • The tube 12 has a tube wall 42 with a thickness of between about 0.01 millimeters and about 30.0 millimeters, although the tube wall 42 may be any appropriate thickness. The thickness of the tube wall 42 allows the tube wall 42 to flex during the centrifuge process yet be rigid enough for further processing of a blood sample disposed in the tube 12. The tube 12 is closed at the bottom end 12 b with a tube bottom 44 formed of the same material as the tube wall 42 and is formed integrally therewith. Generally, the tube bottom 44 has a thickness which is substantially rigid under the forces required to separate the sample such that it does not flex.
  • The buoy 14 includes an upper or collection face 46 that defines an inverse cone or concave surface. Generally, the cone has an angle of between about 0.5° to about 45°, and may be about 0.5° to about 90° from a vertical axis, wherein the apex of the cone is within the buoy 14. The collection face 46 forms a depression in the buoy 14 which collects and concentrates material during the separation process. Additionally, the buoy 14 has a bottom face 48 that defines an inverse cone, dome, or covered surface. The buoy bottom face 48 includes an apex 50 that engages the tube bottom 44 before a buoy edge 52 engages the tube bottom 44. The buoy 14 includes a material that is a substantially rigid such that the buoy edges 52 never meet the tube bottom 44. Therefore, there is a gap or free space 54 formed between the buoy edges 52 and the tube bottom 44 along the perimeter of the buoy 14.
  • The separator 10 is generally provided to separate a multi-component fluid that generally includes various components or constituents of varying densities that are commingled or mixed together. The separator 10 includes the buoy 14 that is of a selected density depending upon a selected constituent of the multi-constituent liquid. Although the buoy 14 may be tuned or of any selected density, the following example relates to separation of whole blood to various components. Therefore, the buoy 14 will be discussed to include a selected density relative to whole blood separation. It will be understood, however, that the buoy 14 may be of any appropriate density depending upon the multi-component fluid being separated including, for example, the concentrating of bone marrow aspirate.
  • The buoy 14 may be formed of any appropriate material that may have a selected density. For example, when the separator 10 is to separate blood, the buoy 14 generally has a density which is greater than that of red blood cells in a whole blood sample, but less than the plasma or non-red blood cell fraction of a whole blood sample. For blood, the density of the buoy 14 may be between about 1.00 g/cc to about 1.12 g/cc or between about 1.02 g/cc and about 1.09 g/cc.
  • To achieve the selected density, the buoy 14 may be formed as a composite or multi-piece construction, including a plurality of materials. Particularly, a first or outside portion 56 defines the upper or collection face 46 and the buoy edges 52 and is formed of the same material as the tube 12. The outside portion 56 defines a cup or void into which a plug or insert 58 is placed. The insert 58 has a mass such that the density of the entire buoy 14 is within the selected range, for example, the range described above. Generally, a high density polyethylene may be used, but the material and size of the insert 58 may be altered to produce the desired density of the buoy 14. Alternatively, the buoy 14 may be formed of a single suitable material that has a density in the selected range. Nevertheless, the buoy 14 formed unitarily or of a single material would still include the other portions described in conjunction with the buoy 14.
  • The outside portion 56 of the buoy 14 also defines the outside circumference of the buoy 14. The outside circumference of the buoy 14 is very close to the internal circumference of the tube 12. Due to the operation of the buoy 14, however, described further herein, there is a slight gap between the outside of the buoy 14 and the inside of the tube 12. Generally, this gap is between about 1 and about 10 thousandths of an inch around the entire circumference of the buoy 14. Generally, it is desired that the distance between the outside circumference of the buoy 14 and the inside circumference of the tube 12 is great enough to allow a selected material or component to pass. For example, in whole blood the distance is selected so that red blood cells may pass through the gap without being lysed, damaged, or activated.
  • The plunger 16 includes a plunger front or collection face 60 and a plunger wall 62 that extends from the plunger front face 60. The plunger wall 62 extends relatively perpendicular to the plunger front face 60 and substantially parallel to the tube wall 42. Extending from the center of the plunger 16 is a sample collection projection 64. Extending from the top of the sample collection projection 64 is the first plunger port 22. The sample collection projection 64 includes a plunger sample collection bore 68 defined therethrough. The plunger sample collection bore 68 terminates at a sample collection aperture 70 that is substantially in the center of the plunger front face 60. The plunger front face 60 also defines an inverse cone where the sample collection aperture 70 is the apex of the cone. The plunger front face 60 defines a cone with an angle substantially similar or complimentary to the collection face 46 of the buoy 14. In this way, the plunger front face 60 may mate substantially completely with the collection face 46 for reasons described more fully herein.
  • The plunger 16 also includes a back face 72. Extending from the plunger front face 60 to the back face 72 is a bore 74. A check valve 76 is operably connected to the bore 74. The check valve 76 allows a liquid to move from the plunger front face 60 to the back face 72 while not allowing the liquid to move from the back face 72 to the plunger front face 60. Therefore, the check valve 76 is substantially a one-way valve which allows a material to move in only one direction. The check valve 76 may also operate automatically allowing flow in only one predetermined direction. Alternatively, the check valve 76 may be operated manually and include a portion extending from the check valve 76 requiring manipulation to stop or start a flow through the check valve 76.
  • The plunger 16 may be made out of any appropriate material which does not interfere with the separation of the fractions of the fluid, such as whole blood. The plunger 16, however, is made of a material that is flexible or at least partially deformable. A flexible material allows the plunger 16 to have an external circumference defined by the plunger walls 62 that is substantially equal to the internal circumference of the tube 12. Because of the deformability of the plunger 16, however, the plunger 16 is still able to move within the tube 12. The plunger 16 is able to move through the tube 12 and also substantially wipe the interior of the tube wall 42. This creates, generally, a moveable seal within the tube 12. Thus, substantially no material escapes the action of the separator 10 when the plunger 16 is plunged into the tube 12. This also helps concentrate the portion of the sample desired to be collected, described more fully herein.
  • The cap 18 provides a structure to substantially close the tube 12. The cap 18 particularly includes a plate 78 that has an external circumference substantially equal to the external circumference of the tube 12. Extending from the plate 78 and into the tube 12 is a flange 80. The external circumference of the flange 80 is substantially equal to the internal circumference of the tube 12. In this way, the cap 18 substantially closes the tube 12. It will be understood the cap 18 may be in any form so long as the cap 18 substantially closes and/or seals the tube 12 when installed.
  • Formed through the center of the plate 78 is the depth gage port 19. The depth gage port 19 is also adapted to receive the sample collection projection 64. The first plunger port 22 extends above the plate 78 through the depth gage port 19. The circumference of the depth gage port 19 is substantially equal to the external circumference of the sample collection projection 64 such that a liquid seal is formed. The plate 78 defines a sample face 84 that includes an interior side of the cap 18. The area between the sample face 84 of the cap 18 and the back face 72 of the plunger 16 define a plasma collection area 86. Although the plasma collection area 86 is exemplary called the plasma collection area, it will be understood that the plasma collection area 86 may also collect any appropriate fraction of the sample that is positioned within a separator 10. The plasma collection area 86 is merely an exemplary name and an example of what material may be collected in the area of the separator 10. As discussed herein, the separator 10 may used to separate whole blood into various fractions, therefore, the plasma collection area 86 is used to collect plasma. The plasma collection area 86 also allows a space for the check valve 76 to be installed.
  • A second bore 88 is formed in the plate 78. Extending through the second bore 88 is the plasma collection valve 20. In liquid communication with the plasma collection valve 20 is a plasma collection tube 92. The plasma collection tube 92 has a length such that the plasma collection tube 92 is able to extend from the plasma collection valve 20 to substantially the tube bottom 44. The plasma collection tube 92, however, is flexible enough such that it may be folded or compressed to fit within the plasma collection area 86 when the plunger 16 is substantially near the open end 12 a of the tube 12. The plasma collection tube 92 may also be connected to a hose barb 93 that includes a plasma collection bore 93 a. The plasma collection bore 93 a is substantially level with the plunger back face 72. Alternatively, the plasma collection bore 93 a may be positioned below the plunger back face 72 but in fluid communication with the plasma collection tube 92.
  • The outboard side of the plasma collection valve 20 may include external threads 94 to mate with internal threads of a plasma valve cap 96. Therefore, the plasma collection valve 20 may be selectively opened and closed via the plasma valve cap 96. It will be understood, however, that other appropriate means may be used to open and close the plasma collection valve 20 such as a clip or a plug. It will be understood that the plasma collection valve 20, plasma collection tube 92, plasma collection bore 23 a may be used to collect any appropriate material or fraction from the separator 10.
  • Also formed in the plate 78 is a vent bore 98. The vent bore 98 allows air to flow into the plasma collection area 86 as the plunger 16 is being plunged into the tube 12. The vent bore 98 may include a filter 100 such that liquid cannot escape from the tube 12. The filter 100 allows air to enter or escape from the plasma collection area 86 while maintaining the liquid seal of the tube 12 produced by the cap 18.
  • Selectively attachable to the first plunger port 22 is the depth gage 24. The female connector 26 interconnects the depth gage housing 28 to the first plunger port 22. Internal threads in the female connector 26 mate with an external thread 102 formed on the first plunger port 22. It will be understood, however, that other engagement mechanisms between the depth gage 24 and the plunger 16 may be used. For example, a snap connection rather than a threaded connection between the two may be used.
  • The depth gage housing 28 is formed to be substantially rigid. Suitable materials, when sized properly, include polycarbonate and CYRO MED2®. The material preferably is both rigid and does not substantially react with the sample. It is rigid enough to provide a mechanism to plunge the plunger 16 into the tube 12. In addition, the external circumference of the depth gage housing 28 is substantially equal to the circumference of the depth gage port 19 in the plate 78. Therefore, as the plunger 16 is being plunged into the tube 12 with the depth gage 24, no liquid material is allowed to escape around the depth gage housing 28 and through depth gage port 19.
  • Formed within the depth gage housing 28 is the bore 30 which receives the depth gage rod 38. The depth gage rod 38 extends through the plunger sample collection bore 68 of the sample collection projection 64 and protrudes through the sample collection aperture 70 a predetermined length. The depth gage rod 38 extends through the sample collection aperture 70 a length such that when an end 104 of the depth gage rod 38 meets the buoy 14, the volume defined by the collection face 46 and the plunger front face 60 is between about 5% and about 30% of the total volume of the sample that the tube 12 holds. The projection of the depth gage rod 38 allows for an easily reproducible collection amount and concentration over several trials.
  • The compression nut 36 locks the depth gage rod 38 in the predetermined position. Nevertheless, once the plunger 16 has been plunged to the desired depth in the tube 12, the compression nut 36 may be loosened so that the depth gage rod 38 may be removed from the plunger 16 and the depth gage housing 28 without moving the plunger 16. A syringe or other appropriate device may then be affixed to the external neck threads 34 of the depth gage 24 to extract the fraction or phase that is between the plunger front face 60 and the collection face 46. As described further herein, the fraction or phase that is left between the plunger front face 60 and the collection face 46 may be the buffy coat of a whole blood sample. Nevertheless, it will be understood that the fraction between the plunger front face 60 and the collection face 46 may be any appropriate fraction of the sample that is disposed in the separator 10.
  • The separator 10 may be provided alone or in a kit 200, as illustrated in FIG. 4. The kit 200 may be placed in a tray 202 which is covered to provide a clean or sterile environment for the contents of the kit 200. The kit 200 may include at least a first separator 10 and a second separator 10′. A first depth gage 24 and a second depth gage 24′ are also provided, one for each separator 10, 10′. The kit 200 also generally includes a first syringe 204, including a needle, to draw a biological sample, such as blood from a patient. The first syringe 204 may also be used to place the sample in the first separator 10. After centrifuging the sample a second device or syringe 210 may be used to extract a first fraction of the sample, while a third device or syringe 212 may be used to extract a second fraction of the sample. Also, a tourniquet 214 and other medical supplies, such as gauze 216 and tape 218, may be provided to assist the practitioner. It will be understood the elements of the kit 200 are merely exemplary and other appropriate items or elements may be included.
  • With reference to FIGS. 5A-5D, a method using the separator 10 is illustrated according to various embodiments. The following example relates specifically to the taking and separating of a sample of whole blood from a patient. Nevertheless, it will be understood that another appropriate biological material may be separated and concentrated using the separator 10. For example, bone marrow may be separated and concentrated using the separator 10. The various fractions of the bone marrow are similar to the fractions of whole blood. Generally, the bone marrow includes a fraction that includes substantially dense material and a second phase that is less dense and has other components suspended therein such as, for example, nucleated cells. The bone marrow sample may be positioned in the separator 10, similarly to the whole blood as described herein, and separated in a substantially similar manner as the whole blood. The separator 10 can then be used to remove nucleated cells from the bone marrow sample (which may be referred to as buffy coat), whereas the separator 10, as described herein, is used to remove the buffy coat from the whole blood which includes platelets and other appropriate materials (which may be referred to as platelet rich plasma (PRP)).
  • A mixture of whole blood and bone marrow may be positioned in the separator 10 for separation and concentration. Similar methods and steps will be used to separate the mixture of whole blood and bone marrow with a main difference being the material that is separated. It will also be understood that various centrifuge times or forces may be altered depending upon the exact material that is being separated with the separator 10. It will also be understood that the separation of whole blood, bone marrow, or a mixture of whole blood and bone marrow are merely exemplary of the materials that may be separated using the separator 10.
  • According to various embodiments, and with reference to FIGS. 5A-5D and to a whole blood sample, a sample of whole blood taken from a patient is placed in the tube 12 with an anticoagulant using the first syringe 204 or other appropriate delivery method. In particular, the first syringe 204 may be connected to the first plunger port 22. After which the blood sample is provided to the tube 12 via the sample collection bore 68 and sample collection aperture 70. A cap 220 is then placed over the first plunger port 22 to substantially seal the tube 12.
  • After the whole blood sample is delivered to the tube 12, the separator 10 is placed in a centrifuge. The second separator 10′, substantially identical to the first, is placed opposite the first separator 10 including the sample in a centrifuge. The second separator 10′ may also include a second sample or may include a blank, such as water, so that the centrifuge is balanced. The second separator 10′ balances the centrifuge by both weight and dynamics.
  • The separator 10 is then spun in the centrifuge in a range between about 1,000 and about 8,000 RPM. This produces a force between about 65 and about 4500 times greater than the force of normal gravity, as generally calculated in the art, on the separator 10 and the blood sample placed in the separator 10. At this force, the more dense material in a whole blood sample is forced toward the bottom end 12 b of the tube 12. The dense material, such as red blood cells or a red blood cell fraction 222, collects on the tube bottom 44. Because the buoy 14 has a density that is less than the red blood cell fraction 222, it is forced in a direction toward the top end 12 a of the tube 12 in the centrifuge. Nevertheless, because the buoy 14 is denser than a plasma fraction 224, the buoy 14 does not reach the top end 12 a of the tube 12.
  • The forces also affect the tube wall 42. The forces compress the tube 12 linearly along axis A thereby bowing or flexing the tube wall 42. As the tube wall 42 compresses it increases the diameter of the tube 12 making it easier for the buoy 14 to move in the direction of the top 12 a of the tube 12. In addition, the bottom face 48, defining an inverse cone, helps the initial movement of the buoy 14. Because the buoy 14 is not substantially flat along its bottom, it does not form a vacuum interaction with the tube bottom 44. Therefore, the initial movement of the buoy 14 away from the tube bottom 44 is quicker than if the bottom of the buoy 14 was flat.
  • During the centrifuge process, the red bloods cells of the red blood cell fraction 222 force the buoy 14 in the direction of the top end 12 a of the tube 12 because the buoy 14 is less dense than the red blood cell fraction 222. Although the whole blood sample, including the red blood cells, is loaded above the buoy 14, the red blood cells are able to move between the buoy 14 and the tube wall 42 because the circumference of the buoy 14 is less than the internal circumference of the tube 12. During the centrifuge process, the buoy 14 stops at an interface of a plasma fraction 224 and the red blood cell fraction 222 because of the selected or tuned density of the buoy 14.
  • With particular reference to FIG. 5B, the centrifuge process has been completed and the buoy 14 has moved to the interface of the red blood cell fraction 222 and plasma fraction 224. After the centrifuge has slowed or stopped, and before or after the tube 12 has been removed from the centrifuge, the tube wall 42 decompresses which helps support the buoy 14 at the interface position. It is also understood that applying an external pressure to the tube 12 via fingers or another apparatus may help stabilize the buoy 14 during the plunging procedure described herein.
  • On or near collection face 46 is a middle fraction 226, including a small, yet concentrated, amount of red blood cells, white blood cells, platelets, and a substantial portion of a buffy coat of the blood sample. Although the plasma is also present near the collection face 46 at this point, the solid portions of the buffy coat are more compressed against the collection face 46. The position of the buoy 14 also helps in this matter. Because the buoy 14 is a single body it defines the interface of the plasma fraction 224 and the red blood cell fraction 222. Also the density of the buoy 14 assures that it has not passed into the plasma fraction 224. Therefore, the fractions remain separated after the centrifuge process. In addition because the buoy 14 is tuned to the density of the red blood cell fraction 222, it is not affected by variations in the density of the plasma fraction 224 and the buoy's 14 position is always at the interface of the red blood cell fraction 222 and the plasma fraction 224.
  • With particular reference to FIG. 5C, the depth gage 24 is affixed to the first plunger port 22 of the sample collection projection 64. After connecting the depth gage 24 to the first plunger port 22, the plunger 16 is plunged into the tube 12 by pushing on the depth gage 24. As this is performed the plasma fraction 224, formed and separated above the buoy 14, is able to flow through the check valve 76 into the plasma collection area 86. This displacement of the plasma fraction 224 allows the plunger 16 to be plunged into the tube 12 containing the blood sample.
  • The plunger 16 is plunged into the tube 12 until the point where the end 104 of the depth gage rod 38 reaches the buoy 14. The volume left in the collection face 46 is the middle fraction 226 and is determined by the depth gage 24. It may be adjusted by selectively determining the amount that the depth gage rod 38 extends below the plunger front face 60. By adjusting the depth gage 24, the concentration of the middle fraction 226 can be adjusted depending upon the desires of the operator.
  • The plasma fraction 224 is held in the plasma collection area 86 for later withdrawal. Therefore, the use of the plunger 16 and the buoy 14 creates three distinct fractions that may be removed from the tube 12 after only one spin procedure. The fractions include the red blood cell fraction 222, held between the buoy 14 and the tube bottom 44. The middle or buffy coat fraction 226 is held between the plunger 16 and the buoy 14. Finally, the plasma fraction 224 is collected in the plasma collection area 86. In various embodiments, the middle fraction 226 may be a platelet rich plasma (PRP) fraction and the plasma fraction 224 may be a platelet poor plasma (PPP) fraction.
  • The middle fraction 226 may be extracted from the tube 12 first, without commingling the other fractions, through the sample collection bore 68. With particular reference to FIG. 5D, the depth gage rod 38 may be removed from the depth gage housing 28. This creates a sample collection cannula which includes the depth gage bore 30, the sample collection bore 68, and the sample collection aperture 70. After the depth gage rod 38 has been removed, the second syringe 210 may be affixed to the depth gage housing 28 via the external neck threads 34. The second syringe 210 may be substantially similar to the first syringe 204.
  • Before attempting to withdraw the middle fraction 226 the separator 10 may be agitated to re-suspend of the platelets and concentrated red blood cells in a portion of the plasma remaining in the collection face 46. This allows for easier and more complete removal of the middle fraction 226 because it is suspended rather than compressed against the collection face 46. A vacuum is then created in the second syringe 210 by pulling back the plunger 16 to draw the middle fraction 226 into the second syringe 210.
  • As the middle fraction 226 is drawn into the second syringe 210 the plunger 16 moves toward the buoy 14. This action is allowed because of the vent bore 98 formed in the cap 18. Atmospheric air is transferred to the plasma collection area 86 through the vent bore 98 to allow the middle fraction 226 to be removed. This also allows the movement of the plunger 16 toward the buoy 14. This action also allows the plunger 16 to “wipe” the collection face 46. As the plunger front face 60 mates with the collection area 46 the middle fraction 226 is pushed into the sample collection aperture 70. This ensures that substantially the entire middle fraction 226 collected in the collection area 46 is removed into the second syringe 210. It can also increase the repeatability of the collection volumes. In addition, because the second syringe 210 does not protrude out the sample collection aperture 70, it does not interfere with the collection of the middle fraction 226. Once the plunger front face 60 has mated with the collection face 46 there is substantially no volume between the plunger 16 and the buoy 14.
  • Once the middle fraction 226 is extracted the second syringe 210 is removed from the first plunger port 22. Also the extraction of the middle fraction 226 leaves the plasma fraction 224 and the red blood cell fractions 222 separated in the tube 12. At this point, a third syringe 212 may be affixed to the plasma collection valve 20. The third syringe 212 is connected to the external threads 94 of the plasma collection valve 20 to ensure a liquid tight connection. It will be understood, however, that another connection mechanism such as a snap or compression engagement may be used to connect the third syringe 212 to the plasma collection valve 20.
  • A vacuum is then created in the third syringe 212 to draw the plasma fraction 224 from the plasma collection area 86 through the plasma collection tube 92. As discussed above, the plasma collection tube 92 is connected to the hose barb 93. Therefore, the plasma flows through the plasma collection bore 93 a through the hose barb 93, and then through the plasma collection tube 92. It will be understood that the plasma collection tube 92 may alternatively simply rest on the plunger back face 72 to collect the plasma fraction 224. In this way, the plasma fraction 224 may be removed from the blood separator 10 without commingling it with the red blood cell fraction 222. After the plasma fraction 224 is removed, the separator 10 may be dismantled to remove the red blood cell fraction 222. Alternatively, the separator 10 may be discarded in an appropriate manner while retaining the red blood cell fraction 222.
  • The separator 10 allows for the collection of three of a whole blood sample's fractions with only one centrifugation spin. The interaction of the buoy 14 and the plunger 16 allows a collection of at least 40% of the available buffy coat in the whole blood sample after a centrifuge processing time of about 5 minutes to about 15 minutes. The complimentary geometry of the plunger front face 60 and the collection face 46 help increase the collection efficiency. Although only the cone geometry is discussed herein, it will be understood that various other geometries may be used with similar results.
  • The plunger front face 60 being flexible also helps ensure a complete mating with the collection face 46. This, in turn, helps ensure that substantially the entire volume between the two is evacuated. The process first begins with the suction withdrawal of the middle fraction 226 via the second syringe 210, but is completed with a fluid force action of the middle fraction 226 as the plunger front face 60 mates with the collection face 46. As the plunger front face 60 mates with the collection face 46, the fluid force assists in removal of the selected fraction.
  • The plunger 16 also substantially wipes the tube wall 42. Because the plunger 16 is formed of a flexible material it forms a seal with the tube wall 42 which is movable. Therefore, substantially no liquid is able to move between the plunger wall 62 and the tube wall 42. Material is substantially only able to go past the plunger front face 60 via the check valve 76.
  • The complimentary geometry also helps decrease the collection time of the middle fraction 226. Therefore, entire time to prepare and remove the middle fraction 226 is generally about 5 to about 40 minutes. This efficiency is also assisted by the fact that the separator 10 allows for the removal of the middle fraction 226 without first removing the plasma fraction 224, which includes the buffy coat, and re-spinning the plasma fraction 224. Rather, one spin in the separator 10 with the whole blood sample allows for the separation of the buffy coat for easy extraction through the plunger 16.
  • As discussed above, the separator 10 may be used to separate any appropriate multi-component material. For example, a bone marrow sample may be placed in the separator 10 to be centrifuged and separated using the separator 10. The bone marrow sample may include several fractions or components that are similar to whole blood fractions or may differ therefrom. Therefore, the buoy 14 may be altered to include a selected density that is dependent upon a density of a selected fraction of the bone marrow. The bone marrow may include a selected fraction that has a different density than another fraction and the buoy 14 may be designed to move to an interface between the two fractions to allow for a physical separation thereof. Similar to the whole blood fraction, the plunger 16 may then be moved to near a collection face 46 of the buoy 14. The fraction that is then defined by the collection face 46 and the plunger 16 may be withdrawn, as described for the removal of the buffy coat from the whole blood sample. For example, the middle fraction 226 in the bone marrow sample may include a fraction of undifferentiated or stem cells. In various embodiments, the middle fraction 226 in a bone marrow sample may include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, or endothelial cells. In various embodiments, the middle fraction 226 is concentrated bone marrow aspirate.
  • It will also be understood that mixtures of various fluids may be separated in the separator 10. For example, a mixture of whole blood and bone marrow may be positioned in the separator 10 at a single time. The buoy 14 may be tuned to move to an interface that will allow for easy removal of both the buffy coat, from the whole blood sample, and the undifferentiated cells, from the bone marrow sample. Nevertheless, it will be understood that the separator 10 may be used within any appropriate biological material or other material having multiple fractions or components therein. Simply, the buoy 14 may be tuned to the appropriate density and the plunger 16 may be used to cooperate with the buoy 14 to remove a selected fraction.
  • According to various embodiments and with reference to FIGS. 6A and 6B, a buoy system 300 is illustrated. The buoy system 300 generally includes a first buoy or fraction separator member 302 and a second buoy member or fraction separator 304. The first buoy 302 and the second buoy 304 may be operably interconnected with a buoy system cylinder or member 306. The buoy system 300 may be placed in a tube, such as the tube 12. The tube 12 may be formed of any appropriate material, such as the Cryolite Med®2 as discussed above. Nevertheless, the buoy system 300 may be designed to fit in the tube 12 or may be formed to fit in any appropriate member that may be disposed within a selected centrifuging device. It will be understood that the following discussion relating to buoy system 300 to be substantially matched to the size of the tube 12 is merely exemplary. As the buoy 14 may be sized to fit in any appropriate tube, the buoy system 300 may also be sized to fit in any appropriate tube. It will be further understood that the tube 12 may be any appropriate shape. The tube 12 need not only be cylindrical but may also be or include conical portions, polygonal portions, or any other appropriate shapes.
  • The first buoy 302 of the buoy system 300 may be generally similar in geometry to the buoy 14. It will be understood that the first buoy member 302 may be formed in the appropriate manner including shape or size to achieve selected results. Nevertheless, the first buoy member 302 generally includes an exterior diameter that may be slightly smaller than the interior diameter of the tube 12. Therefore, the first buoy member 302 may be able to move within the tube 12 during the centrifugal process. Also, as discussed above, the tube 12 may flex slightly during the centrifuging process, thus allowing the first buoy member 302 to include an exterior diameter substantially equivalent to the interior diameter of the tube 12. As discussed further herein, during the centrifugation process, a portion of the fraction of a sample may pass between the exterior wall of the first buoy member 302 and the tube 12.
  • The first buoy member 302 may generally include a density that is substantially equivalent to a first or selected fraction of the sample. If the sample to be separated includes whole blood and is desired to separate the red blood cells from the other portions of the sample, the first buoy member 302 may have a selected density that may be about 1.00 grams per cc (g/cc) to about 1.10 g/cc. It will be understood that the density of the first buoy member 302 may be any appropriate density, depending upon the fraction to be separated, and this range of densities is merely exemplary for separating red blood cells from a whole blood sample.
  • In addition, the first buoy member 302 includes a collection face or area 308 at a proximal or upper portion of the first buoy member 302. The collection face 308 generally defines a concave area of the first buoy member 302 and may have a selected angle of concavity. The buoy assembly 300 defines a central axis D. The collection face 308 defines a surface E that is formed at an angle γ to the central axis D of the buoy system 300. The angle γ may be any appropriate angle and may be about 0.5° to about 90°. The angle γ may, however, be between about 45° and 89.5°. Nevertheless, it will be understood that the angle γ may be any appropriate angle to assist in collection of a selected fraction or portion of the sample by the first buoy member 302.
  • A bottom or lower surface 310 of the first buoy member 302 may define a bottom face. The bottom face 310 may also be formed at an angle D relative to the central axis D. The bottom surface 310 defines a surface or plane F that may be formed at an angle Δ relative to the central axis D of the buoy system 300. The angle Δ may be any appropriate angle and may be about 90° to about 160°. For example, the angle Δ may be about 15°. Similarly to the buoy bottom face 48, the bottom surface 310 defines an apex 312 that may first engage the bottom 12d of the tube 12, such that most or the majority of the bottom surface 310 does not engage the tube 12. As illustrated further herein, the apex 312 allows for a free space or gap to be formed between the bottom face 310 of the first buoy member 302 and the bottom 12 b of the tube 12.
  • The second buoy member 304 may include an outer diameter substantially equivalent to the outer diameter of the first buoy member 302. Therefore, the second buoy 304 may move with the first buoy 302, particularly if the second buoy 304 is interconnected with the first buoy 302 with the buoy central cylinder 306. Nevertheless, the second buoy member 304 may be allowed to move substantially freely within the tube 12 during the centrifuging process.
  • The second buoy member 304 also includes an upper or superior surface 314 that defines a plane G that is formed at an angle relative to the central axis D of the buoy system 300. The angle ε of the plane G relative to the central axis D of the buoy system 300 may be any appropriate angle. For example, the angle ε may be about 90° to about 150°. Generally, the angle ε may assist in allowing a selected fraction or a portion of the sample to pass over the top surface 314 and past the second buoy member 304 during the centrifuging process.
  • The second buoy member 304 also define a bottom or inferior surface 316 that also defines a plane H that may be formed at an angle K relative to the central axis D of the buoy system 300. The angle K may be any appropriate angle, such as about 90° to about 150°. Nevertheless, the angle K may be substantially complimentary to the angle γ of the collection face 308 of the first buoy member 302. For example, if the angle γ is about 80°, the angle K may be about 100°, such that substantially 180° or a straight line is formed when the first buoy member 302 engages the second buoy member 304. This may be for any appropriate reason, such as extraction of a fraction that may be disposed near the collection face 308 of the first buoy member 302. Nevertheless, the angle K may be any appropriate angle as the angle γ.
  • The second buoy member 304 may be formed to include any appropriate density. For example, the second buoy member 304 may include a density that is less than the plasma fraction of a whole blood sample. It will be understood that the second buoy member 304 may include any appropriate density and a density that is less than the plasma fraction of a whole blood sample is merely exemplary. Nevertheless, if a whole blood sample is desired to be separated and the plasma sample is to be substantially separated from another fraction, the second buoy member 304 may include a density that is less than the plasma fraction of the whole blood sample. Therefore, the density of the second buoy member 304 may be about 0.01 g/cc to about 1.03 g/cc. As described herein, if the second buoy member 304 includes a density less than the plasma fraction of a whole blood sample and the first buoy member 302 includes a density greater than that of the red blood cells, the buoy system 300 may be substantially positioned near an interface between the red blood cell fraction and the plasma fraction of a whole blood sample. Therefore, as discussed above, and further described herein, the platelet or buffy coat fraction of the whole blood sample may be substantially collected near or in the collection face 308 of the buoy system 300.
  • The buoy post 306 may operably interconnect the first buoy member 302 and the second buoy member 304. The buoy post 306 may be any appropriate connection member. The buoy post need not be a single cylindrical portion. For example the buoy post 306 may include one or more members interconnecting the first buoy member 302 and the second buoy member 304, such as around a perimeter thereof. In addition, the buoy post 306 may include any appropriate shape or geometry.
  • The buoy system post 306 may be rigidly affixed to the first buoy member 302 and the second buoy member 304, such that the first buoy member 302 may not move relative to the second buoy member 304 and vice versa. Alternatively, the buoy post 306 may be slide ably connected to either or both the first buoy member 302 and the second buoy member 304. According to various embodiments, the buoy post 306 is generally fixedly connected to the first buoy member 302 and slide ably interconnected to the second buoy member 304. The buoy post 306 may include a catch portion or lip 320 that is able to engage a portion of the second buoy member 304, such that a range of travel of the second buoy member 304, relative to the first buoy member 302 is limited. Nevertheless, the range of travel of the second buoy member 304 toward the first buoy member 302 may be substantially unlimited until the second buoy member 304 engages the first buoy member 302.
  • In various embodiments, the buoy post 306 may also define a central cannula or bore 322. The post bore 322 may include a connection portion 324 substantially defined near an upper or a proximal end of the buoy post 306. This may allow for interconnection of various components with the buoy post 306, such that various components may be moved through the bore 322 from an exterior location. The buoy post 306 may also define a port or cannula 326 that connects the post cannula 322 with the collection face 308. Therefore, a substance may travel through the post cannula 322 and through the port 326. Various substances may then be provided to or removed from the collection face 308 of the first buoy member 302.
  • In various embodiments, the buoy system 300 may be used to separate a selected multi component sample, such as a whole blood sample. With continuing reference to FIGS. 6A and 6B, and reference to FIGS. 7A-7D, a method of using the buoy system 300, according to various embodiments, is illustrated and described. With reference to FIGS. 7A-7D, like reference numerals are used to indicate like portions of the tube 12 and the associated mechanisms described in FIGS. 1-3. Therefore, it will be understood that the buoy system 300 may be used with the tube 12 or any other appropriate tube or container system or apparatus. Nevertheless, for simplicity, the description of a method of use of the buoy system 300 will be described in conjunction with the tube 12.
  • The tube 12 may include the cap 18 that further defines a plasma valve or port 20. Extending through the cap 18 and interconnecting with a first flexible tube or member 92, the plasma port 20 may be used to extract a selected fraction of the sample that is positioned above the second buoy member 304. The tube 12 may also define a second port 21, which may also be referred to as a platelet rich plasma (PRP) port. As discussed herein, a second flexible member, such as a flexible tube 21 a, may interconnect the PRP port 21 and a connection portion 324 of a buoy cylinder 306. As illustrated above, the first tube 92 may also be interconnected with a selected portion of the system, such as the top surface 314 of the second buoy member 304. As illustrated above, a valve may be positioned and is operably interconnect the tube 92 with the upper surface 314 of the second buoy member 304. Nevertheless, such a valve is not necessary and it may be provided merely for convenience.
  • Other portions of the blood separator system 20, particularly those portions of the tube 12 and the cap 18 that have various valves connected therewith may be included in the tube 12 and used with the buoy system 300. Nevertheless, once the buoy system 300 is interconnected, it may be positioned in the interior of the tube 12 and the syringe 204 used to place a sample into the tube 12. The sample may be expressed from the syringe 204 into the interior of the tube 12 and the sample may be any appropriate sample, such as a whole blood sample. Nevertheless, it will be understood, such as discussed above, various other samples may be used, such as bone marrow samples, a mixture of bone marrow and whole blood or non-biological fluids or materials. It will be understood that two buoys 302 and 304 may generally be near one another when the sample is positioned in the tube 12, but are illustrated apart for clarity of the present discussion.
  • Also, the sample may be placed in the tube 12 according to various embodiments. As described above, an anticoagulant or other components may be mixed with the whole blood sample, if a whole blood sample is used, before the whole blood sample is positioned within the tube 12. As is apparent to one skilled in the art, an anticoagulant or other components may be mixed with a bone marrow aspirate sample or a sample of bone marrow aspirate and whole blood, if such samples are used before such sample is positioned within the tube 12. The syringe 204 is connected with the plunger port 22 extending from the cap 18, although a plunger may not be used in various embodiments.
  • After the sample is positioned within the tube 12, as described above, a cap may be positioned over the port 22, such that the sample is not allowed to escape from the tube 12. After the sample is placed in the tube 12 and the cap placed on the port 22, the tube 12 including the sample and the buoy system 300 may be centrifuged.
  • With reference to FIG. 7B, after a centrifugation of the tube 12, including the buoy system 300, substantially three fractions of the sample may be formed. A first fraction 330 may be positioned between the bottom face 310 and the bottom of the tube 44. A middle fraction 332 may be positioned between the collection face 308 and the bottom surface 316 of the second buoy 304. In addition, a third fraction 334 may be positioned between the upper surface 314 and the cap 18 of the tube 12. Generally, the first fraction 330, the middle fraction 332, and the third fraction 334 are substantially physically separated with the buoy system 300. During the centrifugation process, the tube 12 may flex slightly to allow for ease of movement of the buoy system 300 through the tube 12 and the sample. Nevertheless, the buoy system 300, during the centrifugation process, substantially creates the three fractions 330, 332, and 334 without the operation of an operator. Therefore, the formation of at least three fractions may be substantially simultaneous and automatic using the buoy system 300.
  • The buoy system 300 substantially separates the fractions 330, 332, and 334, such that they may be easily removed from the tube 12. For example, with reference to FIG. 7C, a syringe or other instrument 340 may be used to extract the middle fraction 332 by interconnecting a cannula or bored tube 342 with the connection portion 324 of the buoy cylinder 306. By drawing the plunger 344 into the extraction syringe 340, a vacuum or upward force is produced within the extraction syringe 340. This force draws the middle fraction 332 through the ports 326 of the buoy post 306 and through the buoy cannula 322. Therefore, the middle fraction 332 may be extracted from the tube 12 without substantially commingling the middle fraction 332 with either the first fraction 330 or the third fraction 334. The middle fraction 332 is drawn in the direction of arrow M through the cannula 322 and into the extraction syringe 340.
  • It will be understood that the second tube 21 a may also be used. The extraction syringe 340 may be interconnected with the PRP port 21 that is interconnected with the connection portion 324 of the buoy cylinder 306. As discussed herein, the buoy cylinder allows access to the middle fraction 332 (platelet rich portion) between the buoy portions. Thus, it will be understood, that access may be obtained and the middle fraction 332 (platelet rich portion or buffy coat of the sample), between the two buoys, may be extracted in a plurality of ways. The illustrations and method described herein is merely exemplary. For example, if bone marrow aspirate is used as the sample, the PRP port 21 would allow for extraction of undifferentiated nucleated cells. In various embodiments, the PRP port 21 allows for extraction of the buffy coat.
  • Alternatively, if the post 306 is not provided other portions may be provided to gain access to the middle fraction 332. For example, if a plurality of members are provided around the perimeter of the first buoy 302 and the second buoy 304 a valve portion, such as a puncture-able valve, may be provided in the second buoy 304 to be punctured with an object. In this way an extraction needle may puncture the valve to gain access to the middle fraction 332. Regardless, it will be understood that the buoy system 300 may be able to form a plurality of fractions, such as the three fractions 330, 332, and 334 and at least the middle fraction 332 may be extracted without substantially commingling the various fractions.
  • During the extraction of the middle fraction 332 through the cannula 322, the second buoy member 304 may move in the direction of arrow M toward the first buoy member 302. As described above, the collection face 308 of the first buoy member may include an angle γ that is substantially complementary to the bottom face 316 of the second buoy member 304. Therefore, if the second buoy member 304 is allowed to move along the buoy cylinder 306, the bottom face 316 of the second buoy member 304 may be able to substantially mate with the collection face 308 of the first buoy member 302. Alternatively, if the second buoy member 304 is not allowed to move, the second buoy member may be provided with a vent port or valve, such that the extraction of the middle fraction 332 from the collection face 308 may not be hindered by the buildup of undesirable forces. Nevertheless, if the second buoy member 304 may move, the interaction of the bottom face 316 of the second buoy member 304 may assist in substantially removing the entire middle fraction 332 from the tube 12. As described above, the bottom face 60 of the plunger 16 may also serve a similar purpose when engaging the collection face 46 of the buoy 14.
  • With reference to FIG. 7D, once the middle fraction 332 has been extracted from the tube 12, the second buoy member 304 may substantially mate with a portion of the first buoy member 302. As discussed above, the second buoy member 304 may substantially only mate with the first buoy member 302 if the second buoy member 304 is able to substantially move relative to the first buoy member 302. Therefore, it will be understood that the second buoy member 304 need not necessarily mate with the first buoy member 302 and is merely exemplary of an operation of various embodiments. Nevertheless, once the middle fraction 332 has been extracted from the tube 12, the port 20 may be used in conjunction with a selected instrument, such as a plasma extraction syringe 212 to remove the plasma or the third fraction 334 from the tube 12 using the extraction tube 92 interconnected with the port 20.
  • As described above, the tube 92 allows for extraction of the third fraction 334 from the tube 12 without commingling the third fraction 334 with the remaining first fraction 330 in the tube 12. Therefore, similar to the separator and extraction system 10, three fractions may be substantially formed within the tube 12 with the buoy system 300 and may be extracted without substantially commingling the various fractions. Once the third fraction 334 is extracted from the tube 12, the buoy system 300 may be removed from the tube 12, such that the first fraction 330 may be removed from the tube 12. Alternatively, the first fraction 330 may be discarded with the tube 12 and the buoy system 300 as a disposable system. Alternatively, the system may be substantially reusable, such that it can be sterilized and may be sterilized for various uses.
  • The description of the method of use of the buoy system 300 is exemplary of a method of using a system according to various other embodiments. It will be understood, however, that various specifics may be used from various embodiments to allow for the extraction of selected fractions. For example, the centrifugation process may be substantially a single step centrifugation process. The buoy system 300, according to various embodiments, may allow for the formation of three fractions during a single centrifugation process. This centrifugation process may occur at any appropriate speed, such as about 1000 RPM to about 8000 RPM. This speed may produce a selected gravity that may be approximately 4500 times greater than the normal force of gravity. Nevertheless, these specifics are not necessary to the operation of the buoy system 300 according to various embodiments. The buoy system 300, according to various embodiments, may be used to extract a plurality of fractions of a sample after only a single centrifuging process and without substantially commingling the various fractions of the sample.
  • With reference to FIG. 8, the blood collection and separation system that includes the tube 12, according to various embodiments, may be filled with a multi-component fluid or solution, such as blood from a patient, is illustrated. The tube 12 may include any appropriate separation system, such as the separation system 300. Nevertheless, in addition to filling the tube 12 with a fluid from the syringe 204 any appropriate method may be used to fill the tube 12. For example, when a solution, including a plurality of components, is placed into the tube 12 it may be collected directly from a source.
  • For example, a patient 350 may be provided. The patient 350 may be provided for a selected procedure, such as generally an operative procedure or other procedure that requires an intravenous connection 352, such as a butterfly needle, to be provided in the patient 350. The intravenous connection 352 generally provides a tube 354 extending therefrom. The tube 354 may be used to withdraw fluids from the patient 350 or provide materials to the patient 350, such as medicines or other selected components. Nevertheless, the intravenous connection 352 is generally provided for various procedures and may be used to fill the tube 12.
  • The tube 354 may interconnect with the plunger port 22 or any appropriate portion of the tube 12. The port 22 may be used to connect with the tube 354 in a similar manner as it would connect with the syringe 204, if the syringe 204 was provided. Nevertheless, it will be understood that the tube 354 may be provided directly to the tube 12 from the patient 350. This may reduce the number of steps required to fill the tube 12 and reduce possible cross-contamination from the patient 350 with the various components. Moreover, making a connection directly with the patient 350 may make the withdrawal and collection of blood from the patient 350 more efficient.
  • Once the tube 354 is interconnected with the tube 12 the pressure differential between the patient 350, such as the intravenous pressure of the blood, may be used to fill the tube 12 to a selected volume. In addition, a vacuum system 356 may be provided The vacuum system 356 may include a vacuum inducing portion or member 358, such as a resilient bulb. The vacuum inducing member 358 may be interconnected with the tube 12 through a selected connecting portion 360.
  • The vacuum connecting portion 360 may interconnect with an orifice 362. The orifice 362 may be interconnected or extend from the cap 18 or provided in any appropriate portion with the tube 12. Nevertheless, a first one-way valve 364 may be provided along the connection portion 360 or near the orifice 362. The first one-way valve 364 provides that a flow of a fluid, such as a gas, may pass in a first direction but not in a second. A second one-way valve 366 may also be provided downstream from the first one-way valve 364. In this way, a vacuum may be created with the vacuum inducing member 358, such that air is drawn out of the tube 12 and removed through the second one-way valve 366 in the direction of arrow V. Due to the first and second one-way valves 364, 366 the air is generally withdrawn from the tube 12 without substantially allowing the air to flow back into the tube 12. Thus, a vacuum can be created within the tube 12 to assist with removing a selected volume of fluid, such as blood, from the patient 350.
  • Because the tube 12 may be filled substantially directly from the patient 350, the collection of the fluid, such as blood, may be provided substantially efficiently to the tube 12. Although any appropriate mechanism may be used to assist in withdrawing the blood from the patient 350 the vacuum system 356 may be provided including the vacuum inducing member 358. Any appropriate vacuum creating device may be used, such as a mechanical pump or the like. Nevertheless, the tube 12 may be filled for use during a selected procedure.
  • As discussed above, the tube 12 may be used to separate a selected portion of the blood obtained from the patient 350 substantially intraoperatively. Therefore, the collection or separation of the various components may be substantially autologous and substantially intraoperatively. Moreover, obtaining the fluid directly from the patient 350 may increase the efficiency of the procedure and the efficiency of the intraoperative or the operative procedure.
  • With reference to FIG. 9, the separator 10 may be used to separate any appropriate material. The material may be separated for any purpose, such as a surgical procedure. For example, a selected fraction of a bone marrow aspirate or a bone marrow portion may be produced with the separator 10 according to various embodiments. The selected fraction of the bone marrow aspirate may include various components, such as undifferentiated cells. The various undifferentiated cells may be positioned in a selected scaffold or relative to a selected portion of a patient for providing a volume of the undifferentiated cells to the patient. As known to those skilled in the art, a selected portion of the patient may include bone, cartilage, connective tissue, or any other tissue. Also as known by those skilled in the art, a selected portion of the patient may include a defect in bone, cartilage, connective tissue and/or any other tissue. It will be understood that the method described according to FIG. 9 is merely exemplary of various embodiments that may be used to provide a selected fraction of a bone marrow aspirate or other material to a patient or selected position. The selected portion may be placed on the scaffold in any appropriate manner, such as by spraying, dipping, infiltrating, or any appropriate method.
  • A method of selecting or creating a selected fraction of a bone marrow aspirate in a selected scaffold according to a method 400 is illustrated in FIG. 9. Generally, the method 400 may start in block 402 in obtaining a bone marrow aspirate volume. The bone marrow aspirate (BMA) may be obtained in any selected or generally known manner. For example, a selected region of bone, such as a portion near an operative procedure, may be used to obtain the bone marrow aspirate. Generally, an accessing device, such as a syringe and needle, may be used to access an intramedullary area of a selected bone. The BMA may then be withdrawn into the syringe for various procedures. Once a selected volume of the BMA is obtained in block 402, the BMA may be positioned in the separator 10 according to various embodiments in block 404. The BMA may be positioned in any appropriate separator, such as those described above including the separator 10. Once the BMA is positioned in the separator 10, a selected fraction of the BMA may be separated from the BMA in block 406.
  • BMA is a complex tissue comprised of cellular components (that contribute to bone growth) including red and white blood cells, their precursors and a connective tissue network termed the stroma. Bone marrow stromal cells or mesenchymal stem cells have the potential to differentiate into a variety of identifiable cell types including osteoblasts, fibroblasts, endothelial cells, reticulocytes, adipocytes, myoblasts and marrow stroma. The selected fraction of the BMA may include undifferentiated cells or any appropriate portion of the BMA. The fractionation or separation of various fractions of the BMA may allow for a volume of BMA to be taken from a single location and the separation or concentration of the selected portion may be performed in the separator 10. Generally, obtaining a small volume of the selected portion from a plurality of locations may be used to obtain an appropriate volume of BMA or selected fraction of the BMA. Nevertheless, the separator 10 may allow for separating a selected volume from a single location from which the BMA is obtained. This may reduce the time of a procedure and increase the efficiency of obtaining the selected fraction of the BMA.
  • In addition to obtaining a volume of the BMA in block 402, a volume of whole blood may be obtained in block 408. The volume of blood obtained in block 408, according to any appropriate procedure, including those described above, may then be positioned in the separator 10, in block 410. The whole blood may be positioned in any appropriate separator, such as those described above or a separator to separate a selected fraction of the whole blood. As described above, the whole blood may be separated into an appropriate fraction, such as a fraction including a platelet portion or buffy coat. The whole blood may be separated into selected fractions in block 412. It will be understood that the BMA and the whole blood volume may be obtained substantially simultaneously or consecutively in block 402 and 408. In various embodiments, concentrated BMA, such as the middle fraction 332, 226 comprising nucleated cells in separator 10 has a concentration of nucleated cells that is at least 4 times the concentrate of nucleated cells in BMA. Similarly, the selected fractions of the BMA obtained in block 406 and whole blood obtained in block 412 may also be performed substantially sequentially or simultaneously. For example, the separator 10 including the volume of the BMA may be positioned in a separating device, such as a centrifuge, substantially opposite, so as to balance, the separator 10 including the volume of the whole blood. Therefore, a single separation, such as centrifuge procedure may be used to separate both the BMA and the whole blood into selected fractions. This again may increase the efficiency of the procedure to provide both a selected fraction of the BMA and a selected fraction of the whole blood substantially simultaneously.
  • The selected fractions of the BMA and the whole blood, provided in block 406 and 412 may be harvested in block 414. The selected fractions of the BMA and the whole blood, may be harvested in block 414 for appropriate purposes, such as those described herein. The separator 10 may be used to obtain the selected fractions of the BMA and the whole blood, through various procedures, such as those described above.
  • A plurality of separators 10 may be used to obtain a larger quantity of the selection fractions and such quality of selected fractions may be pooled together. In various embodiments, the BMA aspirate can be concentrated alone or in combination with whole blood. In various embodiments, whole blood may be added to the separator 10, and the resulting buffy coat fraction (middle fraction 332, 226) may not only contain the at least 4 times greater concentration of nucleated cells from bone marrow, and may include at least 5 times greater concentration of white blood cells from the whole blood and at least 8 times greater concentration in platelets from the whole blood. In addition, circulating stem cells from whole blood may be concentrated with the mature white blood cells in the buffy coat.
  • After harvesting the selected fractions of the BMA and the whole blood in block 414, the selected fraction of the BMA may be positioned on an appropriate scaffold in block 416. The scaffold in block 416 may be any appropriate scaffold, such as synthetic bone substitutes or allergenic tissue. Examples of a scaffold include, but are not limited to, bone, cartilage, bone substrates, ceramics, biopolymers, collagens, metal, and the like. The scaffolds may be used for appropriate procedures, such as hard or soft tissue grafting, including uses in non-union or chronic wounds. The undifferentiated cells of the BMA may allow for a substantial source of cells for use during a substantially natural healing after an operative procedure, for example, the natural healing of a patient may use the supplied undifferentiated cells. In such a natural healing of a patient, the undifferentiated cells may be applied to a wound, a defect, a graft site, a bone, cartilage, connective tissue. and the like. Therefore, the scaffold may be positioned in a selected portion of the anatomy and the cells may be allowed to grow and differentiate into selected portions in the implanted position.
  • It is well known to those skilled in the art that bone marrow contains hematopoietic and mesenchymal stems cells that are precursors for most of the cells found within the body. In general, the hematopoietic cells, along with angiogeneic growth factors, such as those found in platelets, will promote angiogenesis. Angiogenesis is a necessary stage in wound healing of most tissues and treatment of ischemia. The mesenchymal stem cells are the cells responsible for the formation of bone, tendon, ligament, articular cartilage, muscle, fat, intervertebral discs, meniscus, skin, and any other structural tissue found in the body. In various embodiments, a concentration and delivery of these precursor cells, with or without platelet concentrate, will improve therapeutic uses over the native bone marrow.
  • In addition to positioning the selected fractioning of the BMA and the scaffold in block 416, the platelets of the whole blood may be positioned on or near the scaffold of block 418. The platelets of the whole blood fraction positioned in the scaffold of block 418 may assist the undifferentiated cells and the anatomy into which the scaffold is positioned to allow for a substantially efficient and complete healing. The platelet rich fraction of the whole blood sample may include various healing and growth factors that may assist in providing an efficient and proper healing in the anatomy. Therefore, the undifferentiated cells of the BMA, or other selected fraction obtained from the separation of the BMA, and the selected fraction of the whole blood, obtained from the separator, may be used with the scaffold to provide a substantially efficient implant.
  • In some embodiments, harvest block 414 may be combined with a growth factors which may include any of the well-known growth factors such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-β), Insulin-Like Growth Factor (IGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Bone Morphogenetic Proteins (BMPs), and vectors for gene therapy. In various embodiments, harvest block 414 may be combined with cellular solutions, suspensions, and materials including osteoblasts, osteoprogenitor cells, chondroblasts, stem cells, or fibroblasts may also be used, as may solutions or suspensions containing other therapeutic agents such as antibiotics, analgesics, pharmaceutical agents, antithrombinolytics, or chemotherapeutic agents. In various embodiments, the buffy coat, platelet fraction, and/or undifferentiated cell fraction (the middle fraction 332, 226) may be combined with an activator such as thrombin solutions and the like. In various embodiments the middle fraction 332, 226 may be used alone for cartilage repair. In various embodiments, the platelet rich fraction may be used to fill a cartilage defect with a fibrin matrix, or it may be mixed with other cell sources such as autologous chondrocytes, synovial cells, bone marrow cells, or to mix with the blood clot formed during microfracture. In addition, the separator 10, or any appropriate separator, such as that described above, may allow for a substantially quick and efficient separation of the BMA and the whole blood into an appropriate fraction for use in the procedure. Other examples include pooling whole blood and/or BMA from different sites of the anatomy or from different sources.
  • In various embodiments, the concentrated bone marrow cells can also be included with a carrier to aide in delivery and to help maintain the cells' location after implantation. Examples of carriers can include fibrin, concentrated fibrin, demineralized bone matrix, gelatin, collagen, porous calcium based ceramics, porous metal, synthetic fiber matrices, or resorbable matrices. In addition, carriers can be made from other autogeneic, allogenic, and xenogeneic tissues.
  • After the selected portion of the BMA and the whole blood are positioned on the scaffold in blocks 416 and 418 the scaffold may be implanted in block 420. As described above, the scaffold may be implanted in any appropriate position in the block 420 for various procedures. It will be understood that the scaffold may be implanted for any appropriate procedure and may allow for positioning the selected portion of the BMA, such as undifferentiated cells, and the selected portion of the whole blood, such as platelets, relative to a selected portion of the anatomy. The scaffold may allow for a bone ingrowth, such as allowed with the undifferentiated cells, to assist in healing of a selected portion of the anatomy. In various embodiments, concentrated bone marrow aspirate can be used in articular cartilage repair. The middle fraction 332, 226 can be added to a focal defect or to an osteoarthritic defect. The defects can be in any joint that contains articular cartilage. In various embodiments, the middle fraction 332, 226 can promote the formation of repair tissue. In addition, these cells can be added to a microfracture technique in order to increase the mesenchymal cells present in the defect and increase the amount and quality of repair tissue that forms. In various embodiments, the middle fraction 332, 226 can be delivered in one of the carriers listed above. In various embodiments, for delivery to cartilage, the middle fraction 332, 226 in an autologous fibrin or concentrated fibrin is activated with an activating solution so that it forms a 3-D gel in situ and holds the middle fraction 332, 226 within the cartilage defect. In various embodiments, the concentrated bone marrow can also be used in meniscus repair. The concentrated bone marrow can be used to fill a tear with the meniscus, or in can be used to soak a graft used to replace the meniscus after a full or partial meniscectomy. In various embodiments, concentrated bone marrow aspirate used in combination with platelet rich plasma can also be used for repair of meniscus. In various embodiments, concentrated bone marrow aspirate can be used to repair bone. In various embodiments, the middle fraction 332, 226 can used alone, or mixed with an appropriate carrier such as demineralized bone matrix, calcium based ceramics, fibrin, or concentrated fibrin. The defects in bone could be found in long bones, cranium, sternum, and spine. One specific placement of concentrated bone marrow aspirate would be to deliver the undifferentiated cells to a freeze dried demineralized bone product (such as the Bonus DBM product from Biomet Biologics) under vacuum. In various embodiments, the concentrated bone marrow can infiltrate the graft, and the plasma in the bone marrow may hydrate the bone matrix and create an injectable carrier. The undifferentiated cells may have differentiating growth factors included within the demineralized bone to stimulate cartilage and bone formation. In various embodiments, the concentrated bone marrow can be delivered to the patient with a growth factor that will induce proliferation, chemotaxis, and/or morphogeneis. Examples of growth factors that could be used include PDGF, TGF-b, IGF, VEGF, EGF, CTGF, FGF, and any of the BMPs.
  • The description of the invention is merely exemplary in nature and, thus, variations that do not depart from the gist of the invention are intended to be within the scope of the invention. Such variations are not to be regarded as a departure from the spirit and scope of the invention.

Claims (32)

1. A method for concentrating bone marrow aspirate, the method comprising:
obtaining a volume of bone marrow aspirate from a mammal;
loading the volume of bone marrow aspirate into a separator comprising two buoys, the separator operable to separate the aspirate into three or more fractions;
centrifuging the separator creating at least one fraction comprising a concentrated bone marrow aspirate; and
extracting the at least one fraction comprising a concentrated bone marrow aspirate.
2. The method according to claim 1 wherein the at least one fraction comprises at least one of the group consisting essentially of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
3. The method according to claim 1 wherein an amount of nucleated cells in the at least one fraction is greater than or equal to 4 times an amount of nucleated cells found in the volume of bone marrow aspirate.
4. The method according to claim 1 further comprising applying the at least one fraction into a patient.
5. A method for concentrating bone marrow aspirate and peripheral blood, the method comprising:
collecting a volume of bone marrow aspirate and a volume of peripheral
blood from a patient;
loading the volume of bone marrow aspirate and the volume of peripheral blood into a separator comprising two buoys, separator being operable to separate a combination of the volume of aspirate and the volume of blood into three or more fractions;
centrifuging the at least one separator operably creating at least one fraction comprising a concentration of at least one of bone marrow aspirate and peripheral blood; and
withdrawing the at least one fraction comprising the concentration.
6. The method according to claim 5 wherein the concentration comprises at least one of the group consisting essentially of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
7. The method according to claim 5 wherein an amount of nucleated cells in the concentration is greater than or equal to 4 times an amount of nucleated cells in the combination of the volume of aspirate and the volume of blood.
8. A method for treating a defect in a mammal using a concentrated bone marrow aspirate, the method comprising:
drawing a volume of bone marrow aspirate from the mammal;
loading the volume of bone marrow aspirate into a separator comprising two buoys, the separator being operable to separate the aspirate into three or more fractions;
centrifuging the separator;
separating the volume of bone marrow aspirate into a plurality of fractions including a fraction comprising a concentrated bone marrow aspirate;
extracting the fraction comprising a concentrated bone marrow aspirate; and
applying the fraction comprising a concentrated bone marrow aspirate to site of the defect.
9. The method according to claim 8 wherein the fraction comprising a concentrated bone marrow aspirate is essentially buffy coat including a plurality of undifferentiated cells.
10. The method according to claim 8 wherein the fraction comprises at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
11. The method according to claim 8 further comprising combining the fraction with a carrier.
12. The method according to claim 11 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
13. The method according to claim 8 further comprising combining an activating agent with the fraction.
14. The method according to claim 8 further comprising combining a pharmaceutical agent with the fraction.
15. A method for treating a defect in an animal, the method comprising:
obtaining a volume of bone marrow aspirate and a volume of whole blood from the animal;
loading the volume of bone marrow aspirate into a first separator comprising two buoys, the separator being operable to separate the aspirate into three or more fractions;
loading the volume of whole blood into a second separator comprising two buoys, the separator being operable to separate the aspirate into three or more fractions;
centrifuging the first separator and the second separators, thereby separating the volume of bone marrow aspirate into a plurality of fractions and separating the volume of whole blood into a plurality of fractions.
collecting a fraction of the bone marrow aspirate;
collecting a fraction of the whole blood; and
applying at least one of the fraction of bone marrow aspirate and the fraction of whole blood to site of the defect.
16. The method according to claim 15 wherein the at least one of the fraction of bone marrow aspirate and the fraction of whole blood comprises at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
17. The method according to claim 15 further comprising combining the at least one of the fraction of bone marrow aspirate and the fraction of whole blood with a carrier.
18. The method according to claim 17 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
19. The method according to claim 17 further comprising adding an activating agent to the at least one of the fraction of bone marrow aspirate and the fraction of whole blood
20. The method according to claim 17 further comprising adding a pharmaceutical agent to the at least one of the fraction of bone marrow aspirate and the fraction of whole blood.
21. A method for treating a defect in a patient, the method comprising:
drawing a volume of bone marrow aspirate and a volume of whole blood from the patient;
adding a first anticoagulant to the volume of bone marrow aspirate;
adding a second anticoagulant to the volume of whole blood;
loading the volume of bone marrow aspirate and the volume of whole blood into a separator comprising two buoys, the separator being operable to separate the volume of bone marrow aspirate and the volume of whole blood into three or more fractions;
centrifuging the separator, separating the volume of bone marrow aspirate and the volume of whole blood into a plurality of fractions.
withdrawing a fraction comprising at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.; and
applying the fraction to site of the defect.
22. The method according to claim 21 wherein the fraction is essentially buffy coat including a plurality of undifferentiated cells.
23. The method according to claim 21 further comprising combining the fraction with a carrier.
24. The method according to claim 32 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
25. The method according to claim 21 further comprising combining an activating agent with the fraction.
26. The method according to claim 21 further comprising combining a pharmaceutical agent with the fraction.
27. A method of treating a patient with combination of a concentrated bone marrow aspirate and buffy coat, the method comprising:
obtaining a volume of a whole blood from the patient;
obtaining a volume of a bone marrow aspirate from the patient;
forming a buffy coat fraction of the whole blood;
forming a concentrated bone marrow aspirate fraction of the bone marrow aspirate; and
applying at least one of the buffy coat fraction or the concentrated bone marrow aspirate fraction to the patient.
28. The method according to claim 27, wherein the forming a first fraction of the first whole material and the forming a second fraction of the second whole material includes:
loading the volume of whole blood and the volume of bone marrow aspirate in a container; and
applying a force to the container to form at least three fractions.
29. The method according to claim 27, wherein the forming a first fraction of the first whole material and the forming a second fraction of the second whole material includes:
loading the volume of whole blood and the volume of bone marrow aspirate in the container having a separating member, the separating member having a specific gravity substantially dependent upon at least one of the at least three fractions; and
centrifuging the container to move the separating member to a selected position relative to the at least one of the volume of whole blood and the volume of bone marrow aspirate to substantially physically separate the at least three fractions.
30. The method according to claim 27 wherein the at least one of the first fraction or the second fraction comprises at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
31. The method according to claim 27 further comprising combining the at least one of the first fraction or the second fraction with a carrier.
32. The method according to claim 31 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
US11/442,631 2002-05-24 2006-05-26 Apparatus and method for separating and concentrating fluids containing multiple components Abandoned US20060278588A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/442,631 US20060278588A1 (en) 2002-05-24 2006-05-26 Apparatus and method for separating and concentrating fluids containing multiple components
US13/663,637 US20130226149A1 (en) 2002-05-24 2012-10-30 Apparatus and method for separating and concentrating fluids containing multiple components
US14/510,828 US9897589B2 (en) 2002-05-24 2014-10-09 Apparatus and method for separating and concentrating fluids containing multiple components
US15/866,658 US10393728B2 (en) 2002-05-24 2018-01-10 Apparatus and method for separating and concentrating fluids containing multiple components

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38301302P 2002-05-24 2002-05-24
US10/445,381 US7179391B2 (en) 2002-05-24 2003-05-23 Apparatus and method for separating and concentrating fluids containing multiple components
US10/932,882 US7374678B2 (en) 2002-05-24 2004-09-02 Apparatus and method for separating and concentrating fluids containing multiple components
US11/442,631 US20060278588A1 (en) 2002-05-24 2006-05-26 Apparatus and method for separating and concentrating fluids containing multiple components

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/932,882 Continuation-In-Part US7374678B2 (en) 2002-05-03 2004-09-02 Apparatus and method for separating and concentrating fluids containing multiple components

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/663,637 Continuation US20130226149A1 (en) 2002-05-24 2012-10-30 Apparatus and method for separating and concentrating fluids containing multiple components

Publications (1)

Publication Number Publication Date
US20060278588A1 true US20060278588A1 (en) 2006-12-14

Family

ID=46324551

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/442,631 Abandoned US20060278588A1 (en) 2002-05-24 2006-05-26 Apparatus and method for separating and concentrating fluids containing multiple components
US13/663,637 Abandoned US20130226149A1 (en) 2002-05-24 2012-10-30 Apparatus and method for separating and concentrating fluids containing multiple components
US14/510,828 Active 2024-10-24 US9897589B2 (en) 2002-05-24 2014-10-09 Apparatus and method for separating and concentrating fluids containing multiple components
US15/866,658 Expired - Lifetime US10393728B2 (en) 2002-05-24 2018-01-10 Apparatus and method for separating and concentrating fluids containing multiple components

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/663,637 Abandoned US20130226149A1 (en) 2002-05-24 2012-10-30 Apparatus and method for separating and concentrating fluids containing multiple components
US14/510,828 Active 2024-10-24 US9897589B2 (en) 2002-05-24 2014-10-09 Apparatus and method for separating and concentrating fluids containing multiple components
US15/866,658 Expired - Lifetime US10393728B2 (en) 2002-05-24 2018-01-10 Apparatus and method for separating and concentrating fluids containing multiple components

Country Status (1)

Country Link
US (4) US20060278588A1 (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070255203A1 (en) * 2004-10-13 2007-11-01 Hyprotek, Inc. Syringe Devices and Methods for Mixing and Administering Medication
US20080193424A1 (en) * 2007-02-09 2008-08-14 Biomet Biologics, Inc. Treatment of tissue defects with a therapeutic composition
US20080306431A1 (en) * 2007-05-11 2008-12-11 Biomet Biologics, Llc Methods of reducing surgical complications in cancer patients
US20090014391A1 (en) * 2002-05-03 2009-01-15 Biomet Biologics, Llc Buoy Suspension Fractionation System
US20090084737A1 (en) * 2007-10-02 2009-04-02 Becton, Dickinson And Company Apparatus and method for separating particles within a specimen
US20090220482A1 (en) * 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20100016830A1 (en) * 2006-04-28 2010-01-21 Ellsworth James R Injection of Anticoagulant Into Bone Marrow Space
US20100055087A1 (en) * 2008-02-27 2010-03-04 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US7780860B2 (en) 2002-05-24 2010-08-24 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US7806276B2 (en) 2007-04-12 2010-10-05 Hanuman, Llc Buoy suspension fractionation system
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US7837884B2 (en) 2002-05-03 2010-11-23 Hanuman, Llc Methods and apparatus for isolating platelets from blood
US7845499B2 (en) 2002-05-24 2010-12-07 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
US20110114640A1 (en) * 2009-11-13 2011-05-19 Black Eric L Device for dispensing cream laden gauze
US8002737B2 (en) 2007-10-04 2011-08-23 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20120045424A1 (en) * 2009-04-21 2012-02-23 Aaron Esteron Assembly, device kit and method for preparing platelet-rich plasma (prp)
US8137307B2 (en) 2005-11-09 2012-03-20 Hyprotek, Inc. Syringe devices, components of syringe devices, and methods of forming components and syringe devices
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8313954B2 (en) 2009-04-03 2012-11-20 Biomet Biologics, Llc All-in-one means of separating blood components
US8328024B2 (en) 2007-04-12 2012-12-11 Hanuman, Llc Buoy suspension fractionation system
US8337711B2 (en) 2008-02-29 2012-12-25 Biomet Biologics, Llc System and process for separating a material
US20130001157A1 (en) * 2008-12-01 2013-01-03 Kyungyoon Min Apparatus and method for processing biological material
US8444620B2 (en) 2005-02-21 2013-05-21 Biomet Biologics, Llc Method and apparatus for application of a fluid
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
US20130253657A1 (en) * 2010-11-25 2013-09-26 University Of Tsukuba Method for producing implant material
US8567609B2 (en) 2006-05-25 2013-10-29 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8591391B2 (en) 2010-04-12 2013-11-26 Biomet Biologics, Llc Method and apparatus for separating a material
US8783470B2 (en) 2009-03-06 2014-07-22 Biomet Biologics, Llc Method and apparatus for producing autologous thrombin
US8794452B2 (en) 2009-05-15 2014-08-05 Becton, Dickinson And Company Density phase separation device
US20140231335A1 (en) * 2012-03-05 2014-08-21 Dongkoo Bio & Pharma Co., Ltd. Ingredient separator
WO2014144505A2 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
WO2014149300A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
WO2014149270A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Treatment of pain using protein solutions
WO2014149301A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
WO2014149979A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140360944A1 (en) * 2012-01-23 2014-12-11 Estar Technologies Ltd System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (prp)
US20150004702A1 (en) * 2011-08-29 2015-01-01 Stempeutics Research Private Limited System for isolating stromal vascular fraction (svf) cells from the adipose tissue and a method thereof
WO2015021189A1 (en) 2013-08-06 2015-02-12 Regenerative Sciences, Llc Bone marrow adipose portion isolation device and methods
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
US20150151294A1 (en) * 2012-05-21 2015-06-04 Korea Advanced Institute Of Science And Technology Container For Multiple Particle/Layer Separations And Particle/Layer Separtion Method Using The Same
US9119829B2 (en) 2010-09-03 2015-09-01 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US9272083B2 (en) 2009-05-29 2016-03-01 Endocellutions, Inc. Apparatus and methods for aspirating and separating components of different densities from a physiological fluid containing cells
US9339741B2 (en) 2008-07-21 2016-05-17 Becton, Dickinson And Company Density phase separation device
US20160287836A1 (en) * 2012-01-30 2016-10-06 Ipsumpro, S.L. Modified medical syringe with a flow regulator for the administration of local anaesthetic
US9522097B2 (en) 2007-10-04 2016-12-20 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9682373B2 (en) 1999-12-03 2017-06-20 Becton, Dickinson And Company Device for separating components of a fluid sample
US9694359B2 (en) 2014-11-13 2017-07-04 Becton, Dickinson And Company Mechanical separator for a biological fluid
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US20170258849A1 (en) * 2016-03-10 2017-09-14 Arthrex, Inc. Systems and methods for preparing protein enhanced serums
US9763875B2 (en) 2009-08-27 2017-09-19 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
US9897589B2 (en) 2002-05-24 2018-02-20 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US20180353954A1 (en) * 2017-06-08 2018-12-13 Patrick Pennie Dual Piston Centrifuge Tube
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US10576130B2 (en) 2013-03-15 2020-03-03 Biomet Manufacturing, Llc Treatment of collagen defects using protein solutions
US10596236B2 (en) 2016-03-10 2020-03-24 Arthrex, Inc. Systems and methods for preparing a thrombin serum
US10603665B2 (en) 2013-01-29 2020-03-31 Endocellutions, Inc. Cell concentration devices and methods that include an insert defining a lumen and a cannula assembly
US10729552B2 (en) 2015-03-18 2020-08-04 Biomet C.V. Implant configured for hammertoe and small bone fixation
CN114273091A (en) * 2021-12-30 2022-04-05 青岛市中心血站 Blood rapid centrifugal separation and collection device and control method
US20220133962A1 (en) * 2019-11-11 2022-05-05 Jun Seok Lee Body fluid component separating device
EP3912654A4 (en) * 2019-11-11 2023-01-18 Jun Seok Lee Body fluid component separating device

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101585857B1 (en) * 2014-05-23 2016-01-15 주식회사 라온 Platelet rich plasma extraction kit
BR112018002009B1 (en) 2015-07-31 2021-06-08 DePuy Synthes Products, Inc. composition of an osteogenic bone graft and method for preparing it
JP2021511814A (en) 2018-01-29 2021-05-13 フォーエバー・ラボラトリーズ・インコーポレイテッドForever Labs,Inc. Systems and methods for isolating extracellular vesicles
WO2020004174A1 (en) * 2018-06-26 2020-01-02 積水メディカル株式会社 Blood collection container
EP3820541A4 (en) 2018-07-09 2022-04-06 Hanuman Pelican, Inc. Apparatus and methods for processing blood
US11478787B2 (en) 2018-07-09 2022-10-25 Hanuman Pelican, Inc. Apparatus and methods for separating blood components
WO2020154305A1 (en) 2019-01-21 2020-07-30 Eclipse Medcorp, Llc Methods, systems and apparatus for separating components of a biological sample
EP3890799A4 (en) 2019-02-06 2022-10-26 Hanuman Pelican, Inc. Apparatus and methods for concentrating platelet-rich plasma

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US280820A (en) * 1883-07-10 Milk-can
US3508653A (en) * 1967-11-17 1970-04-28 Charles M Coleman Method and apparatus for fluid handling and separation
US3814248A (en) * 1971-09-07 1974-06-04 Corning Glass Works Method and apparatus for fluid collection and/or partitioning
US3879295A (en) * 1973-08-17 1975-04-22 Eastman Kodak Co Vacutainer with positive separation barrier
US3897343A (en) * 1974-02-27 1975-07-29 Becton Dickinson Co Plasma separator-hydrostatic pressure type
US3896733A (en) * 1973-10-18 1975-07-29 Pall Corp Autotransfusion apparatus
US3931018A (en) * 1974-08-09 1976-01-06 Becton, Dickinson And Company Assembly for collection, separation and filtration of blood
US3957654A (en) * 1974-02-27 1976-05-18 Becton, Dickinson And Company Plasma separator with barrier to eject sealant
US4001122A (en) * 1973-08-22 1977-01-04 Telan Corporation Method and device for separating blood components
US4077396A (en) * 1976-04-02 1978-03-07 Wardlaw Stephen C Material layer volume determination
US4152270A (en) * 1976-05-06 1979-05-01 Sherwood Medical Industries Inc. Phase separation device
US4187979A (en) * 1978-09-21 1980-02-12 Baxter Travenol Laboratories, Inc. Method and system for fractionating a quantity of blood into the components thereof
US4269718A (en) * 1980-05-05 1981-05-26 The Institutes Of Medical Sciences Process and device for centrifugal separation of platelets
US4322298A (en) * 1981-06-01 1982-03-30 Advanced Blood Component Technology, Inc. Centrifugal cell separator, and method of use thereof
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4675117A (en) * 1984-03-21 1987-06-23 Fresenius Ag Method of separating blood and apparatus for carrying out the method
US4818386A (en) * 1987-10-08 1989-04-04 Becton, Dickinson And Company Device for separating the components of a liquid sample having higher and lower specific gravities
US4850952A (en) * 1985-09-10 1989-07-25 Figdor Carl G Method and device for the separation and isolation of blood or bone marrow components
US4917801A (en) * 1984-12-04 1990-04-17 Becton Dickinson And Company Lymphocyte collection tube
US4929242A (en) * 1986-11-26 1990-05-29 Baxter International Inc. Solution and method for maintaining patency of a catheter
US4939081A (en) * 1987-05-27 1990-07-03 The Netherlands Cancer Institute Cell-separation
US5019243A (en) * 1987-04-03 1991-05-28 Mcewen James A Apparatus for collecting blood
US5024613A (en) * 1988-07-18 1991-06-18 Pfizer Hospital Products Group, Inc. Blood recovery system and method
US5131907A (en) * 1986-04-04 1992-07-21 Thomas Jefferson University Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself
US5178602A (en) * 1990-02-07 1993-01-12 Wells John R Automatic decanting centrifuge
US5185001A (en) * 1990-01-18 1993-02-09 The Research Foundation Of State University Of New York Method of preparing autologous plasma fibrin and application apparatus therefor
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5203825A (en) * 1991-06-07 1993-04-20 Becton, Dickinson And Company Capillary tube assembly including a vented cap
US5207638A (en) * 1989-08-24 1993-05-04 Hemotrans, Inc. Blood transfer apparatus
US5318782A (en) * 1986-10-03 1994-06-07 Weis Fogh Ulla S Method for preparing tissue repair promoting substances
US5322620A (en) * 1987-01-30 1994-06-21 Baxter International Inc. Centrifugation system having an interface detection surface
US5387187A (en) * 1992-12-01 1995-02-07 Haemonetics Corporation Red cell apheresis method
US5393674A (en) * 1990-12-31 1995-02-28 Levine Robert A Constitutent layer harvesting from a centrifuged sample in a tube
US5403272A (en) * 1992-05-29 1995-04-04 Baxter International Inc. Apparatus and methods for generating leukocyte free platelet concentrate
US5494592A (en) * 1993-04-27 1996-02-27 Haemonetics Corporation Apheresis apparatus and method
US5599558A (en) * 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
US5601727A (en) * 1991-11-04 1997-02-11 Pall Corporation Device and method for separating plasma from a biological fluid
US5614106A (en) * 1993-03-12 1997-03-25 Baxter International Inc. Method and apparatus for collection of platelets
US5632905A (en) * 1995-08-07 1997-05-27 Haynes; John L. Method and apparatus for separating formed and unformed components
US5641622A (en) * 1990-09-13 1997-06-24 Baxter International Inc. Continuous centrifugation process for the separation of biological components from heterogeneous cell populations
US5645540A (en) * 1994-10-11 1997-07-08 Stryker Corporation Blood conservation system
US5646004A (en) * 1994-08-31 1997-07-08 Activated Cell Therapy, Inc. Methods for enriching fetal cells from maternal body fluids
US5648223A (en) * 1994-08-31 1997-07-15 Activated Cell Therapy, Inc. Methods for enriching breast tumor cells
US5707876A (en) * 1996-03-25 1998-01-13 Stephen C. Wardlaw Method and apparatus for harvesting constituent layers from a centrifuged material mixture
US5707647A (en) * 1994-04-08 1998-01-13 Atrix Laboratories, Inc. Adjunctive polymer system for use with medical device
US5707331A (en) * 1995-05-05 1998-01-13 John R. Wells Automatic multiple-decanting centrifuge
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5736033A (en) * 1995-12-13 1998-04-07 Coleman; Charles M. Separator float for blood collection tubes with water swellable material
US5738796A (en) * 1994-02-25 1998-04-14 Pall Corporation Method for separating components from a biological fluid
US5785700A (en) * 1992-06-03 1998-07-28 Zimmer Patient Care, A Division Of Zimmer, Inc. Autotransfusion system with portable detachable vacuum source
US6022306A (en) * 1995-04-18 2000-02-08 Cobe Laboratories, Inc. Method and apparatus for collecting hyperconcentrated platelets
US6025201A (en) * 1995-12-28 2000-02-15 Bayer Corporation Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples
US6051146A (en) * 1998-01-20 2000-04-18 Cobe Laboratories, Inc. Methods for separation of particles
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6053856A (en) * 1995-04-18 2000-04-25 Cobe Laboratories Tubing set apparatus and method for separation of fluid components
US6063297A (en) * 1994-12-07 2000-05-16 Plasmaseal Llc Method and apparatus for making concentrated plasma and/or tissue sealant
US6071422A (en) * 1995-04-18 2000-06-06 Cobe Laboratories, Inc. Particle separation method and apparatus
US6090793A (en) * 1992-02-12 2000-07-18 Monsanto Europe S.A. Non-mitogenic substance, its preparation and use
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6196987B1 (en) * 1995-06-07 2001-03-06 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US6200287B1 (en) * 1997-09-05 2001-03-13 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US6200606B1 (en) * 1996-01-16 2001-03-13 Depuy Orthopaedics, Inc. Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
US6245900B1 (en) * 1994-02-23 2001-06-12 Kyowa Hakko Kogyo Co., Ltd. Platelet production promoting agent
US6264890B1 (en) * 1997-01-15 2001-07-24 Boehringer Labiratories, Inc. Method and apparatus for collecting and processing blood
US6355239B1 (en) * 1998-03-13 2002-03-12 Osiris Therapeutics, Inc. Uses for non-autologous mesenchymal stem cells
US6398972B1 (en) * 1999-04-12 2002-06-04 Harvest Technologies Corporation Method for producing platelet rich plasma and/or platelet concentrate
US6406671B1 (en) * 1998-12-05 2002-06-18 Becton, Dickinson And Company Device and method for separating components of a fluid sample
US6410344B1 (en) * 1999-12-28 2002-06-25 Hyundai Electronics Industries Co., Ltd. Ferroelectric random access memory device and method for the manufacture thereof
US20020082220A1 (en) * 2000-06-29 2002-06-27 Hoemann Caroline D. Composition and method for the repair and regeneration of cartilage and other tissues
US6508778B1 (en) * 1998-06-01 2003-01-21 Harvest Technologies Corporation System for withdrawal of blood
US6516953B1 (en) * 1998-12-05 2003-02-11 Becton, Dickinson And Company Device for separating components of a fluid sample
US20030050709A1 (en) * 2001-02-23 2003-03-13 Ulrich Noth Trabecular bone-derived human mesenchymal stem cells
US20030050710A1 (en) * 2001-09-06 2003-03-13 Petersen Donald W. Bone graft substitute composition
US6558341B1 (en) * 1996-05-07 2003-05-06 Sherwood Services, Ag Continuous autotransfusion filtration system
US20050084962A1 (en) * 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
US20050100536A1 (en) * 2002-04-13 2005-05-12 Allan Mishra Compositions and minimally invasive methods for treating incomplete tissue repair
US6905612B2 (en) * 2003-03-21 2005-06-14 Hanuman Llc Plasma concentrate apparatus and method
US20050130301A1 (en) * 2003-07-09 2005-06-16 Mckay William F. Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation
US20060051865A1 (en) * 2004-08-31 2006-03-09 Higgins Joel C Systems and methods for isolating stromal cells from adipose tissue and uses thereof
US20060057693A1 (en) * 2003-08-20 2006-03-16 Ebi, L.P. Methods of treatment using electromagnetic field stimulated stem cells
US7179391B2 (en) * 2002-05-24 2007-02-20 Biomet Manufacturing Corp. Apparatus and method for separating and concentrating fluids containing multiple components
US20070075016A1 (en) * 2005-08-23 2007-04-05 Biomet Manufacturing Corp. Method and apparatus for collecting biological materials
US7223346B2 (en) * 2002-05-03 2007-05-29 Hanuman Llc Methods and apparatus for isolating platelets from blood
US20080011684A1 (en) * 2005-02-07 2008-01-17 Dorian Randel E Apparatus and method for preparing platelet rich plasma and concentrates thereof
US7374678B2 (en) * 2002-05-24 2008-05-20 Biomet Biologics, Inc. Apparatus and method for separating and concentrating fluids containing multiple components
US20090014391A1 (en) * 2002-05-03 2009-01-15 Biomet Biologics, Llc Buoy Suspension Fractionation System
US7553413B2 (en) * 2005-02-07 2009-06-30 Hanuman Llc Plasma concentrator device
US20090192528A1 (en) * 2008-01-29 2009-07-30 Biomet Biologics, Inc. Method and device for hernia repair
US20100055087A1 (en) * 2008-02-27 2010-03-04 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment

Family Cites Families (455)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US593333A (en) 1897-11-09 Device for separating liquids of different
DE56103C (en) A. SCHLEE in Altona, Blücherstrafse 24 Erase roller
US1468313A (en) 1920-07-03 1923-09-18 Firm Luftfahrzeugbau Schutte L Process of producing a cold glue from blood
GB229644A (en) 1924-02-19 1925-10-08 Robert Vogel A method of producing a substance adapted to tampon wounds
US2722257A (en) 1953-02-12 1955-11-01 Compule Corp Sampling tube equipment
SE169293C1 (en) 1958-03-13 1959-11-10
US3013557A (en) 1959-04-13 1961-12-19 Hazleton Lab Inc Combination syringe, shipping container and centrifuge tube
US3159159A (en) 1960-06-01 1964-12-01 Milton J Cohen Fluid withdrawal device and container
SE358894B (en) 1961-10-25 1973-08-13 Pharmacia Ab
US3141846A (en) 1962-04-05 1964-07-21 Western States Machine Co Load control unit for cyclical centrifugal installation
DK113248B (en) 1963-09-02 1969-03-03 Pharmacia Ab Process for the preparation of dextran substituted by one or more mono- or dihydroxyalkyl groups.
US3300051A (en) 1963-09-26 1967-01-24 Internat Equipment Co Filter tube for use in a centrifuge
JPS497539B1 (en) 1966-04-13 1974-02-21
US3469369A (en) 1966-12-29 1969-09-30 Bell Telephone Labor Inc Method for preparing and applying a viscous fluid
US3441143A (en) 1967-02-10 1969-04-29 Marvel Eng Co Plural element filter assembly
US3545671A (en) 1967-02-14 1970-12-08 Eugene Ross Lab Inc Apparatus for and method of collecting,storing,separating and dispensing blood and blood components
US3409165A (en) 1967-04-03 1968-11-05 Olin Mathieson Floating deck
US3596652A (en) 1968-10-14 1971-08-03 Bio Science Labor Fluid separatory device
US3583627A (en) 1969-09-04 1971-06-08 Onslow H Wilson Apparatus for the concentration of macromolecules and subcellular particles from dilute solutions
US3654925A (en) 1969-09-23 1972-04-11 Becton Dickinson Co Plasma separator system
US3647070A (en) 1970-06-11 1972-03-07 Technicon Corp Method and apparatus for the provision of fluid interface barriers
US3741400A (en) 1970-06-15 1973-06-26 J Dick Blood sample container
US3661265A (en) 1970-07-27 1972-05-09 Contemporary Research And Dev Serum separator type container
USRE32089E (en) 1970-08-25 1986-03-04 Amicon Corporation Blood fractionating process and apparatus for carrying out same
US3723244A (en) 1971-01-18 1973-03-27 Atomic Energy Commission Fibrous fibrin sheet and method for producing same
US3706306A (en) 1971-03-03 1972-12-19 Harold J Berger Combination blood sampling vacuum syringe centrifuge container and specimen cup
US3706305A (en) 1971-03-03 1972-12-19 Harold J Berger Combination blood sampling vacuum syringe centrifuge container and specimen cup
DE2115032C3 (en) 1971-03-29 1975-05-07 Kernforschungsanlage Juelich Gmbh, 5170 Juelich Device for separating two phases in liquid-liquid extraction in a centrifuge
US3965889A (en) 1971-11-26 1976-06-29 Commissariat A L'energie Atomique Apparatus for the sampling of blood and the separation of plasma under anaerobic conditions
US3779383A (en) 1972-04-25 1973-12-18 Becton Dickinson Co Sealed assembly for separation of blood components and method
US3849072A (en) 1972-04-25 1974-11-19 Becton Dickinson Co Plasma separator
US3785549A (en) 1972-07-31 1974-01-15 Haemonetics Corp Centrifuge chuck for disposable, snap-in centrifuge rotor
DE7239445U (en) 1972-10-27 1973-08-02 Merten Utz P Disposable syringes, especially for taking blood samples
SE452109B (en) 1973-01-29 1987-11-16 Pharmacia Ab SCIENTIFIC CLEANER EXTENDED SARYTOR
US4537767A (en) 1973-01-29 1985-08-27 Pharmacia Aktiebolag Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method
US3850369A (en) 1973-03-08 1974-11-26 Coulter Electronics Centrifuge for preparing platelet rich plasma
US3962085A (en) 1973-12-19 1976-06-08 Abbott Laboratories Skimmer assembly
US3909419A (en) 1974-02-27 1975-09-30 Becton Dickinson Co Plasma separator with squeezed sealant
US3945928A (en) 1974-02-27 1976-03-23 Becton, Dickinson And Company Serum/plasma separators with centrifugal valves
US3887466A (en) 1974-02-27 1975-06-03 Becton Dickinson Co Serum/plasma separator cannula fluid by-pass type centrifugal valve cannula seal
US3941699A (en) 1974-02-27 1976-03-02 Becton, Dickinson And Company Plasma separator with centrifugal valve
US3935113A (en) 1974-02-27 1976-01-27 Becton, Dickinson And Company Serum/plasma separator with centrifugal valve
US3951801A (en) 1974-02-27 1976-04-20 Becton, Dickinson And Company Serum/plasma separator-strut stop type
US3897337A (en) 1974-02-27 1975-07-29 Becton Dickinson Co Plasma separator assembly having interface-seeking piston with centrifugal valve
US3894952A (en) 1974-02-27 1975-07-15 Becton Dickinson Co Serum/plasma separator assembly having interface-seeking piston
US3931010A (en) 1974-02-27 1976-01-06 Becton, Dickinson And Company Serum/plasma separators with centrifugal valves
US3929646A (en) 1974-07-22 1975-12-30 Technicon Instr Serum separator and fibrin filter
US4204537A (en) 1974-08-15 1980-05-27 Haemonetics Corporation Process for pheresis procedure and disposable plasma
US4059108A (en) 1974-08-15 1977-11-22 Haemonetics Corporation Process for pheresis procedure and disposable pheresis bowl therefor
DE2444524A1 (en) 1974-09-18 1976-04-08 Oeser Henning Dr METHOD AND DEVICE FOR EXPLORATION OF HUMAN BLOOD PLASMA COMPONENTS
US3982691A (en) 1974-10-09 1976-09-28 Schlutz Charles A Centrifuge separation and washing device and method
US3972812A (en) 1975-05-08 1976-08-03 Becton, Dickinson And Company Blood serum separation filter disc
US4020831A (en) 1975-12-04 1977-05-03 Technicon Instruments Corporation Blood collecting syringe
US4055501A (en) 1976-01-16 1977-10-25 Sherwood Medical Industries Inc. Fluid collection device with phase partitioning means
US4088582A (en) 1976-01-16 1978-05-09 Sherwood Medical Industries Inc. Blood phase separation means
US4046699A (en) 1976-11-01 1977-09-06 Corning Glass Works Access device for centrifugal separation assemblies
DE2800934C2 (en) 1977-01-10 1986-09-18 Robert Aaron Guilford Conn. Levine Method for performing volume measurements on the intermediate layer between the erythrocyte layer and the plasma layer of a centrifuged blood sample
AT381466B (en) 1977-03-16 1986-10-27 Ballies Uwe SEPARATING TUBES FOR CENTRIFUGAL SEPARATION
US4189385A (en) 1977-05-03 1980-02-19 Greenspan Donald J Method and apparatus for separating serum or plasma from the formed elements of the blood
US5217426A (en) 1977-08-12 1993-06-08 Baxter International Inc. Combination disposable plastic blood receiving container and blood component centrifuge
US4146172A (en) 1977-10-18 1979-03-27 Baxter Travenol Laboratories, Inc. Centrifugal liquid processing system
US4303193A (en) 1979-01-22 1981-12-01 Haemonetics Corporation Apparatus for separating blood into components thereof
US4229298A (en) 1979-02-05 1980-10-21 The Western States Machine Company Method and apparatus for determining the thickness of a charge wall formed in a centrifugal basket
US4453927A (en) 1979-02-07 1984-06-12 Gesco International Method and apparatus for microfiltration of blood
AT359653B (en) 1979-02-15 1980-11-25 Immuno Ag METHOD FOR PRODUCING A TISSUE ADHESIVE
AT359652B (en) 1979-02-15 1980-11-25 Immuno Ag METHOD FOR PRODUCING A TISSUE ADHESIVE
US4314823A (en) 1979-03-05 1982-02-09 Dionex Corporation Combination apparatus and method for chromatographic separation and quantitative analysis of multiple ionic species
JPS5917386B2 (en) 1979-03-23 1984-04-20 テルモ株式会社 Blood separation method and device
US4300717A (en) 1979-04-02 1981-11-17 Haemonetics Corporation Rotary centrifuge seal
NO146616C (en) 1979-10-04 1982-11-03 Ken Heimreid PROCEDURE AND APPARATUS FOR PREPARATION FOR INVESTIGATION OF UNCOAGULATED BLOOD.
EP0039898B1 (en) 1980-05-08 1984-08-22 Terumo Corporation Apparatus for separating blood
US4332351A (en) 1980-09-22 1982-06-01 International Business Machines Corporation Blood fraction extracting centrifuge
DE3101752A1 (en) 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "METHOD FOR PURIFYING THE BLOOD COAGINING FACTORS II, VII, IX AND / OR X AND PREPARATIONS PRODUCED THEREFORE"
DE3101733C2 (en) 1981-01-21 1982-10-14 Uwe Dr.Med. 2300 Kiel Ballies Separating element in a separating tube for centrifugal separation
US4424132A (en) 1981-02-05 1984-01-03 Asahi Kasei Kogyo Kabushiki Kaisha Apparatus and method for separating blood components
DE3105624A1 (en) 1981-02-16 1982-09-02 Hormon-Chemie München GmbH, 8000 München MATERIAL FOR SEALING AND HEALING Wounds
US4417981A (en) 1981-05-04 1983-11-29 Becton, Dickinson And Company Blood phase separator device
ATE20824T1 (en) 1981-06-25 1986-08-15 Serapharm Gmbh & Co Kg ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING.
ATE13810T1 (en) 1981-06-25 1985-07-15 Serapharm Gmbh & Co Kg ENRICHED PLASMA DERIVES TO ASSIST WOUND CLOSURE AND COVERAGE.
US4442655A (en) 1981-06-25 1984-04-17 Serapharm Michael Stroetmann Fibrinogen-containing dry preparation, manufacture and use thereof
US4735726A (en) 1981-07-22 1988-04-05 E. I. Du Pont De Nemours And Company Plasmapheresis by reciprocatory pulsatile filtration
GB2104401B (en) 1981-08-25 1985-03-20 Krauss Maffei Ag Support plate for centrifuges
US4416654A (en) 1981-09-03 1983-11-22 Haemonetics Corporation Pheresis apparatus
US4464167A (en) 1981-09-03 1984-08-07 Haemonetics Corporation Pheresis apparatus
DE3203775A1 (en) 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg FIBRINOGEN PREPARATION, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE3212412C2 (en) 1982-04-02 1986-01-02 Dr. Ruhland Nachf. GmbH, 8425 Neustadt Tissue-bondable collagen wound dressing
US4443345A (en) 1982-06-28 1984-04-17 Wells John R Serum preparator
JPS5928766A (en) 1982-08-10 1984-02-15 Sony Corp Delay circuit
US4445550B1 (en) 1982-08-20 1999-03-09 Scholle Corp Flexible walled container having membrane fitment for use with aseptic filling apparatus
US4680025A (en) 1982-08-24 1987-07-14 Baxter Travenol Laboratories, Inc. Blood component collection systems and methods
WO1984000905A1 (en) 1982-08-24 1984-03-15 Baxter Travenol Lab Blood component collection systems and methods
US4839058A (en) 1982-09-13 1989-06-13 Cawley Leo P On-line plasma modification method
US4722790A (en) 1982-09-13 1988-02-02 Cawley Leo P On-line plasma modification means
EP0109374A1 (en) 1982-10-08 1984-05-23 Antoon Soetens Apparatus for capturing solar energy on a roof or the like
SE8206767D0 (en) 1982-11-26 1982-11-26 Seroteknik Hb SET AND DEVICE FOR BATTERY CENTRIFUGAL SEPARATION OF BLOOD
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4632761A (en) 1983-08-15 1986-12-30 W. R. Grace & Co. Centrifugal microconcentrator and methods for its use
US4755301A (en) 1983-08-15 1988-07-05 W. R. Grace & Co. Apparatus and method for centrifugal recovery of retentate
JPS6053845A (en) 1983-09-05 1985-03-27 Terumo Corp Blood separating tube
US4672969A (en) 1983-10-06 1987-06-16 Sonomo Corporation Laser healing method
CH665565A5 (en) 1983-10-22 1988-05-31 Mitsui Toatsu Chemicals METHOD FOR CONTROLLING THE CONCENTRATION OF AN AQUEOUS SOLUTION OR EMULSION CONTAINING A MACROMOLECULAR CONNECTION.
JPS60250014A (en) 1984-05-28 1985-12-10 Mitsui Toatsu Chem Inc Resin for concentration
CA1244774A (en) 1983-11-09 1988-11-15 Thomas Jefferson University Medium for storing blood platelets
AT379311B (en) 1984-03-29 1985-12-27 Immuno Ag DEVICE FOR APPLICATING A TISSUE ADHESIVE
US4577514A (en) 1984-04-09 1986-03-25 Vanderbilt University Method and apparatus for sampling liquid phase components from a liquid-semisolid fluid
JPS6144825A (en) 1984-08-09 1986-03-04 Unitika Ltd Hemostatic agent
US4610656A (en) 1984-08-21 1986-09-09 Mehealus Partnership Fully portable semi-automatic mechanical heart-lung substitution system and method
US4776964A (en) 1984-08-24 1988-10-11 William F. McLaughlin Closed hemapheresis system and method
US4928603A (en) 1984-09-07 1990-05-29 The Trustees Of Columbia University In The City Of New York Method of preparing a cryoprecipitated suspension and use thereof
US4627879A (en) 1984-09-07 1986-12-09 The Trustees Of Columbia University In The City Of New York Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma
US5165938A (en) 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US5053134A (en) 1984-12-04 1991-10-01 Becton Dickinson And Company Lymphocyte collection tube
US4639316A (en) 1984-12-14 1987-01-27 Becton, Dickinson And Company Automatic liquid component separator
US5372945A (en) 1985-06-06 1994-12-13 Alchas; Paul G. Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endothelial cell product
AT382783B (en) 1985-06-20 1987-04-10 Immuno Ag DEVICE FOR APPLICATING A TISSUE ADHESIVE
SE448323B (en) 1985-08-27 1987-02-09 Ersson Nils Olof PROCEDURE AND PROCEDURE TO SEPARATE SERUM OR PLASMA FROM BLOOD
US4724317A (en) 1985-12-05 1988-02-09 Baxter Travenol Laboratories, Inc. Optical data collection apparatus and method used with moving members
US4755300A (en) 1985-12-23 1988-07-05 Haemonetics Corporation Couette membrane filtration apparatus for separating suspended components in a fluid medium using high shear
US4871462A (en) 1985-12-23 1989-10-03 Haemonetics Corporation Enhanced separation of blood components
AU578554B2 (en) 1986-01-24 1988-10-27 Japanese Red Cross Society Centrifugal method of separating blood components
US5112490A (en) 1986-02-19 1992-05-12 Jon Turpen Sample filtration, separation and dispensing device
SE8601891D0 (en) 1986-04-24 1986-04-24 Svante Jonsson PLASMA SWITCH TREATMENT AND TROMBOCYTING MACHINE
DE3615558A1 (en) 1986-05-09 1987-11-12 Behringwerke Ag METHOD FOR PRODUCING A FACTOR V CONCENTRATE
DE3622642A1 (en) 1986-07-05 1988-01-14 Behringwerke Ag ONE-COMPONENT TISSUE ADHESIVE AND METHOD FOR THE PRODUCTION THEREOF
US4983158A (en) 1986-07-22 1991-01-08 Haemonetics Corporation Plasmapheresis centrifuge bowl
US4943273A (en) 1986-07-22 1990-07-24 Haemonetics Corporation Disposable centrifuge bowl for blood processing
US4714457A (en) 1986-09-15 1987-12-22 Robert Alterbaum Method and apparatus for use in preparation of fibrinogen from a patient's blood
US4915847A (en) 1987-08-04 1990-04-10 Baxter International Inc. Cryoglobulin separation
CH673117A5 (en) 1986-12-10 1990-02-15 Ajinomoto Kk
US4933291A (en) 1986-12-22 1990-06-12 Eastman Kodak Company Centrifugable pipette tip and pipette therefor
US5053127A (en) 1987-01-13 1991-10-01 William F. McLaughlin Continuous centrifugation system and method for directly deriving intermediate density material from a suspension
US5641414A (en) 1987-01-30 1997-06-24 Baxter International Inc. Blood processing systems and methods which restrict in flow of whole blood to increase platelet yields
US4834890A (en) 1987-01-30 1989-05-30 Baxter International Inc. Centrifugation pheresis system
US5370802A (en) 1987-01-30 1994-12-06 Baxter International Inc. Enhanced yield platelet collection systems and methods
US4832851A (en) 1987-02-02 1989-05-23 W. R. Grace & Co. Centrifugal force-enhanced filtration of fluids
US4983157A (en) 1987-03-23 1991-01-08 Ceramics Process Systems Corp. Centrifugation system using static layer
US5030341A (en) 1987-04-03 1991-07-09 Andronic Technologies, Inc. Apparatus for separating phases of blood
IT1203461B (en) 1987-04-08 1989-02-15 Dideco Spa BLOOD CENTRIFUGATION CELL
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US4738655A (en) 1987-06-17 1988-04-19 Utah Bioresearch, Inc. Apparatus and method for obtaining a rapid hematocrit
DE3723092C1 (en) 1987-07-13 1989-01-26 Westfalia Separator Ag Continuous centrifuge for the industrial production of proteins from human blood plasma
US5260420A (en) 1987-07-30 1993-11-09 Centre Regional De Transfusion Sanguine De Lille Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
DE3726227A1 (en) 1987-08-07 1989-02-16 Krauss Maffei Ag DEVICE FOR RESULTS CONTROLLING A FILTER CENTRIFUGE
US4877520A (en) 1987-10-08 1989-10-31 Becton, Dickinson And Company Device for separating the components of a liquid sample having higher and lower specific gravities
US4844818A (en) 1987-10-23 1989-07-04 Becton Dickinson & Company Method for separating the cellular components of blood samples
US4957638A (en) 1987-10-23 1990-09-18 Becton Dickinson And Company Method for separating the cellular components of blood samples
US5290552A (en) 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
ES2064439T3 (en) 1988-05-02 1995-02-01 Project Hear SURGICAL ADHESIVE MATERIAL.
US4957637A (en) 1988-05-23 1990-09-18 Sherwood Medical Company Serum separator system for centrifuge with piercable membrane
AT397203B (en) 1988-05-31 1994-02-25 Immuno Ag FABRIC ADHESIVE
AU617265B2 (en) 1988-06-23 1991-11-21 Asahi Medical Co. Ltd. Method for separating blood into blood components, and blood components separator unit
US4874368A (en) 1988-07-25 1989-10-17 Micromedics, Inc. Fibrin glue delivery system
US4846780A (en) 1988-08-10 1989-07-11 Exxon Production Research Company Centrifuge processor and liquid level control system
US4902281A (en) 1988-08-16 1990-02-20 Corus Medical Corporation Fibrinogen dispensing kit
US4946601A (en) 1988-08-22 1990-08-07 Sherwood Medical Company Blood serum separator tube
JPH02129224A (en) 1988-11-10 1990-05-17 Terumo Corp Preparation of fibrin
US4973168A (en) 1989-01-13 1990-11-27 Chan Kwan Ho Vacuum mixing/bone cement cartridge and kit
DE8900469U1 (en) 1989-01-17 1990-05-23 Espe Stiftung & Co Produktions- Und Vertriebs Kg, 8031 Seefeld, De
US5002571A (en) 1989-02-06 1991-03-26 Donnell Jr Francis E O Intraocular lens implant and method of locating and adhering within the posterior chamber
SE8900586L (en) 1989-02-21 1990-08-22 Pharmacia Ab COMPOSITION AND PROCEDURES TO PREVENT ADHESION BETWEEN BODY TISSUE
CA2011100C (en) 1989-05-24 1996-06-11 Stephen C. Wardlaw Centrifuged material layer measurements taken in an evacuated tube
US5226877A (en) 1989-06-23 1993-07-13 Epstein Gordon H Method and apparatus for preparing fibrinogen adhesive from whole blood
US5000970A (en) 1989-06-30 1991-03-19 Horizons International Foods, Inc. Process for preparing reheatable french fried potatoes
WO1991001383A1 (en) 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
US5316674A (en) 1989-09-12 1994-05-31 Pall Corporation Device for processing blood for human transfusion
US5258126A (en) 1989-09-12 1993-11-02 Pall Corporation Method for obtaining platelets
US5152905A (en) 1989-09-12 1992-10-06 Pall Corporation Method for processing blood for human transfusion
US5100564A (en) 1990-11-06 1992-03-31 Pall Corporation Blood collection and processing system
IL95641A0 (en) 1989-09-15 1991-06-30 Curative Tech Inc Preparation of a platelet releasate product
US5104375A (en) 1989-10-16 1992-04-14 Johnson & Johnson Medical, Inc. Locking holder for a pair of syringes and method of use
US5039401A (en) 1990-05-16 1991-08-13 Eastman Kodak Company Blood collection and centrifugal separation device including a valve
US5219328A (en) 1990-01-03 1993-06-15 Cryolife, Inc. Fibrin sealant delivery method
US5030215A (en) 1990-01-03 1991-07-09 Cryolife, Inc. Preparation of fibrinogen/factor XIII precipitate
US5318524A (en) 1990-01-03 1994-06-07 Cryolife, Inc. Fibrin sealant delivery kit
NL9000090A (en) 1990-01-15 1991-08-01 Harimex Ligos Bv METHOD FOR PREPARING A FIBRINOGEN CONCENTRATE FROM BLOOD PLASMA, APPARATUS FOR CARRYING OUT THIS PROCESS AND METHOD FOR PREPARING FIBRINOGEN FROM THE CONCENTRATE
US5047004A (en) 1990-02-07 1991-09-10 Wells John R Automatic decanting centrifuge
US5045048A (en) 1990-03-29 1991-09-03 Haemonetics Corporation Rotary centrifuge bowl and seal for blood processing
US5204537A (en) 1990-03-30 1993-04-20 Recognition Equipment Incorporated Thickness sensor comprising a leaf spring means, and a light sensor
DK119490D0 (en) 1990-05-14 1990-05-14 Unes As Apparatus for the preparation of a concentrate of coagulation factors, such as the fibrinogen, from a blood portion
US5171456A (en) 1990-06-14 1992-12-15 Baxter International Inc. Automated blood component separation procedure and apparatus promoting different functional characteristics in multiple blood components
US5156586A (en) 1990-07-10 1992-10-20 Bardyne Orbital separator for orbitally separating a mixture
FR2665378B1 (en) 1990-08-03 1992-10-09 Guigan Jean DEVICE FOR SEPARATING BY CENTRIFUGATION TWO PHASES FROM A SAMPLE OF A HETEROGENEOUS LIQUID, USABLE IN PARTICULAR FOR THE SEPARATION OF TOTAL BLOOD PLASMA.
US5420250A (en) 1990-08-06 1995-05-30 Fibrin Corporation Phase transfer process for producing native plasma protein concentrates
US5173295A (en) 1990-10-05 1992-12-22 Advance Biofactures Of Curacao, N.V. Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor
US5112484A (en) 1990-10-11 1992-05-12 Zuk, Inc. Filtration apparatus
US5217627A (en) 1990-11-06 1993-06-08 Pall Corporation System and method for processing biological fluid
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5955436A (en) 1990-11-20 1999-09-21 Alcon Laboratories, Inc. Use of platelet derived growth factor to enhance wound healing
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US5234608A (en) 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
US5137832A (en) 1991-01-02 1992-08-11 Becton Dickinson & Company Quantification of fibrinogen in whole blood samples contained in a tube using a float to separate materials
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5156613A (en) 1991-02-13 1992-10-20 Interface Biomedical Laboratories Corp. Collagen welding rod material for use in tissue welding
US5762798A (en) 1991-04-12 1998-06-09 Minntech Corporation Hollow fiber membranes and method of manufacture
US5236604A (en) 1991-05-29 1993-08-17 Sherwood Medical Company Serum separation blood collection tube and the method of using thereof
US5269927A (en) 1991-05-29 1993-12-14 Sherwood Medical Company Separation device for use in blood collection tubes
SE9101853D0 (en) 1991-06-17 1991-06-17 Jonas Wadstroem IMPROVED TISSUE ASHESIVE
FR2679251B1 (en) 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San PROCESS FOR THE PREPARATION OF A HUMAN THROMBIN CONCENTRATE FOR THERAPEUTIC USE.
DE4126341C1 (en) 1991-08-09 1993-01-28 Fresenius Ag, 6380 Bad Homburg, De
US5251786A (en) 1991-08-16 1993-10-12 Helena Laboratories Corporation Biological fluid collection and delivery apparatus and method
BR9103724A (en) 1991-08-29 1993-03-30 Univ Estadual Paulista Julio D FIBRINE GLUE DERIVED FROM SNAKE POISON AND PROCESS FOR ITS PREPARATION
DE69229272T2 (en) 1991-09-05 2000-02-03 Baxter Int TOPICAL FIBRINOGEN COMPLEX
DE4129516C2 (en) 1991-09-06 2000-03-09 Fresenius Ag Method and device for separating blood into its components
EP0534178B1 (en) 1991-09-27 2001-04-18 Omrix Biopharmaceuticals S.A. Improved tissue glue prepared by using cryoprecipitate
JP3388352B2 (en) 1991-10-18 2003-03-17 バクスター、インターナショナル、インコーポレイテッド Bone marrow kit
US5344752A (en) 1991-10-30 1994-09-06 Thomas Jefferson University Plasma-based platelet concentrate preparations
US5190057A (en) 1991-12-13 1993-03-02 Faezeh Sarfarazi Sarfarazi method of closing a corneal incision
US5833866A (en) 1991-12-23 1998-11-10 Baxter International Inc. Blood collection systems and methods which derive instantaneous blood component yield information during blood processing
US5690835A (en) 1991-12-23 1997-11-25 Baxter International Inc. Systems and methods for on line collection of cellular blood components that assure donor comfort
DE4202667C1 (en) 1992-01-29 1993-05-13 Behringwerke Ag, 3550 Marburg, De
AU670075B2 (en) 1992-02-26 1996-07-04 Allergan, Inc. Use of platelet derived growth factor in ophthalmic wound healing
US5298016A (en) 1992-03-02 1994-03-29 Advanced Haemotechnologies Apparatus for separating plasma and other wastes from blood
SE9201413L (en) 1992-04-30 1993-10-31 Stiftelsen Foer Medicinsk Tekn Preparation and Methods for Apheresis Preparation of Platelet Concentrate with Significantly Extended Durability
US5271852A (en) 1992-05-01 1993-12-21 E. I. Du Pont De Nemours And Company Centrifugal methods using a phase-separation tube
FR2691911B1 (en) 1992-06-05 1994-11-25 Delmas Olivier Device for obtaining a supernatant of activated thrombocytes, process using the device and obtained supernatant.
DK83092D0 (en) 1992-06-24 1992-06-24 Unes As PROCEDURE FOR THE EXTRACTION OF THROMBIN
US5443481A (en) 1992-07-27 1995-08-22 Lee; Benjamin I. Methods and device for percutaneous sealing of arterial puncture sites
AU4926193A (en) 1992-09-21 1994-04-12 Vitaphore Corporation Embolization plugs for blood vessels
FR2696095B1 (en) 1992-09-30 1994-11-25 Inoteb Biological glue based on proteins coagulable by thrombin, enriched in platelet factors, its preparation and its application.
US5354483A (en) 1992-10-01 1994-10-11 Andronic Technologies, Inc. Double-ended tube for separating phases of blood
CN1091315A (en) 1992-10-08 1994-08-31 E·R·斯奎布父子公司 Fibrin sealant compositions and using method thereof
CN1074709A (en) 1992-11-26 1993-07-28 刘高东 A kind of making method of zymoplasm
US5520885A (en) 1993-01-19 1996-05-28 Thermogenesis Corporation Fibrinogen processing apparatus, method and container
US5370221A (en) 1993-01-29 1994-12-06 Biomet, Inc. Flexible package for bone cement components
US5290918A (en) 1993-02-23 1994-03-01 Haemacure Biotech Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US5395923A (en) 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
US5330974A (en) 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
GB9307321D0 (en) 1993-04-07 1993-06-02 Knight Scient Ltd Method of separating particles from a filter
US5409833A (en) 1993-07-01 1995-04-25 Baxter International Inc. Microvessel cell isolation apparatus
US5456885A (en) 1993-07-12 1995-10-10 Coleman; Charles M. Fluid collection, separation and dispensing tube
US6189704B1 (en) 1993-07-12 2001-02-20 Baxter International Inc. Inline filter
JPH07103969A (en) 1993-08-13 1995-04-21 Niigata Kako Kk Blood separation member and blood collecting tube for blood separation
US5571418A (en) 1993-08-20 1996-11-05 Lee; Patrice A. Hemofiltration of toxic mediator-related disease
US5916557A (en) 1993-11-12 1999-06-29 The Trustees Of Columbia University In The City Of New York Methods of repairing connective tissues
CA2131738C (en) 1993-11-17 2001-09-04 Lonny R. Kelley Flow enhanced one-pass centrifuge separator
ZA948564B (en) 1993-11-19 1995-07-26 Bristol Myers Squibb Co Liquid separation apparatus and method
US5411885A (en) 1993-12-17 1995-05-02 New York Blood Center, Inc. Methods for tissue embedding and tissue culturing
US5437598A (en) 1994-01-21 1995-08-01 Cobe Laboratories, Inc. Automation of plasma sequestration
US5533518A (en) 1994-04-22 1996-07-09 Becton, Dickinson And Company Blood collection assembly including mechanical phase separating insert
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5795751A (en) 1994-06-09 1998-08-18 Lockheed Martin Idaho Technologies Company Biofilter for removal of nitrogen oxides from contaminated gases under aerobic conditions
US5501371A (en) 1994-07-07 1996-03-26 Schwartz-Feldman; Jean Mixing syringe
US5840502A (en) 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US5663051A (en) 1994-08-31 1997-09-02 Activated Cell Therapy, Inc. Separation apparatus and method
US5577513A (en) 1994-08-31 1996-11-26 Activated Cell Therapy, Inc. Centrifugation syringe, system and method
US5474687A (en) 1994-08-31 1995-12-12 Activated Cell Therapy, Inc. Methods for enriching CD34+ human hematopoietic progenitor cells
US5575778A (en) 1994-09-21 1996-11-19 B. Braun Melsungen Ag Blood-taking device
US5588958A (en) 1994-09-21 1996-12-31 C. R. Bard, Inc. Closed wound orthopaedic drainage and autotransfusion system
US5733253A (en) 1994-10-13 1998-03-31 Transfusion Technologies Corporation Fluid separation system
US5601711A (en) 1994-10-31 1997-02-11 Gelman Sciences Inc. Selective separation filter device
CA2206516C (en) 1994-12-02 2007-04-17 Bristol-Myers Squibb Company Centrifuge reagent delivery system
WO1996016714A1 (en) 1994-12-02 1996-06-06 Bristol-Myers Squibb Company Method and device for separating fibrin monomer from blood plasma
US5733446A (en) 1994-12-02 1998-03-31 Bristol-Myers Squibb Company Centrifuge with annular filter
CA2182862C (en) 1994-12-07 2006-10-03 Richard D. Antanavich Plasma concentrate and tissue sealant compositions
US5560830A (en) 1994-12-13 1996-10-01 Coleman; Charles M. Separator float and tubular body for blood collection and separation and method of use thereof
NO301562B1 (en) 1994-12-21 1997-11-10 Exxon Production Research Co Device for measuring
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US6676629B2 (en) 1995-02-06 2004-01-13 Mark S. Andrew Tissue liquefaction and aspiration for dental treatment
US7011644B1 (en) 1995-02-06 2006-03-14 Andrew Mark S Tissue liquefaction and aspiration for dental treatment
US5823986A (en) 1995-02-08 1998-10-20 Medtronic, Inc. Perfusion system
US5733545A (en) 1995-03-03 1998-03-31 Quantic Biomedical Partners Platelet glue wound sealant
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US5900245A (en) 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5674173A (en) 1995-04-18 1997-10-07 Cobe Laboratories, Inc. Apparatus for separating particles
USRE38730E1 (en) 1995-05-05 2005-04-26 Harvest Technologies Corporation Automatic multiple-decanting centrifuge and method of treating physiological fluids
JPH11508813A (en) 1995-06-06 1999-08-03 クウォンティック バイオメディカル パートナーズ Apparatus and method for concentrating plasma
US5958250A (en) 1995-06-07 1999-09-28 Baxter International Inc. Blood processing systems and methods which optically derive the volume of platelets contained in a plasma constituent
US6544727B1 (en) 1995-06-07 2003-04-08 Cerus Corporation Methods and devices for the removal of psoralens from blood products
US5837150A (en) 1995-06-07 1998-11-17 Cobe Laboratories, Inc. Extracorporeal blood processing methods
US20020192632A1 (en) 1995-06-07 2002-12-19 Hei Derek J. Method and devices for the removal of psoralens from blood products
US5750025A (en) 1995-06-07 1998-05-12 Cobe Laboratories, Inc. Disposable for an apheresis system with a contoured support
US6351659B1 (en) 1995-09-28 2002-02-26 Brainlab Med. Computersysteme Gmbh Neuro-navigation system
WO1997012679A1 (en) 1995-10-03 1997-04-10 Beckman Instruments, Inc. Axial spin blood separation system and method
US5643193A (en) 1995-12-13 1997-07-01 Haemonetics Corporation Apparatus for collection washing and reinfusion of shed blood
US5817519A (en) 1995-12-28 1998-10-06 Bayer Corporation Automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples
US5733466A (en) 1996-02-06 1998-03-31 International Business Machines Corporation Electrolytic method of depositing gold connectors on a printed circuit board
US5865785A (en) 1996-02-23 1999-02-02 Baxter International Inc. Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes
US5834418A (en) 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
EP0912250B1 (en) 1996-04-24 1999-11-03 Claude Fell Cell separation system for biological fluids like blood
WO2000062828A1 (en) 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
WO1997040864A1 (en) 1996-04-30 1997-11-06 Medtronic, Inc. Method for making autologous fibrin sealant
US6020196A (en) 1996-05-09 2000-02-01 Baxter International Inc. Devices for harvesting and homogenizing adipose tissue containing autologous endothelial cells
JP2859845B2 (en) 1996-05-09 1999-02-24 照明 伊藤 Serum collection aid
US5811151A (en) 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US5824084A (en) 1996-07-03 1998-10-20 The Cleveland Clinic Foundation Method of preparing a composite bone graft
WO1998004681A2 (en) 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
WO1998012274A1 (en) 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
FR2757770B1 (en) 1996-12-30 1999-02-26 Inoteb PROCESS FOR THE PREPARATION OF A BIOLOGICAL GLUE CAPABLE OF COAGULATING BY SIMPLE ADDITION OF CALCIUM IONS
US5961210A (en) 1997-01-24 1999-10-05 Mccardel; Brian R. Bone cement preparation device, and methods of constructing and utilizing same
US5889584A (en) 1997-03-10 1999-03-30 Robert A. Levine Assembly for rapid measurement of cell layers
WO1998043720A1 (en) 1997-04-03 1998-10-08 Baxter International Inc. Interface detection and control systems and methods
AU7153998A (en) 1997-04-25 1998-11-24 Washington State University Research Foundation Semi-continuous, small volume centrifugal blood separator
US5860937A (en) 1997-04-30 1999-01-19 Becton, Dickinson & Company Evacuated sample collection tube with aqueous additive
DE19718648A1 (en) 1997-05-02 1998-11-05 Merck Patent Gmbh Method and device for producing sterile packed bone cement
US6063624A (en) 1997-06-09 2000-05-16 Baxter International Inc. Platelet suspensions and methods for resuspending platelets
CA2295247C (en) 1997-06-18 2009-05-26 Cohesion Technologies, Inc. Compositions containing thrombin and microfibrillar collagen
IT1292410B1 (en) 1997-06-24 1999-02-08 Roberto Beretta READY-TO-USE CONTAINER TO OBTAIN AUTOLOGOUS FIBRIN GLUE
US6979307B2 (en) 1997-06-24 2005-12-27 Cascade Medical Enterprises Llc Systems and methods for preparing autologous fibrin glue
US5918622A (en) 1997-07-01 1999-07-06 Bermad Separation valve
US6007811A (en) 1997-07-01 1999-12-28 Sea Run Holdings, Inc. Method of producing fibrin sealant from clotting factors in fish blood
US6623472B1 (en) 1997-08-16 2003-09-23 Orthogen Gentechnologic. Gmbh Method for inducing therapeutically-effective proteins
US5938621A (en) 1997-09-12 1999-08-17 Becton Dickinson And Company Collection container assembly
US5955032A (en) 1997-09-12 1999-09-21 Becton Dickinson And Company Collection container assembly
JP2001521786A (en) 1997-10-30 2001-11-13 ザ ジュネラル ホスピタル コーポレーション Adhesion of cartilage matrix using isolated chondrocytes
US5934803A (en) 1997-10-30 1999-08-10 Physical Systems, Inc. Apparatus and method for mixing multi-part reaction materials under vacuum
US7031775B2 (en) 1997-11-07 2006-04-18 Medtronic, Inc. Method and system for myocardial infarction repair
US5951160A (en) 1997-11-20 1999-09-14 Biomet, Inc. Method and apparatus for packaging, mixing and delivering bone cement
US6478808B2 (en) 1997-12-17 2002-11-12 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
WO1999047190A1 (en) 1998-03-16 1999-09-23 Medtronic, Inc. Hemostatic system and components for extracorporeal circuit
US5924972A (en) 1998-03-24 1999-07-20 Turvaville; L. Jackson Portable D.C. powered centrifuge
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
US6327491B1 (en) 1998-07-06 2001-12-04 Neutar, Llc Customized surgical fixture
US6274090B1 (en) 1998-08-05 2001-08-14 Thermogenesis Corp. Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
US5999558A (en) 1998-08-13 1999-12-07 Ucar Carbon Technology Corporation Integral spray cooled furnace roof and fume elbow
US6308747B1 (en) 1998-10-01 2001-10-30 Barry Farris Needleless method and apparatus for transferring liquid from a container to an injecting device without ambient air contamination
US6563953B2 (en) 1998-11-30 2003-05-13 Microsoft Corporation Predictive image compression using a single variable length code for both the luminance and chrominance blocks for each macroblock
US6328765B1 (en) 1998-12-03 2001-12-11 Gore Enterprise Holdings, Inc. Methods and articles for regenerating living tissue
US6479298B1 (en) 1998-12-05 2002-11-12 Becton, Dickinson And Company Device and method for separating components of a fluid sample
US6280400B1 (en) 1998-12-05 2001-08-28 Becton Dickinson And Company Device and method for separating component of a liquid sample
ATE319995T1 (en) 1998-12-05 2006-03-15 Becton Dickinson Co DEVICE AND METHOD FOR SEPARATING COMPONENTS OF A LIQUID SAMPLE
DE19903876B4 (en) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Process for the in vitro formation and accumulation of interleukin-1 receptor antagonists
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6294187B1 (en) 1999-02-23 2001-09-25 Osteotech, Inc. Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same
US6322785B1 (en) 1999-03-02 2001-11-27 Natrex Technologies Methods and compositions for bone graft implants
KR100979664B1 (en) 1999-03-10 2010-09-02 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Adipose-derived stem cells and lattices
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US20050076396A1 (en) 1999-03-10 2005-04-07 Katz Adam J. Adipose-derived stem cells and lattices
US6334842B1 (en) 1999-03-16 2002-01-01 Gambro, Inc. Centrifugal separation apparatus and method for separating fluid components
US6296602B1 (en) 1999-03-17 2001-10-02 Transfusion Technologies Corporation Method for collecting platelets and other blood components from whole blood
US6432119B1 (en) 1999-03-17 2002-08-13 Angiotrax, Inc. Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials
US6417004B1 (en) 1999-04-29 2002-07-09 Helena Laboratories Corporation Enhancing clot detection in activated clotting time and other fibrin endpoint based tests
EP1057534A1 (en) 1999-06-03 2000-12-06 Haemonetics Corporation Centrifugation bowl with filter core
US6629919B2 (en) 1999-06-03 2003-10-07 Haemonetics Corporation Core for blood processing apparatus
US6472162B1 (en) 1999-06-04 2002-10-29 Thermogenesis Corp. Method for preparing thrombin for use in a biological glue
US6316247B1 (en) 1999-06-15 2001-11-13 University Of Pittsburgh System and method for refining liposuctioned adipose tissue
US6716187B1 (en) 1999-07-08 2004-04-06 Implant Innovations, Inc. Platelet concentration syringe kit
AU5918800A (en) 1999-07-08 2001-01-30 Implant Innovations, Inc. Platelet concentration syringe kit
US6758978B1 (en) 1999-08-06 2004-07-06 Gl&V Management Hungary Kft. Deep bed thickener/clarifiers with enhanced liquid removal
US6284142B1 (en) 1999-09-03 2001-09-04 Baxter International Inc. Sensing systems and methods for differentiating between different cellular blood species during extracorporeal blood separation or processing
US6294094B1 (en) 1999-09-03 2001-09-25 Baxter International Inc. Systems and methods for sensing red blood cell hematocrit
WO2001020999A1 (en) * 1999-09-23 2001-03-29 Trimedyne, Inc. Materials and methods for inducing angiogenesis and the repair of mammalian tissue
US6487992B1 (en) 1999-11-22 2002-12-03 Robert L. Hollis Dog behavior monitoring and training apparatus
US6803022B2 (en) 1999-12-06 2004-10-12 Becton, Dickinson And Company Device and method for separating components of a fluid sample
US6471069B2 (en) 1999-12-03 2002-10-29 Becton Dickinson And Company Device for separating components of a fluid sample
US6409528B1 (en) 1999-12-06 2002-06-25 Becton, Dickinson And Company Device and method for collecting, preparation and stabilizing a sample
ITAL990010U1 (en) 1999-12-14 2001-06-14 Maria Cristina Sacchi NEW LABORATORY METHOD FOR PREPARING GEL AND PLATE MEMBRANES OBTAINED FROM THE PLATE CONCENTRATE.
US6286670B1 (en) 2000-03-14 2001-09-11 Biomet, Inc. Method and apparatus for mixing a compound utilizing a gas permeable barrier
US20020104808A1 (en) 2000-06-30 2002-08-08 Lou Blasetti Method and apparatus for producing platelet rich plasma and/or platelet concentrate
WO2001083068A1 (en) 2000-04-28 2001-11-08 Harvest Technologies Corporation Blood components separator disk
US6368498B1 (en) 2000-08-30 2002-04-09 Paul Guilmette Liquid separator
US7411006B2 (en) 2000-10-23 2008-08-12 Shanbrom Technologies, Llc Enhanced production of blood clotting factors and fibrin fabric
CZ20031277A3 (en) 2000-11-08 2003-08-13 Octapharma Ag Process for preparing latent antithrombin III
US20020090711A1 (en) 2000-11-20 2002-07-11 Goran Karlsson Process for preparing latent antithrombin III
WO2002060925A1 (en) 2001-01-30 2002-08-08 Genzymes Corporation Method of producing latent antithrombin iii
US6911202B2 (en) 2001-02-06 2005-06-28 Abraham Amir Cosmetic repair using cartilage producing cells and medical implants coated therewith
AU2002232104A1 (en) 2001-02-26 2002-09-12 Ben-Ami Ballin Syringe for use in blood analysis
US6723131B2 (en) 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit
JP2005098704A (en) 2001-03-13 2005-04-14 Hajime Ogata Method for fractionating particulate of different specific gravity
JP2004536794A (en) 2001-04-09 2004-12-09 メドトロニック、インコーポレイテッド Method for separating blood components using microcentrifuge and method for using the same
ES2338868T3 (en) 2001-06-06 2010-05-13 PERFUSION PARTNERS & ASSOCIATES, INC. SET OF CENTRIFUGE PIPES.
US6623959B2 (en) 2001-06-13 2003-09-23 Ethicon, Inc. Devices and methods for cell harvesting
US6764531B2 (en) 2001-07-06 2004-07-20 J. S. Hogan Method and apparatus for cleaning a gas
AU2002316696B2 (en) 2001-07-16 2007-08-30 Depuy Products, Inc. Cartilage repair and regeneration scaffold and method
ES2386280T3 (en) 2001-08-09 2012-08-16 Giuseppe Intini Tissue implants and method for preparing and using them
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US6638503B2 (en) 2001-11-28 2003-10-28 Maharashtra Association For The Cultivation Of Science Streptomyces megasporus sd5, process for the isolation thereof, novel fibrinolytic enzyme prepared therefrom, process for the production of said enzyme and method of treatment of thrombolytic disorders using said enzyme
BR0214772A (en) 2001-12-07 2007-01-09 Macropore Biosurgery Inc systems and methods for treating patients with processed liposuction cells
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US7514075B2 (en) 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US20030162707A1 (en) 2001-12-20 2003-08-28 Fraser John K. Systems and methods for treating patients with collagen-rich material extracted from adipose tissue
US8313742B2 (en) 2002-03-29 2012-11-20 Depuy Acromed, Inc. Cell-containing bone graft material
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US20040182795A1 (en) 2003-03-21 2004-09-23 Randel Dorian Apparatus and method for concentration of plasma from whole blood
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
CN102353569A (en) 2002-05-13 2012-02-15 贝克顿·迪金森公司 Protease inhibitor sample collection system
US7845499B2 (en) 2002-05-24 2010-12-07 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
US7304128B2 (en) 2002-06-04 2007-12-04 E.I. Du Pont De Nemours And Company Carbon nanotube binding peptides
US7176034B2 (en) 2002-07-03 2007-02-13 St. Joseph's Healthcare Apparatus and method for filtering biological samples
WO2004009207A1 (en) 2002-07-18 2004-01-29 Hanuman Llc Plasma concentrating apparatus and method
US7077827B2 (en) 2002-08-30 2006-07-18 Christian John Greenfield Syringe for sequential delivery of different fluids
AU2003272492B2 (en) 2002-09-19 2007-12-20 Harvest Technologies Corporation Sterile disposable unit
US20040120942A1 (en) 2002-12-23 2004-06-24 Mcginnis Daniel Device and process for the preparation of autologous thrombin serum
US20040182394A1 (en) 2003-03-21 2004-09-23 Alvey Jeffrey Arthur Powered air purifying respirator system and self contained breathing apparatus
JP4344528B2 (en) 2003-04-07 2009-10-14 テルモ株式会社 Medical container and method for manufacturing medical container
AU2004242150B2 (en) 2003-05-19 2008-01-10 Harvest Technologies Corporation Method and apparatus for separating fluid components
WO2004113316A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
JP2005013783A (en) 2003-06-23 2005-01-20 Moriai Seiki Kk Liquid centrifugal separator
CN1878470A (en) 2003-09-17 2006-12-13 马克罗珀尔生物外科公司 Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US9050352B2 (en) 2003-10-16 2015-06-09 Stephen John Ralph Immunomodulating compositions and uses therefor
US20050145187A1 (en) 2003-12-29 2005-07-07 Gray James D. Asset management of livestock in an open range using satellite communications
US7354515B2 (en) 2004-02-23 2008-04-08 Millennium Medical Technologies, Inc. Fluid concentrator
SE0402500D0 (en) 2004-10-14 2004-10-14 Astra Tech Ab Method and apparatus for autotransfusion
ITRM20040638A1 (en) 2004-12-24 2005-03-24 Advance Holdings Ltd SEMISINTETIC PIASTRINIC GEL AND METHOD FOR ITS PREPARATION.
WO2006086199A1 (en) 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
WO2006086201A2 (en) 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
US7766900B2 (en) 2005-02-21 2010-08-03 Biomet Manufacturing Corp. Method and apparatus for application of a fluid
US7694828B2 (en) 2005-04-27 2010-04-13 Biomet Manufacturing Corp. Method and apparatus for producing autologous clotting components
US7531355B2 (en) 2005-07-29 2009-05-12 The Regents Of The University Of California Methods and compositions for smooth muscle reconstruction
US8048297B2 (en) 2005-08-23 2011-11-01 Biomet Biologics, Llc Method and apparatus for collecting biological materials
FR2890976B1 (en) 2005-09-20 2007-12-14 Univ La Reunion KIT FOR PREPARING A COMPOSITION COMPRISING ADIPOCYTE CELLS AND METHOD FOR OBTAINING THE SAME
DE102006005016A1 (en) 2006-02-03 2007-08-16 Orthogen Ag Conditioned blood composition and process for its preparation
WO2007127834A2 (en) 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
US8567609B2 (en) 2006-05-25 2013-10-29 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
TWI311388B (en) 2006-06-02 2009-06-21 Hon Hai Prec Ind Co Ltd Printed antenna
WO2008022651A1 (en) 2006-08-21 2008-02-28 Antoine Turzi Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
WO2008030084A2 (en) 2006-09-05 2008-03-13 Maasland N.V. A milking implement
US20080064626A1 (en) 2006-09-08 2008-03-13 Zanella John M Methods of treating tendonitis in a subject by using an anti-cytokine agent
US7708512B2 (en) 2006-10-18 2010-05-04 Newfrey Llc Compression limiter
JP2008104789A (en) 2006-10-27 2008-05-08 Nipro Corp Method and device for separation of platelet rich plasma
WO2008069975A2 (en) 2006-12-01 2008-06-12 New York University Methods of using f-spondin as a biomarker for cartilage degenerative conditions
US20080164204A1 (en) 2007-01-08 2008-07-10 Mehdi Hatamian Valve for facilitating and maintaining separation of fluids and materials
WO2008100442A1 (en) 2007-02-09 2008-08-21 Biomet Biologics, Inc. Treatment of tissue defects with a therapeutic composition
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
JP5479319B2 (en) 2007-04-12 2014-04-23 バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー Buoy suspension fractionation system
US8328024B2 (en) 2007-04-12 2012-12-11 Hanuman, Llc Buoy suspension fractionation system
US20080258064A1 (en) 2007-04-23 2008-10-23 Stephen Anthony Cima Radiation rate meter displaying remaining time parameters
US20080268064A1 (en) 2007-04-25 2008-10-30 Biomet Biologics, Inc. Method for treating cartilage defects
US20080269762A1 (en) 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
US7901344B2 (en) 2007-05-11 2011-03-08 Biomet Biologics, Llc Methods of reducing surgical complications in cancer patients
FR2917872A1 (en) 2007-06-25 2008-12-26 France Telecom METHODS AND DEVICES FOR ENCODING AND DECODING AN IMAGE SEQUENCE REPRESENTED USING MOTION TUBES, COMPUTER PROGRAM PRODUCTS AND CORRESPONDING SIGNAL.
WO2009021257A1 (en) 2007-08-13 2009-02-19 Greiner Bio-One Gmbh Medical separator
US8672869B2 (en) 2007-10-30 2014-03-18 Bellco S.R.L. Kit, system and method of treating myeloma patients
US20090131827A1 (en) 2007-11-21 2009-05-21 Stemcor Systems, Inc. Apparatus and methods for tissue disruption
CA2708218A1 (en) 2007-12-07 2009-06-11 Harvest Technologies Corporation Floating disk for separating blood components
MX2010006823A (en) 2007-12-20 2010-09-30 Xoma Technology Ltd Methods for the treatment of gout.
JP5132303B2 (en) 2007-12-26 2013-01-30 Meiji Seikaファルマ株式会社 Stabilized agrochemical solid pharmaceutical composition
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US8337711B2 (en) 2008-02-29 2012-12-25 Biomet Biologics, Llc System and process for separating a material
AU2009235622C9 (en) 2008-03-13 2015-07-02 Biotest Ag Agent for treating disease
MX2010010027A (en) 2008-03-13 2011-05-02 Biotest Ag Agent for treating disease.
EP2265643B1 (en) 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
US8012077B2 (en) 2008-05-23 2011-09-06 Biomet Biologics, Llc Blood separating device
WO2009152084A2 (en) 2008-06-11 2009-12-17 Cell4Vet Llc Adipose tissue-derived stem cells for veterinary use
US7796259B2 (en) 2008-07-09 2010-09-14 Weifour, Inc. Rapid acquisition ellipsometry
US8460227B2 (en) 2008-11-17 2013-06-11 Arthrex, Inc. Cytokine concentration system
US8177072B2 (en) 2008-12-04 2012-05-15 Thermogenesis Corp. Apparatus and method for separating and isolating components of a biological fluid
US8187475B2 (en) 2009-03-06 2012-05-29 Biomet Biologics, Llc Method and apparatus for producing autologous thrombin
US8313954B2 (en) 2009-04-03 2012-11-20 Biomet Biologics, Llc All-in-one means of separating blood components
EP2416789B1 (en) 2009-04-07 2017-06-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
JP5844258B2 (en) 2009-08-27 2016-01-13 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーBiomet Biologics, Llc Implantable device for the production of interleukin-1 receptor antagonists
US8591391B2 (en) 2010-04-12 2013-11-26 Biomet Biologics, Llc Method and apparatus for separating a material
US20120027746A1 (en) 2010-07-30 2012-02-02 Biomet Biologics, Llc Method for generating thrombin
EP2611456A2 (en) 2010-09-03 2013-07-10 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US280820A (en) * 1883-07-10 Milk-can
US3508653A (en) * 1967-11-17 1970-04-28 Charles M Coleman Method and apparatus for fluid handling and separation
US3814248A (en) * 1971-09-07 1974-06-04 Corning Glass Works Method and apparatus for fluid collection and/or partitioning
US3879295A (en) * 1973-08-17 1975-04-22 Eastman Kodak Co Vacutainer with positive separation barrier
US4001122A (en) * 1973-08-22 1977-01-04 Telan Corporation Method and device for separating blood components
US3896733A (en) * 1973-10-18 1975-07-29 Pall Corp Autotransfusion apparatus
US3897343A (en) * 1974-02-27 1975-07-29 Becton Dickinson Co Plasma separator-hydrostatic pressure type
US3957654A (en) * 1974-02-27 1976-05-18 Becton, Dickinson And Company Plasma separator with barrier to eject sealant
US3931018A (en) * 1974-08-09 1976-01-06 Becton, Dickinson And Company Assembly for collection, separation and filtration of blood
US4077396A (en) * 1976-04-02 1978-03-07 Wardlaw Stephen C Material layer volume determination
US4152270A (en) * 1976-05-06 1979-05-01 Sherwood Medical Industries Inc. Phase separation device
US4187979A (en) * 1978-09-21 1980-02-12 Baxter Travenol Laboratories, Inc. Method and system for fractionating a quantity of blood into the components thereof
US4269718A (en) * 1980-05-05 1981-05-26 The Institutes Of Medical Sciences Process and device for centrifugal separation of platelets
US4322298A (en) * 1981-06-01 1982-03-30 Advanced Blood Component Technology, Inc. Centrifugal cell separator, and method of use thereof
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4675117A (en) * 1984-03-21 1987-06-23 Fresenius Ag Method of separating blood and apparatus for carrying out the method
US4917801A (en) * 1984-12-04 1990-04-17 Becton Dickinson And Company Lymphocyte collection tube
US4850952A (en) * 1985-09-10 1989-07-25 Figdor Carl G Method and device for the separation and isolation of blood or bone marrow components
US5131907A (en) * 1986-04-04 1992-07-21 Thomas Jefferson University Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself
US5318782A (en) * 1986-10-03 1994-06-07 Weis Fogh Ulla S Method for preparing tissue repair promoting substances
US4929242A (en) * 1986-11-26 1990-05-29 Baxter International Inc. Solution and method for maintaining patency of a catheter
US5322620A (en) * 1987-01-30 1994-06-21 Baxter International Inc. Centrifugation system having an interface detection surface
US5494578A (en) * 1987-01-30 1996-02-27 Baxter International Inc. Centrifugation pheresis system
US6071423A (en) * 1987-01-30 2000-06-06 Baxter International Inc. Methods of collecting a blood plasma constituent
US5019243A (en) * 1987-04-03 1991-05-28 Mcewen James A Apparatus for collecting blood
US4939081A (en) * 1987-05-27 1990-07-03 The Netherlands Cancer Institute Cell-separation
US4818386A (en) * 1987-10-08 1989-04-04 Becton, Dickinson And Company Device for separating the components of a liquid sample having higher and lower specific gravities
US5024613A (en) * 1988-07-18 1991-06-18 Pfizer Hospital Products Group, Inc. Blood recovery system and method
US5207638A (en) * 1989-08-24 1993-05-04 Hemotrans, Inc. Blood transfer apparatus
US5599558A (en) * 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
US5185001A (en) * 1990-01-18 1993-02-09 The Research Foundation Of State University Of New York Method of preparing autologous plasma fibrin and application apparatus therefor
US5178602A (en) * 1990-02-07 1993-01-12 Wells John R Automatic decanting centrifuge
US6221315B1 (en) * 1990-09-13 2001-04-24 Baxter International Inc. Apparatus for separation of biologic components from heterogeneous cell populations
US20010009757A1 (en) * 1990-09-13 2001-07-26 Bischof Daniel F. Apparatus for the separation of biologic components from heterogeneous cell populations
US5916743A (en) * 1990-09-13 1999-06-29 Baxter International Inc. Continuous process for the separation of biologic components from heterogeneous cell populations
US5641622A (en) * 1990-09-13 1997-06-24 Baxter International Inc. Continuous centrifugation process for the separation of biological components from heterogeneous cell populations
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5393674A (en) * 1990-12-31 1995-02-28 Levine Robert A Constitutent layer harvesting from a centrifuged sample in a tube
US5203825A (en) * 1991-06-07 1993-04-20 Becton, Dickinson And Company Capillary tube assembly including a vented cap
US5601727A (en) * 1991-11-04 1997-02-11 Pall Corporation Device and method for separating plasma from a biological fluid
US6090793A (en) * 1992-02-12 2000-07-18 Monsanto Europe S.A. Non-mitogenic substance, its preparation and use
US5403272A (en) * 1992-05-29 1995-04-04 Baxter International Inc. Apparatus and methods for generating leukocyte free platelet concentrate
US5785700A (en) * 1992-06-03 1998-07-28 Zimmer Patient Care, A Division Of Zimmer, Inc. Autotransfusion system with portable detachable vacuum source
US5387187A (en) * 1992-12-01 1995-02-07 Haemonetics Corporation Red cell apheresis method
US5614106A (en) * 1993-03-12 1997-03-25 Baxter International Inc. Method and apparatus for collection of platelets
US5607579A (en) * 1993-04-27 1997-03-04 Haemonetics Corporation Apheresis apparatus for separating an intermediate density component from whole blood
US5494592A (en) * 1993-04-27 1996-02-27 Haemonetics Corporation Apheresis apparatus and method
US6245900B1 (en) * 1994-02-23 2001-06-12 Kyowa Hakko Kogyo Co., Ltd. Platelet production promoting agent
US5738796A (en) * 1994-02-25 1998-04-14 Pall Corporation Method for separating components from a biological fluid
US5707647A (en) * 1994-04-08 1998-01-13 Atrix Laboratories, Inc. Adjunctive polymer system for use with medical device
US5648223A (en) * 1994-08-31 1997-07-15 Activated Cell Therapy, Inc. Methods for enriching breast tumor cells
US5646004A (en) * 1994-08-31 1997-07-08 Activated Cell Therapy, Inc. Methods for enriching fetal cells from maternal body fluids
US5645540A (en) * 1994-10-11 1997-07-08 Stryker Corporation Blood conservation system
US6214338B1 (en) * 1994-12-07 2001-04-10 Plasmaseal Llc Plasma concentrate and method of processing blood for same
US6063297A (en) * 1994-12-07 2000-05-16 Plasmaseal Llc Method and apparatus for making concentrated plasma and/or tissue sealant
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US6071422A (en) * 1995-04-18 2000-06-06 Cobe Laboratories, Inc. Particle separation method and apparatus
US6053856A (en) * 1995-04-18 2000-04-25 Cobe Laboratories Tubing set apparatus and method for separation of fluid components
US6022306A (en) * 1995-04-18 2000-02-08 Cobe Laboratories, Inc. Method and apparatus for collecting hyperconcentrated platelets
US5707331A (en) * 1995-05-05 1998-01-13 John R. Wells Automatic multiple-decanting centrifuge
US5895346A (en) * 1995-05-05 1999-04-20 Wells; John R. Automatic multiple-decanting centrifuge
US6196987B1 (en) * 1995-06-07 2001-03-06 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US5632905A (en) * 1995-08-07 1997-05-27 Haynes; John L. Method and apparatus for separating formed and unformed components
US5736033A (en) * 1995-12-13 1998-04-07 Coleman; Charles M. Separator float for blood collection tubes with water swellable material
US6025201A (en) * 1995-12-28 2000-02-15 Bayer Corporation Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples
US6200606B1 (en) * 1996-01-16 2001-03-13 Depuy Orthopaedics, Inc. Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
US5707876A (en) * 1996-03-25 1998-01-13 Stephen C. Wardlaw Method and apparatus for harvesting constituent layers from a centrifuged material mixture
US6558341B1 (en) * 1996-05-07 2003-05-06 Sherwood Services, Ag Continuous autotransfusion filtration system
US6264890B1 (en) * 1997-01-15 2001-07-24 Boehringer Labiratories, Inc. Method and apparatus for collecting and processing blood
US6200287B1 (en) * 1997-09-05 2001-03-13 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US6051146A (en) * 1998-01-20 2000-04-18 Cobe Laboratories, Inc. Methods for separation of particles
US6355239B1 (en) * 1998-03-13 2002-03-12 Osiris Therapeutics, Inc. Uses for non-autologous mesenchymal stem cells
US6508778B1 (en) * 1998-06-01 2003-01-21 Harvest Technologies Corporation System for withdrawal of blood
US6406671B1 (en) * 1998-12-05 2002-06-18 Becton, Dickinson And Company Device and method for separating components of a fluid sample
US6516953B1 (en) * 1998-12-05 2003-02-11 Becton, Dickinson And Company Device for separating components of a fluid sample
US6398972B1 (en) * 1999-04-12 2002-06-04 Harvest Technologies Corporation Method for producing platelet rich plasma and/or platelet concentrate
US6410344B1 (en) * 1999-12-28 2002-06-25 Hyundai Electronics Industries Co., Ltd. Ferroelectric random access memory device and method for the manufacture thereof
US20020082220A1 (en) * 2000-06-29 2002-06-27 Hoemann Caroline D. Composition and method for the repair and regeneration of cartilage and other tissues
US20030050709A1 (en) * 2001-02-23 2003-03-13 Ulrich Noth Trabecular bone-derived human mesenchymal stem cells
US20030050710A1 (en) * 2001-09-06 2003-03-13 Petersen Donald W. Bone graft substitute composition
US20050100536A1 (en) * 2002-04-13 2005-05-12 Allan Mishra Compositions and minimally invasive methods for treating incomplete tissue repair
US20090101599A1 (en) * 2002-05-03 2009-04-23 Hanuman, L.L.C. Methods And Apparatus For Isolating Platelets From Blood
US20090014391A1 (en) * 2002-05-03 2009-01-15 Biomet Biologics, Llc Buoy Suspension Fractionation System
US7223346B2 (en) * 2002-05-03 2007-05-29 Hanuman Llc Methods and apparatus for isolating platelets from blood
US7179391B2 (en) * 2002-05-24 2007-02-20 Biomet Manufacturing Corp. Apparatus and method for separating and concentrating fluids containing multiple components
US7374678B2 (en) * 2002-05-24 2008-05-20 Biomet Biologics, Inc. Apparatus and method for separating and concentrating fluids containing multiple components
US6905612B2 (en) * 2003-03-21 2005-06-14 Hanuman Llc Plasma concentrate apparatus and method
US20050130301A1 (en) * 2003-07-09 2005-06-16 Mckay William F. Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation
US20050084962A1 (en) * 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
US20060057693A1 (en) * 2003-08-20 2006-03-16 Ebi, L.P. Methods of treatment using electromagnetic field stimulated stem cells
US20060051865A1 (en) * 2004-08-31 2006-03-09 Higgins Joel C Systems and methods for isolating stromal cells from adipose tissue and uses thereof
US20080011684A1 (en) * 2005-02-07 2008-01-17 Dorian Randel E Apparatus and method for preparing platelet rich plasma and concentrates thereof
US7553413B2 (en) * 2005-02-07 2009-06-30 Hanuman Llc Plasma concentrator device
US20070075016A1 (en) * 2005-08-23 2007-04-05 Biomet Manufacturing Corp. Method and apparatus for collecting biological materials
US20090192528A1 (en) * 2008-01-29 2009-07-30 Biomet Biologics, Inc. Method and device for hernia repair
US20100055087A1 (en) * 2008-02-27 2010-03-04 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682373B2 (en) 1999-12-03 2017-06-20 Becton, Dickinson And Company Device for separating components of a fluid sample
US8187477B2 (en) 2002-05-03 2012-05-29 Hanuman, Llc Methods and apparatus for isolating platelets from blood
US7992725B2 (en) 2002-05-03 2011-08-09 Biomet Biologics, Llc Buoy suspension fractionation system
US8950586B2 (en) 2002-05-03 2015-02-10 Hanuman Llc Methods and apparatus for isolating platelets from blood
US20090014391A1 (en) * 2002-05-03 2009-01-15 Biomet Biologics, Llc Buoy Suspension Fractionation System
US7837884B2 (en) 2002-05-03 2010-11-23 Hanuman, Llc Methods and apparatus for isolating platelets from blood
US10183042B2 (en) 2002-05-24 2019-01-22 Biomet Manufacturing, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8603346B2 (en) 2002-05-24 2013-12-10 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US7914689B2 (en) 2002-05-24 2011-03-29 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US10393728B2 (en) 2002-05-24 2019-08-27 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9897589B2 (en) 2002-05-24 2018-02-20 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8163184B2 (en) 2002-05-24 2012-04-24 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8062534B2 (en) 2002-05-24 2011-11-22 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US7780860B2 (en) 2002-05-24 2010-08-24 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8048321B2 (en) 2002-05-24 2011-11-01 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US8808551B2 (en) 2002-05-24 2014-08-19 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US7845499B2 (en) 2002-05-24 2010-12-07 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US9114334B2 (en) 2002-05-24 2015-08-25 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8231567B2 (en) 2004-10-13 2012-07-31 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US7731679B2 (en) 2004-10-13 2010-06-08 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US20070255203A1 (en) * 2004-10-13 2007-11-01 Hyprotek, Inc. Syringe Devices and Methods for Mixing and Administering Medication
US11376195B2 (en) 2004-10-13 2022-07-05 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US7985211B2 (en) 2004-10-13 2011-07-26 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US9861555B2 (en) 2004-10-13 2018-01-09 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US7731678B2 (en) * 2004-10-13 2010-06-08 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US7749189B2 (en) 2004-10-13 2010-07-06 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US7753891B2 (en) 2004-10-13 2010-07-13 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US7776011B2 (en) 2004-10-13 2010-08-17 Hyprotek, Inc. Syringe devices and methods for mixing and administering medication
US8444620B2 (en) 2005-02-21 2013-05-21 Biomet Biologics, Llc Method and apparatus for application of a fluid
US9028457B2 (en) 2005-02-21 2015-05-12 Biomet Biologics, Llc Method and apparatus for application of a fluid
US8137307B2 (en) 2005-11-09 2012-03-20 Hyprotek, Inc. Syringe devices, components of syringe devices, and methods of forming components and syringe devices
US10485930B2 (en) 2005-11-09 2019-11-26 Hyprotek, Inc. Syringe devices, components of syringe devices, and methods of forming components and syringe devices
US8608686B2 (en) 2005-11-09 2013-12-17 Hyprotek, Inc. Syringe devices, components of syringe devices, and methods of forming components and syringe devices
US20100016830A1 (en) * 2006-04-28 2010-01-21 Ellsworth James R Injection of Anticoagulant Into Bone Marrow Space
US8567609B2 (en) 2006-05-25 2013-10-29 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US20080193424A1 (en) * 2007-02-09 2008-08-14 Biomet Biologics, Inc. Treatment of tissue defects with a therapeutic composition
US9352002B2 (en) 2007-03-06 2016-05-31 Biomet Biologics, Llc Angiogenesis initiation and growth
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US8663146B2 (en) 2007-03-06 2014-03-04 Biomet Biologics, Llc Angiogenesis initiation and growth
US9649579B2 (en) 2007-04-12 2017-05-16 Hanuman Llc Buoy suspension fractionation system
US8328024B2 (en) 2007-04-12 2012-12-11 Hanuman, Llc Buoy suspension fractionation system
US9138664B2 (en) 2007-04-12 2015-09-22 Biomet Biologics, Llc Buoy fractionation system
US8119013B2 (en) 2007-04-12 2012-02-21 Hanuman, Llc Method of separating a selected component from a multiple component material
US8596470B2 (en) 2007-04-12 2013-12-03 Hanuman, Llc Buoy fractionation system
US7806276B2 (en) 2007-04-12 2010-10-05 Hanuman, Llc Buoy suspension fractionation system
US7901344B2 (en) 2007-05-11 2011-03-08 Biomet Biologics, Llc Methods of reducing surgical complications in cancer patients
US20080306431A1 (en) * 2007-05-11 2008-12-11 Biomet Biologics, Llc Methods of reducing surgical complications in cancer patients
US20090084737A1 (en) * 2007-10-02 2009-04-02 Becton, Dickinson And Company Apparatus and method for separating particles within a specimen
US7846394B2 (en) * 2007-10-02 2010-12-07 Becton, Dickinson And Company Apparatus and method for separating particles within a specimen
US9522097B2 (en) 2007-10-04 2016-12-20 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
US10524983B2 (en) 2007-10-04 2020-01-07 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
US8512278B2 (en) 2007-10-04 2013-08-20 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
US8002737B2 (en) 2007-10-04 2011-08-23 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers
US11725031B2 (en) 2008-02-27 2023-08-15 Biomet Manufacturing, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20090220482A1 (en) * 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US9701728B2 (en) 2008-02-27 2017-07-11 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US9308224B2 (en) 2008-02-27 2016-04-12 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20100055087A1 (en) * 2008-02-27 2010-03-04 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US10106587B2 (en) 2008-02-27 2018-10-23 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US10400017B2 (en) 2008-02-27 2019-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US8801586B2 (en) * 2008-02-29 2014-08-12 Biomet Biologics, Llc System and process for separating a material
US9719063B2 (en) 2008-02-29 2017-08-01 Biomet Biologics, Llc System and process for separating a material
US8337711B2 (en) 2008-02-29 2012-12-25 Biomet Biologics, Llc System and process for separating a material
US9211487B2 (en) 2008-04-04 2015-12-15 Biomet Biologics, Llc Sterile blood separating system
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
US9339741B2 (en) 2008-07-21 2016-05-17 Becton, Dickinson And Company Density phase separation device
US9182328B2 (en) 2008-12-01 2015-11-10 Baxalta Incorporated Apparatus and method for processing biological material
US9423327B2 (en) 2008-12-01 2016-08-23 Baxalta GmbH Apparatus and method for processing biological material
US20130001157A1 (en) * 2008-12-01 2013-01-03 Kyungyoon Min Apparatus and method for processing biological material
US9097631B2 (en) 2008-12-01 2015-08-04 Baxter International Inc. Apparatus and method for processing biological material
US9176038B2 (en) * 2008-12-01 2015-11-03 Baxalta Incorporated Apparatus and method for processing biological material
US8783470B2 (en) 2009-03-06 2014-07-22 Biomet Biologics, Llc Method and apparatus for producing autologous thrombin
US8313954B2 (en) 2009-04-03 2012-11-20 Biomet Biologics, Llc All-in-one means of separating blood components
US8992862B2 (en) 2009-04-03 2015-03-31 Biomet Biologics, Llc All-in-one means of separating blood components
US20120045424A1 (en) * 2009-04-21 2012-02-23 Aaron Esteron Assembly, device kit and method for preparing platelet-rich plasma (prp)
US8734373B2 (en) * 2009-04-21 2014-05-27 Aaron Esteron Assembly, device kit and method for preparing platelet-rich plasma (PRP)
US9919307B2 (en) 2009-05-15 2018-03-20 Becton, Dickinson And Company Density phase separation device
US9802189B2 (en) 2009-05-15 2017-10-31 Becton, Dickinson And Company Density phase separation device
US8998000B2 (en) 2009-05-15 2015-04-07 Becton, Dickinson And Company Density phase separation device
US9731290B2 (en) 2009-05-15 2017-08-15 Becton, Dickinson And Company Density phase separation device
US10343157B2 (en) 2009-05-15 2019-07-09 Becton, Dickinson And Company Density phase separation device
US11786895B2 (en) 2009-05-15 2023-10-17 Becton, Dickinson And Company Density phase separation device
US10456782B2 (en) 2009-05-15 2019-10-29 Becton, Dickinson And Company Density phase separation device
US9364828B2 (en) 2009-05-15 2016-06-14 Becton, Dickinson And Company Density phase separation device
US9919309B2 (en) 2009-05-15 2018-03-20 Becton, Dickinson And Company Density phase separation device
US10413898B2 (en) 2009-05-15 2019-09-17 Becton, Dickinson And Company Density phase separation device
US9919308B2 (en) 2009-05-15 2018-03-20 Becton, Dickinson And Company Density phase separation device
US10376879B2 (en) 2009-05-15 2019-08-13 Becton, Dickinson And Company Density phase separation device
US11351535B2 (en) 2009-05-15 2022-06-07 Becton, Dickinson And Company Density phase separation device
US8794452B2 (en) 2009-05-15 2014-08-05 Becton, Dickinson And Company Density phase separation device
US9079123B2 (en) 2009-05-15 2015-07-14 Becton, Dickinson And Company Density phase separation device
US10807088B2 (en) 2009-05-15 2020-10-20 Becton, Dickinson And Company Density phase separation device
US10005081B2 (en) 2009-05-29 2018-06-26 Endocellutions, Inc. Apparatus and methods for aspirating and separating components of different densities from a physiological fluid containing cells
US9272083B2 (en) 2009-05-29 2016-03-01 Endocellutions, Inc. Apparatus and methods for aspirating and separating components of different densities from a physiological fluid containing cells
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
US9763875B2 (en) 2009-08-27 2017-09-19 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
US20110114640A1 (en) * 2009-11-13 2011-05-19 Black Eric L Device for dispensing cream laden gauze
US8348878B2 (en) * 2009-11-13 2013-01-08 Ab Holdings, Llc Device for dispensing cream laden gauze
US9533090B2 (en) 2010-04-12 2017-01-03 Biomet Biologics, Llc Method and apparatus for separating a material
US8591391B2 (en) 2010-04-12 2013-11-26 Biomet Biologics, Llc Method and apparatus for separating a material
US9119829B2 (en) 2010-09-03 2015-09-01 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20130253657A1 (en) * 2010-11-25 2013-09-26 University Of Tsukuba Method for producing implant material
US9782518B2 (en) * 2010-11-25 2017-10-10 Kuraray Co., Ltd. Method for producing implant material
US9239276B2 (en) 2011-04-19 2016-01-19 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US20150004702A1 (en) * 2011-08-29 2015-01-01 Stempeutics Research Private Limited System for isolating stromal vascular fraction (svf) cells from the adipose tissue and a method thereof
US20140360944A1 (en) * 2012-01-23 2014-12-11 Estar Technologies Ltd System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (prp)
US10617812B2 (en) 2012-01-23 2020-04-14 Estar Technologies Ltd System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP)
US9962480B2 (en) * 2012-01-23 2018-05-08 Estar Technologies Ltd System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP)
US11129930B2 (en) 2012-01-23 2021-09-28 Estar Technologies Ltd System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP)
US9937317B2 (en) * 2012-01-30 2018-04-10 Ipsumpro, S.L. Modified medical syringe with a flow regulator for the administration of local anaesthetic
US20160287836A1 (en) * 2012-01-30 2016-10-06 Ipsumpro, S.L. Modified medical syringe with a flow regulator for the administration of local anaesthetic
US20140231335A1 (en) * 2012-03-05 2014-08-21 Dongkoo Bio & Pharma Co., Ltd. Ingredient separator
US9463270B2 (en) * 2012-03-05 2016-10-11 Dongkoo Bio & Pharma Co., Ltd. Ingredient separator
US9802194B2 (en) * 2012-05-21 2017-10-31 Korea Advanced Institute Of Science And Technology Container for multiple particle/layer separations and particle/layer separation method using the same
US20150151294A1 (en) * 2012-05-21 2015-06-04 Korea Advanced Institute Of Science And Technology Container For Multiple Particle/Layer Separations And Particle/Layer Separtion Method Using The Same
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US11660603B2 (en) 2013-01-29 2023-05-30 Cervos Medical Llc Cell concentration devices and methods including a syringe and a syringe holder
US10603665B2 (en) 2013-01-29 2020-03-31 Endocellutions, Inc. Cell concentration devices and methods that include an insert defining a lumen and a cannula assembly
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9556243B2 (en) 2013-03-15 2017-01-31 Biomet Biologies, LLC Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
WO2014149979A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
WO2014149301A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
WO2014149270A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
EP3881852A1 (en) 2013-03-15 2021-09-22 Biomet Biologics, LLC Treatment of pain using protein solutions
EP3351253A1 (en) 2013-03-15 2018-07-25 Biomet Biologics, LLC Method for making an autologous protein solution
WO2014149300A1 (en) 2013-03-15 2014-09-25 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US10441634B2 (en) 2013-03-15 2019-10-15 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
WO2014144505A2 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10576130B2 (en) 2013-03-15 2020-03-03 Biomet Manufacturing, Llc Treatment of collagen defects using protein solutions
EP3030279A4 (en) * 2013-08-06 2017-03-08 Regenerative Sciences, LLC Bone marrow adipose portion isolation device and methods
US10537596B2 (en) 2013-08-06 2020-01-21 Regenexx Llc Bone marrow adipose portion isolation device and methods
WO2015021189A1 (en) 2013-08-06 2015-02-12 Regenerative Sciences, Llc Bone marrow adipose portion isolation device and methods
JP2016533811A (en) * 2013-08-06 2016-11-04 リジェネレイティブ サイエンシーズ, エルエルシー Bone marrow fat portion isolation device and method
US9976115B2 (en) 2013-08-06 2018-05-22 Regenexx, LLC Bone marrow adipose portion isolation device and methods
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
US10946043B2 (en) 2013-11-26 2021-03-16 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9694359B2 (en) 2014-11-13 2017-07-04 Becton, Dickinson And Company Mechanical separator for a biological fluid
US10729552B2 (en) 2015-03-18 2020-08-04 Biomet C.V. Implant configured for hammertoe and small bone fixation
US11045526B2 (en) 2016-03-10 2021-06-29 Arthrex, Inc. Systems and methods for preparing a thrombin serum
WO2017156379A3 (en) * 2016-03-10 2018-08-16 Arthrex, Inc. Systems and methods for preparing protein enhanced serums
US10960026B2 (en) 2016-03-10 2021-03-30 Arthrex, Inc. Systems and methods for preparing protein enhanced serums
US11617784B2 (en) 2016-03-10 2023-04-04 Arthrex, Inc. Systems and methods for preparing a thrombin serum
US20170258849A1 (en) * 2016-03-10 2017-09-14 Arthrex, Inc. Systems and methods for preparing protein enhanced serums
US10596236B2 (en) 2016-03-10 2020-03-24 Arthrex, Inc. Systems and methods for preparing a thrombin serum
US10987672B2 (en) * 2017-06-08 2021-04-27 Emcyte Corp. Dual piston centrifuge tube
US20180353954A1 (en) * 2017-06-08 2018-12-13 Patrick Pennie Dual Piston Centrifuge Tube
US20220133962A1 (en) * 2019-11-11 2022-05-05 Jun Seok Lee Body fluid component separating device
EP3912654A4 (en) * 2019-11-11 2023-01-18 Jun Seok Lee Body fluid component separating device
CN114273091A (en) * 2021-12-30 2022-04-05 青岛市中心血站 Blood rapid centrifugal separation and collection device and control method

Also Published As

Publication number Publication date
US20130226149A1 (en) 2013-08-29
US9897589B2 (en) 2018-02-20
US10393728B2 (en) 2019-08-27
US20150023939A1 (en) 2015-01-22
US20180196030A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
US10393728B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US9114334B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US7954646B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US7374678B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US9239276B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US10183042B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
CN112237755B (en) Preparation method and preparation device of platelet-rich plasma and prepared platelet-rich plasma
EP4115918A1 (en) Syringe system for processing a fluid

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOMET MANUFACTURING CORP., INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WOODELL-MAY, JENNIFER E.;REEL/FRAME:018205/0185

Effective date: 20060727

AS Assignment

Owner name: BIOMET BIOLOGICS, INC., INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMET MANUFACTURING CORP.;REEL/FRAME:020130/0072

Effective date: 20071010

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT FOR

Free format text: SECURITY AGREEMENT;ASSIGNORS:LVB ACQUISITION, INC.;BIOMET, INC.;REEL/FRAME:020362/0001

Effective date: 20070925

AS Assignment

Owner name: BIOMET BIOLOGICS, LLC, INDIANA

Free format text: CHANGE OF NAME;ASSIGNOR:BIOMET BIOLOGICS, INC.;REEL/FRAME:021380/0803

Effective date: 20080227

Owner name: BIOMET BIOLOGICS, LLC,INDIANA

Free format text: CHANGE OF NAME;ASSIGNOR:BIOMET BIOLOGICS, INC.;REEL/FRAME:021380/0803

Effective date: 20080227

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: LVB ACQUISITION, INC., INDIANA

Free format text: RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 020362/ FRAME 0001;ASSIGNOR:BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:037155/0133

Effective date: 20150624

Owner name: BIOMET, INC., INDIANA

Free format text: RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 020362/ FRAME 0001;ASSIGNOR:BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:037155/0133

Effective date: 20150624